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Abstract 
 
The use of immunotherapy to treat cancer is a rapidly expanding field. Over the last ten years, 
the number of clinical trials of immunotherapy, both alone and in combination with other 
agents, including cytotoxic chemotherapy, has grown exponentially.  While the use of 
immunotherapy has revolutionised the management of cancers such as melanoma, renal cell 
carcinoma and lung cancer, other diseases, including colorectal cancer, have fared less well. In 
going forward, an increased understanding of the mechanism of immunotherapy in cancer 
patients is a vital step in being able to exploit these drugs in cancers where clinical efficacy has 
previously been limited. Better understanding of immune responses in these patients may 
identify potential responders to novel immunotherapy. 
To this end, we developed and validated a panel of immune functional assays, which can be 
used in clinical trials to assess the immune response in peripheral blood. This panel can 
therefore be used to gather translational data from clinical trials of anti-cancer therapy. We 
used these assays to analyse the peripheral blood immune response in patients with 
metastatic colorectal cancer undergoing first-line chemotherapy, with reference to the 
neutrophil lymphocyte ratio (NLR). Analysis of samples from 29 patients revealed that, in 
patients with a high NLR prior to treatment, there was evidence of an attenuated immune 
response, with increased levels of certain immunosuppressive cytokines and depressed NK 
cell function. Over the course of treatment, we demonstrated that chemotherapy could 
partially reverse this phenomenon, potentially enhancing anti -tumour immunity. 
Similarly, we interrogated blood samples of patients with metastatic melanoma receiving 
immune therapy with checkpoint inhibitors. Here, we observed evidence of a more active 
immune response, highlighting the differences between the two patient groups (those with 
colorectal cancer and those with melanoma).  
In conclusion, we confirmed that our functional immune assay panel can be used effectively in 
different groups of cancer patients undergoing a variety of treatments, with the aim of an 
improved understanding of the immune system in cancer, response to therapy and how this 
may be exploited in the development of novel treatment strategies.  
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Aims and Objectives 
 
This project set out to develop and validate a panel of immune assays, which could be 
performed on peripheral blood, with a high degree of quality and reproducibility. As such, we 
aimed to show that clinical samples could be collected from patients receivi ng systemic anti-
cancer therapy (including those partaking in clinical trials of novel therapies), cryopreserved 
and batch analysed in order to produce robust results.  
Using this immune assay panel, we sought to interrogate the response to first-line 
chemotherapy in patients with metastatic colorectal cancer. Patients were stratified according 
to baseline peripheral blood neutrophil lymphocyte ratio (NLR).  We hypothesised that 
patients with a high baseline NLR have suppressed immune responses, which could  be 
reversed by chemotherapy and could contribute to differences in overall survival (OS) 
between those with high NLR and low NLR prior to starting treatment. 
Finally, in order to confirm that these assays can yield meaningful results in different patient 
groups, we analysed peripheral blood samples from those receiving immunotherapy for 
metastatic melanoma. This allowed us to compare immune responses in patients with 
different cancers undergoing different systemic therapies and put this data into the context of 
what we already understand about the immune system in cancer.  
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Chapter 1 Introduction 
1.1 The Immune Response in Cancer 
In order to place into context the effects of anti-cancer therapy on host immunity, we first 
need to have an understanding of the complex role of the immune system in the pathogenesis 
and development of cancer. Broadly, immune activation involves a carefully regulated system 
of checks and balances that first initiate and then attenuate a response . This is initially 
through rapid activation of the innate immune system, followed by the development of 
specific immunity against a particular pathogen. It is now well recognised that these 
mechanisms do not function appropriately in patients with cancer and may be dysfunctional 
in a way that supports tumour growth and metastasis. The ability of cancer to evade the 
immune response has now been incorporated into the ‘Hallmarks of Cancer’ (1), along with 
genetic instability, resistance to cell death, ongoing cellular proliferation, and metastasis. 
Other features of malignant cells have been targeted therapeutically and current interest in 
anti-cancer immunotherapy is increasing exponentially. The ability to manipulate the immune 
system to target cancer has changed the field of oncology in the last 10 years and produced 
results that are truly paradigm changing.  
1.1.1 Adaptive and Innate Immune Response 
The innate immune response is non-specific but has the ability to control and manage 
pathogens until the development of an adaptive response. One of the primary effector cells of 
the innate immune system is the natural killer (NK) cell, which exerts cytotoxic effects against 
abnormal/infected cells and releases cytokines (which assist in priming T cells against specific 
antigens) and chemokines (which recruit immune cells to the site of infection or 
inflammation) (2). In parallel, the detection of pathogens by phagocytic cells such neutrophils 
and macrophages through pattern recognition receptors (PRRs) on the cell surface initiate 
phagocytosis, whereby foreign organisms are engulfed and destroyed (3). NK cells also 
contribute to the maturation of antigen presenting cells (APCs) such as dendritic cells (DCs) 
and macrophages, which process and present antigens. Tumour-associated antigens (TAAs) 
are molecules which can be specific to (or over-expressed in) malignant cells, such as 
carcinoembryonic antigen (CEA) in colorectal cancer (CRC) and melanoma-associated antigen 
recognized by T cells-1 (MART-1). Presentation of antigens on APCs to T cells stimulates 
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proliferation of a clonal population of T cells recognising specific antigens as part of a specific 
adaptive response. Further T cell differentiation is dependent on the immune environment 
and the presence of immunosuppressive or stimulatory cytokines (discussed in more detail in  
section 1.2.2). Activation of B cells, the other component of adaptive immunity, forms the 
humoural immune response and the secretion of antibodies (immunoglobulin) against specific 
antigens. Binding of these antibodies to antigen contributes to their recognition by 
phagocytes. Alongside this is the complement cascade, comprised of three functional systems: 
the classical, alternative and lectin pathways (reviewed in (4)). Their main functions are to 
complement the cellular and humoural immune responses by contributing to the destruction 
of pathogenic organisms through opsonisation (attaching to the surface of damaged cells), 
thereby recruiting macrophages and neutrophils to initiate phagocytosis and directly lysing 
the cell membrane of abnormal cells through the membrane attack complex. These systems 
are interwoven and complex and both the innate and adaptive arms of the immune response 
can influence and regulate one another, depending on the situation, whether that be 
infection, inflammation or cancer.  
1.1.2 Immunosurveillance and Immunoediting 
Through a process of selection, cancerous cells that are naturally more susceptible to 
immune-mediated cytotoxicity are eradicated earlier on in the development of a tumour 
(immunosurveillance). What remains is a clone of relatively resistant malignant cells . These 
are not only impervious to immune-mediated cell death but can manipulate the tumour 
microenvironment (TME) to support tumour growth, with increased levels of 
immunosuppressive cytokines. These cytokines then push infiltrating immune cells towards a 
phenotype which perpetuates this process. The three stages of tumour ‘escape’ from immune 
system control (immunoediting) are known as the ‘three E’s’: 
Elimination 
The immunosurveillance and elimination of cell populations which are susceptible to immune-
mediated cell death involves interferon (IFN)-γ and perforin release from lymphocyte 
populations. To illustrate this simply, it has been demonstrated in in vivo models that mice 
insensitive to IFN-γ are much more susceptible to the development of carcinogen-induced 
tumours (5,6). Similarly, mice deficient in perforin (which is essential to both T cell- and NK 
cell-mediated degranulation and cytotoxicity) developed tumours more readily following 
injections of carcinogen (7).  
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Immune responses against damaged cells are triggered by the presence of molecules in the 
TME. Pathogen-associated molecular patterns (PAMPs) are molecules, such as 
lipopolysaccharide (LPS) from bacterial cell membranes, which are recognised by PRRs on 
innate immune cells, including toll-like receptors (TLRs). Danger theory (6) expands this to 
include molecules that are not related specifically to pathogens but rather to danger signals 
derived from damaged or dying cells (termed danger-associated molecular patterns, DAMPs). 
When cells are killed through the immune-silent process of apoptosis, cellular contents are 
compartmentalised and destroyed in a controlled way that does not stimulate an immune 
response. In contrast, cells that undergo necrosis have a disorganised cell death resulting in 
the release of molecules including fragments of deoxyribonucleic acid (DNA), ribonucleic acid 
(RNA) and other cellular proteins such as reactive oxygen species (ROS). Elements of the 
immune response have also been postulated to act as DAMPs, such as the T cell stimulatory 
ligand CD40-L and inflammatory cytokines such as tumour necrosis factor (TNF)-α and 
interleukin (IL)-1 (6).  
Equilibrium 
If the immune system does not completely eradicate the tumour, there may be a period of 
latency (immune regulation), where clones of malignant cells (not clinically detectable) are 
held in check. This period can last for many years and is illustrated by case reports of 
malignant disease developing in recipients of transplanted organs (8). Similarly, there is also 
evidence that an immune insult could contribute to relapse of cancer at a later date, following 
initial treatment. Raised serum levels of C-reactive protein (CRP) are associated with 
decreased disease-free survival (DFS) and overall survival (OS) in patients who have received 
treatment for breast cancer with curative intent (9). In contrast, a number of studies and 
meta-analysis have found no link between cancer recurrence and immunosuppressive 
therapies for unrelated auto-immune conditions (10), suggesting that the processes 
controlling dormancy of quiescent cancer cells is multi -factorial.   
Escape 
During the equilibrium phase, new clones of cells can develop due to selection pressures, with 
new genetic mutations or variants, which then subvert maintenance by the immune system. 
This leads to the development of clinically detectable disease. There are a number of 
mechanisms aside from genetic instability which can contribute to tumour escape. Recurrent 
tumours in murine models of myeloma were found to have developed due to downregulation 
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of major histocompatibility complex (MHC) class-I and/or co-stimulatory molecules on the 
surface of tumour cells, which would be one mechanism of escaping an anti -tumour cytotoxic 
T lymphocytes (CTL) response (8). In addition to the loss of molecules involved in efficient 
antigen presentation, the expression of TAAs may also change over the course of disease. 
Examination of formalin-fixed paraffin-embedded (FFPE) sections of melanoma specimens 
demonstrated that positivity for MART-1 decreased according to the stage of disease (8).  
1.2 Immune Cells 
1.2.1 Natural Killer Cells 
NK cells (CD3-/CD56+) and Natural Killer T (NKT) cells (CD3+/CD56+) are a vital part of the 
innate immune response, acting against virally-infected cells or tumour cells and releasing 
immune-stimulatory cytokines which, in turn, trigger T cell activation (11). Variable expression 
of CD56 can further characterise NK cells into cytotoxic (CD56dim) and cytokine-producing 
(CD56bright) (2,12). NK and NKT cells are activated by cytokines including IL-12 (also known as 
NK cell-stimulating factor) and can produce a range of both stimulatory and suppressive 
cytokines, including IFN-γ, TNF-α, TNF-β, IL-10 and IL-13 (12).  
Unlike T cells, activation of NK cells is not dependent on either priming by antigen recognition 
or a secondary activating signal. Instead, NK cell activation is controlled by a balance of 
activating and inhibitory surface receptors engaging with appropriate ligands on the target cell 
surface. NK cell-activating receptors include NKG2D and the natural cytotoxicity receptors 
(NCRs) NKp30, NKp44 and NKp46 (13). Infected or malignant cells express ligands to these 
activating receptors and recognition of such initiates NK cell -mediated cytotoxicity and target 
cell lysis (14). As well as viral proteins, NCRs recognise ligands such as B7-H6, which binds to 
NKp30 and has been found to be over-expressed on malignant cells, including in breast cancer 
(15). Downregulation of these activating NK receptors is associated with decreased immune-
surveillance and development of tumours (16). Activating receptors can be down-regulated on 
NK cells of patients with metastatic disease (16,17) due to the effect of transforming growth 
factor (TGF)-β or indoleamine 2,3-dioxygenase (IDO) (18). Soluble NK receptor ligands in the 
TME can also competitively compete with tumour-associated ligands, further impairing the 
anti-tumour NK cell-mediated response (19). NKG2D ligands include MHC (also known as 
human leukocyte antigen, HLA in humans) class I chain-related proteins A and B (MICA and 
MICB).  
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Inhibitory receptors, such as some killer-cell immunoglobulin-like receptors (KIRs) and NKG2A, 
recognise MHC class-I (MHC-I) molecules on target cells; engagement of these prevents NK 
cell-mediated cytotoxicity. This is particularly relevant in the development of self-tolerance: 
inhibitory ligands recognise self MHC-I molecules on the surface of target cells and 
cytotoxicity is prevented. In target cells which do not express MHC-I, the absence of an 
inhibitory signal initiates NK cell-mediated death (the concept of ‘missing-self’ (11)). As these 
inhibitory receptors are extremely polymorphic, populations of NK cells develop which can 
discriminate between a wide variety of ‘self’ and ‘non-self’ targets. NK cells therefore 
preferentially pursue cells which downregulate MHC-I, presumably as a mechanism for 
abrogating T cell-mediated lysis, such as virally-infected or tumour cells (20). 
NK cells employ a number of mechanisms by which they can exert a cytolytic effect. Upon 
activation, NK cells release cytoplasmic granules containing perforin (which perforates cell 
membranes) and granzyme, a proteolytic enzyme which then triggers target cell apoptosis. 
They also express lysosomal-associated membrane protein (LAMP)-1 and LAMP-2 (also known 
as CD107a and CD107b) on their inner surface (21). As the granules merge with the NK cell 
membrane these molecules are expressed on the cell surface (22). They can then be used to 
identify activated (degranulating) NK cells. Target cell apoptosis can also be induced through 
the engagement of Fas-ligand (Fas-L, CD95-L) or TNF-related apoptosis-inducing ligand (TRAIL) 
(expressed on NK cells) and target cell Fas (CD95) and TRAIL-receptor, respectively. NK cells 
also play a role in antibody-dependent cellular cytotoxicity (ADCC). Following the binding of 
monoclonal antibodies to target cell receptors (such as rituximab to CD20), the predominant 
Fc receptor (FcR) expressed by NK cells (FcγRIII/CD16; the others being FcγRI/CD64 and 
FcγRII/CD32) binds to the Fc portion of the antibodies, triggering the release of cytolytic 
granules. Cell death can, in turn, promote an adaptive response through the release of TAAs. 
ADCC has been shown to contribute to the therapeutic effect of monoclonal antibodies such 
as rituximab and trastuzumab, which binds to the human epidermal growth factor (HER) -2 
receptor (23).  
There are a number of ways in which malignant cells can subvert NK-mediated cytotoxicity. In 
addition to NK-specific inhibitory receptors, activated NK cells can upregulate checkpoint 
inhibitors including programmed cell death protein-1 (PD-1, CD279), cytotoxic T-lymphocyte-
associated protein-4 (CTLA-4, CD152) and T-cell immunoglobulin and mucin domain 
containing (TIM) -3 (section 1.5.2), which can inhibit NK cell function following engagement 
with their ligands on target tumour cells (24). As such, therapy with checkpoint inhibitors, 
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which were primarily thought to enhance an adaptive anti -tumour T cell response, may also 
enhance NK cell responses and have been shown to heighten anti-tumour responses in 
models of melanoma (25). 
1.2.2 T Cells 
The major classes of T cell are the T helper (TH) cells (CD3+/CD4+) and cytotoxic T cells 
(CD3+/CD8+, CTLs), the main effector cell of the adaptive immune response. CTLs are effective 
against intracellular pathogens such as viruses and bacteria. Cell surface T cell receptors 
(TCRs) recognise antigen presented on MHC-I, which is present on all nucleated cells. For 
MHC- I, there are 3 HLA molecules: HLA-A, HLA-B and HLA-C. TH cells recognise exogenous 
antigens presented on MHC-II molecules (MHC-II: HLA-DR, HLA-DP, HLA-DM, HLA-DOA, HLA-
DOB and HLA-DQ), found on professional APCs such as DCs. 
In addition to the engagement between the TCR and the MHC/antigen complex, another 
costimulatory signal is required to induce T cells to proliferate and become effector cells 
against a specific antigen. The most well-defined of these is engagement of the CD28 
receptor, expressed on the T cell surface and it’s ligands B7-1 (CD80) and B7-2 (CD86) on the 
APC. There is, however, a complex network of other co-stimulatory signals at the immune 
synapse, including CD40-L, CD278 (inducible T cell co-stimulator, ICOS) and TIM-1. 
Furthermore, not only is T cell function controlled by activating receptors, it is also governed 
by inhibitory molecules (such as CTLA-4, PD-1, TIM-3 and lymphocyte-activation gene (LAG)-
3), the immune checkpoints. In the case of CTLA-4, for example, T cell activation causes 
upregulation of the molecule, which binds with greater affinity than CD28 to CD80 and CD86, 
abrogating cellular activity (26)(Figure 1.1).  
Once T cells have been stimulated, they will proliferate into effector cells, each with 
characteristic functions. A cohort will remain, however, as memory T cells that can proliferate 
rapidly should the same antigen be encountered in the future. These memory cells are further 
differentiated into central memory T cells (TCM) and effector memory T cells (TEM). Memory T 
cells express CD45RO, differentiating them from naïve T cells, which express the CD45RA 
isoform. As TCM cells also express the lymph node (LN) homing receptor C-C chemokine 
receptor (CCR) 7, they are found in LN as well as peripheral blood. In contrast, TEM cells are 
CCR7-negative and hence reside in peripheral blood and tissues (27). CCR7 is expressed on T 
cells, regulatory T cells (Tregs) and DCs and regulates the migration of these cells to LNs where 
chemokine (C-C motif) ligand (CCL) 19 and CCL21 are expressed. As such, expression of CCR7 
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on gastric carcinoma cells is associated with a significantly higher incidence of LN metastases 
and poorer survival (28). 
1.2.2.1 T Helper Cells 
Naïve CD4+ cells (TH0) can differentiate into a number of effector T cells under different 
environmental conditions, each with specific functions. For example, under the influence of IL-
12 and IFN-γ, TH0 cells differentiate into TH1 cells, which in turn produce IL-2, TNF-α and IFN-γ, 
activating CTLs and macrophages (29). The fact that these cytokines can be more directly 
cytotoxic to tumour cells, contribute to DC maturation, activity of macrophages and 
proliferation of CTLs means that TH1 responses are generally thought to be weighted towards 
anti-tumour immunity. Conversely, TH0 cells differentiate into TH2 cells under the influence of 
IL-2 and IL-4 and produce IL-4, IL-5, IL-10 and IL-13 (30). Although TH2 cells can activate B cells 
to produce antibodies, cytokines including IL-10 and IL-13 can exert more of an 
immunosuppressive effect and favour a pro-tumour environment. Clinical studies have borne 
this out, with sera or peripheral blood lymphocytes from patients with melanoma (31) and 
colon cancer (32) showing elevated levels of TH2 cytokines, specifically IL-4 and IL-10. In 
contrast, when infiltrating immune cells from CRC specimens were examined, higher TH1 gene 
expression was associated with prolonged DFS (33). 
IL-6 and TGF-β induce differentiation into a TH17 phenotype. TH17 cells produce IL-17 and are 
implicated in hypersensitivity reactions, autoimmune disease and inflammation (34). The role 
of this population of CD4+ cells in tumour immunology is unclear. Notably, although patients 
with advanced gastric cancer have increased levels of TH17 cells in peripheral blood (35), the 
reverse has been demonstrated in patients with ovarian cancer (36).  
Under the influence of TGF-β (without IL-6), naïve CD4+ T cells differentiate into Tregs which 
express the transcription factor Forkhead box P3 (Fox-P3) (37). As the name suggests, Tregs 
are involved in the regulation of the immune response (and pertinently, the anti-tumour 
immune response) through the production of IL-10. Tregs are discussed in detail in 
section 1.2.3. 
1.2.2.2 Cytotoxic T Cells 
Activated CTLs can kill target cells (infected cells or tumour cells) in a number of ways. In a 
mechanism similar to NK cells, CTLs kill target cells via release of granzyme/perforin granules 
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(38). In addition, CTLs can induce apoptosis of target cells through engagement of Fas-L on the 
T cell and Fas receptor of the tumour cell, triggering apoptotic pathways and cell death (39). 
Activated T cells also produce cytokines which boost the immune response; for example, IFN-γ 
increases MHC expression on DCs (and thus further antigen presentation) (40).  
The presence of cytotoxic tumour-infiltrating lymphocytes (TILs) within the TME is associated 
with an improved prognosis in many different cancers including CRC (41,42), breast cancer 
(43) and melanoma (44).  
Some viruses cause down-regulation of host cell MHC to prevent CD8+ T cell-mediated cell 
death and subsequent destruction of the virus. Tumour cells employ similar mechanisms to 
avoid immune-mediated cytotoxicity by upregulating inhibitory receptors such as 
programmed cell death ligand 1 (PD-L1), the ligand for PD-1, in response to IFN-γ produced by 
activated CTLs (45). Downregulation of MHC-I by malignant cells (and hence decreased 
antigen presentation to CTLs) also contributes to immune evasion by tumours (20).  
Prolonged stimulation of the CTL population can eventually lead to tolerance to tumour 
antigens (46) with upregulation of immune checkpoints including PD-1 on T cells (47), 
decreased production of immune-stimulatory cytokines such as IFN-γ, reduced ability to 
control tumour growth in vivo and diminished T cell proliferation (48).  
1.2.3 Regulatory T Cells 
Tregs are thought to play a major role in the suppression of anti -tumour immunity and the 
subversion of T cell responses against tumour cells (49). They can be phenotypically defined as 
CD3+/CD4+/CD25high/CD127low/Fox-P3+.  
Patient-derived Tregs, analysed in vitro, produce both IL-10 and TGF-β (50) and prevent the 
proliferation and function (IFN-γ production) of both effector CD4+ (Fox-P3-negative) and 
CD8+ T cells (51,52). Immunosuppressive cytokines can themselves stimulate the 
differentiation of naïve TH0 cells into Tregs in peripheral blood. CD4+/CD25- T cells can be 
induced to differentiate into Tregs by TGF-β and TCR stimulation (53). In in vivo models of 
melanoma, Tregs accumulated at the site of B16 melanoma tumours (54). While CD8+ TILs 
demonstrated a specific anti-tumour response, the CD4+ TILs produced high levels of both IL-
10 and TGF-β but low levels of IFN-γ (suggesting a Treg rather than a TH1 phenotype) (54). 
Interestingly, inhibition of IL-10 in tumour-bearing mice led to a reduction in the proportion of 
CD4+ Tregs in splenocytes and decreased tumour growth. This was associated with diminished 
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TGF-β and elevated IFN-γ production, suggesting a further role for IL-10 (as well as TGF-β) in 
the development of Tregs and the suppression of anti -tumour immunity (54). 
Elevated populations of Tregs have been noted in both the peripheral blood and TILs of 
patients with many other cancers, including gastric (51), breast cancer (55) and CRC (56). As 
such, an increased proportion of Tregs has also been linked to poorer disease-specific survival 
(50,57). Antibodies against CD25 (daclizumab and basiliximab) are currently being investigated 
in the clinical setting (glioblastoma, NCT00626483 and melanoma, NCT00847106) with some 
evidence that they can deplete Treg populations and enhance anti -tumour responses (58).  
Tregs can act in a number of ways to suppress the anti-tumour immune response. CTLs and 
NK cells both exert direct cytolytic effects through secretion of granules containing perforin 
and granzyme. Tregs can induce apoptosis of CD8+ effector cells through engagement of Fas, 
which is upregulated on CD4+ and CD8+ T cells in response to activation by anti-CD3 antibody 
and IL-2 (59). Interestingly, upregulation of Fas-L expression is proportionately higher on Tregs 
from cancer patients, prompting the suggestion that Tregs can mediate apoptosis of tumour-
specific CTLs (59). In addition, Tregs have an adverse effect on DC function. Not only can Tregs 
can downregulate CD80/CD86 on DCs, thereby inhibiting DC-mediated stimulation of T cells 
(60) but engagement of CTLA-4 on Tregs with CD80/CD86 expressed on DCs can also suppress 
the function of these APCs (60).  
1.2.4 γδT Cells  
On average, γδT cells (CD3+/γδTCR+) constitute up to 10 % of the CD3+ T cell population. 
Unlike CD4+ and CD8+ T cells, the TCR of γδT cells is formed of one γ and one δ chain, rather 
than the α and β chains which make up the TCR of other T cel l subsets. As they are activated 
independently of MHC molecules, they produce a rapid (non-specific) immune response, more 
similar to that of innate effector cells (61). As with the differentiation of CD4+ T helper cells, 
γδT cells can also show a degree of plasticity in their functional capaci ty, acting in both 
immune-stimulatory and regulatory ways (62).  
Although their activation is largely independent of MHC, γδT cells actually have the capacity to 
be professional APCs: upregulating MHC-I in response to antigen stimulation, enhancing 
proliferation of effector CD8+ T cells and cytotoxicity of antigen-specific target tumour cells in 
vitro (63). Similar antigen-priming has also been observed by stimulation of CD4+ cells with 
γδT cells, enhancing their differentiation into a TH1 phenotype (64). γδT cells also exhibit 
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direct cytotoxic effects when expressing CD56. These CD56+ γδT cells have cytotoxic activity 
against tumour cells ex vivo: increased expression of CD107a suggests that cell death is 
mediated by perforin and granzyme release (65). Finally, in another mechanism similar to NK 
cells, γδT cells have ADCC capability (66).  
Contrary to these immune-stimulatory effects, γδT cells also exert regulatory, or 
immunosuppressive, properties. γδT cells stimulated with monoclonal antibody against the 
δTCR can be induced to express the transcription factor Fox -P3 as well as CD25 (a similar 
phenotype to ‘classical’ Tregs) (67). Furthermore, these regulatory γδT ce lls produce TGF-β 
and suppress T cell proliferation (67).  
1.2.5 Dendritic Cells 
DCs are a population of bone marrow progenitor-derived cells which can be broadly classified 
as either myeloid DCs (mDCs, also known as conventional/classical DCs, cDCs) or plasmacytoid 
DCs (pDCs). While pDCs produce high levels of type I interferons (IFN-α and -β) in response to 
activation of TLR-7 and TLR-9 (68) by PAMPs, they are very much in the minority, constituting 
less than 0.5 % of all peripheral blood mononuclear cells (PBMCs). Although pDCs can present 
antigen to T cells (as they express MHC-II and co-stimulatory molecules such as CD80/86 upon 
activation), they are much less potent than mDCs. Unlike mDCs, they do not express CD11c.  
Although a small proportion of circulating PBMCs, pDCs have shown a role in priming both an 
innate and adaptive immune response. Through production of type 1 IFNs, pDCs can stimulate 
activation of NK cells (68). Similarly, IFN production from pDCs can initiate differentiation of B 
cells into plasma cells and production of specific antibodies following stimulation with 
influenza (69). Despite mDCs being the more effective APC, pDCs are capable of antigen cross-
presentation (presentation of exogenous peptides to CD8+ cells on MHC-I through the 
phagocytosis of peptide antigens), triggering an IFN-γ response from antigen specific CD8+ T 
cells (70). Conversely, pDCs can initiate the differentiation of naïve CD4+ T cells to IL-10-
producing Tregs (71).  
mDCs are essential to the development of an antigen-specific adaptive immune response. 
They classically present endogenous antigens on MHC-I to CD8+ T cells and exogenous 
antigens on MHC-II to CD4+ T cells. Recognition of antigen on MHC molecules by TCRs initiate 
antigen-specific T cell activation and proliferation in the presence of a co-stimulatory signal 
(such as binding of CD28 on the T cell to CD80/86 on the APC). mDCs commonly express TLRs 
 
 
11 
 
2-6 and 8, plus CD11c (3) and can produce cytokines such as IL-12 upon activation. Although 
exposure and processing of antigens can take place in peripheral blood, tissue or tumour, 
upregulation of the chemokine receptor CCR7 on activated mDCs initiates their migration to 
LNs expressing the CCR7 ligands CCL19 and CCL21 (72). It is in the LNs that DCs encounter and 
prime naïve T cells.  
In the same way that pDCs can influence the differentiation of naïve T cells, mDCs can also 
direct polarisation of T cells. Activation of T cells is dependent on three signals from DCs: (i) 
engagement of MHC-antigen complex with the TCR; (ii) an additional co-stimulatory signal and 
(iii) the production of cytokines. Release of cytokines from DCs is modulated by stimulation 
through different signals: for example, interaction of OX40 on the T cell (also known as CD134, 
a member of the TNF family) with its ligand OX40-L, another co-stimulatory signal, stimulates 
TH2 differentiation (73). Upon activation of specific TLRs by pathogens, DCs will express 
various immunomodulatory cytokines which, in turn, exert effects on T cells. Activation of 
TLR-4 on human DCs in vitro, for example, has been demonstrated to initiate release of 
interferon-γ-induced protein-10 (IP-10, also known as CXCL-10) favouring TH1 differentiation, 
whereas TLR-2 stimulation provokes release of IL-12p40 and TH2 differentiation (74).  
In summary, DCs act to bridge elements of both the innate and adaptive immune system and 
are themselves influenced by their environment in how they are activated and how they, in 
turn, affect the priming and differentiation of naïve T cells.  
1.2.6 Monocytes and Macrophages 
Aside from the phagocytosis of pathogens, macrophages can act as APCs and produce a range 
of immune-modulatory cytokines. Mature macrophages differentiate from monocytes under 
the influence of macrophage-colony stimulating factor (M-CSF) and are resident in tissue and 
tumour sites. Monocytes can also differentiate into mDCs when stimulated in vitro by IL-4 and 
granulocyte macrophage-colony stimulating factor (GM-CSF). Usually identified by their 
expression of CD14, monocytes can also differentially express CD16: ‘classical’ monocytes 
highly express CD14, whereas the other subset of monocytes express proportionately lower 
CD14 but also CD16. These CD14+CD16+ monocytes (constituting 15-20 % of the monocyte 
population) also express high level MHC-II but exhibit decreased phagocytic potential than 
CD16- monocytes (75) and therefore are similar phenotypically to tissue-resident 
macrophages (TRMs) (76). TRMs maintain tissue homeostasis and so differentiate and 
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function in a plethora of ways dependent on the tissues they reside in: these i nclude Kupffer 
cells (liver), alveolar macrophages (lung) and Langerhans cells (skin).  
Chemotaxis of classical monocytes to the tumour environment is controlled by CCR2 and its 
ligand CCL2, also known as monocyte chemoattractant protein (MCP)-1, which is over-
expressed in various malignancies and is associated with inflammation (77). 
Similar to DCs, activation of classical monocytes though TLRs, for example TLR-4, stimulates an 
effector immune response. As IFN-γ and IL-2 upregulate monocyte expression of TLR-4, this 
illustrates the role of classical monocytes in the host response to bacterial pathogens (78,79).  
As with other cell types, variations in the immune environment can initiate differentiation of 
macrophages into cells with different functional capabilities. Ergo, IFN-γ can polarise 
macrophages into the TH1-like ‘M1’ phenotype, producing IFN-γ, TNF, IL-12 and IL-2. In 
contrast, cytokines such as IL-4, IL-10 and IL-13, produced in the TME (80), facilitate 
differentiation into the ‘M2’ phenotype, which are not only poor APCs but have similar 
properties to TH2 cells and produce cytokines such as IL-4 and IL-10 (81). Tumour-associated 
macrophages (TAMs, which exhibit the M2 phenotype) produce cytokines which potentiate 
the ‘pro-tumourigenic’ environment, such as CCL22, which induces Treg migration into 
tumour in vivo (57).  
Moreover, M2 TAMs can stimulate angiogenesis in the TME, further supporting tumour 
growth and survival by contributing to the ‘angiogenic switch’ which initiates vascular 
development in hypoxic tumours. This is associated with the production of pro-angiogenic 
factors such as IL-8 (also known as neutrophil chemotactic factor or CXCL-8) (82) and vascular 
endothelial growth factor (VEGF) (83). As such, increased TAM infiltration is associated with 
increased tumour neo-vascularisation. Other mechanisms by which TAMs encourage tumour 
growth and progression include expression of PD-L1, the engagement of which by PD-1 on T 
cells inhibits adaptive immune responses against tumour antigens (84).  
High TAM infiltration is poorly prognostic and/or associated with distant metastasis in a 
variety of tumours, including bladder (85,86), gastric (86) and ovarian cancers (86). 
Interestingly, an increased macrophage population in the TME of patients with prostate 
cancer (87) and CRC (86) is associated with an improved prognosis, although this may be 
skewed by the phenotype of infiltrating cells being predominately M1. This further highlights 
the complexities of the immune milieu in the TME, which determines the phenotype of TAMs 
and their clinical effect.  
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1.2.7 Myeloid-Derived Suppressor Cells 
Myeloid-derived suppressor cells (MDSCs) are a heterogenous population of immature cells of 
myeloid lineage which are increased in states of infection, inflammation and cancer where 
they exert an immunosuppressive effect on anti-tumour immune responses. MDSCs express 
the myeloid markers CD11b and CD33 but are negative for lineage markers including CD3, 
CD4, CD19 and CD56, in addition to HLA-DR. Differentiation of this population of 
immunosuppressive cells is in response to various cytokines and chemokines, including GM-
CSF (88), IL-13 (89), IL-10 and TGF-β (90) and they are recruited into tumour sites by 
chemokines such as CCR2 (91). MDSCs have been associated with poorer prognosis in a 
number of different malignancies, likely due to their suppressive effects on the anti -tumour 
response (92).  
MDSCs can exert an immunosuppressive action through the interruption of IFN signalling 
pathways (section 1.3.1.1) and responsiveness of immune cells to TH1 signalling by nitric oxide 
(NO), as demonstrated in murine in vivo melanoma models (93). They can also, through 
production of IL-10 and TGF-β, induce the differentiation of Tregs in the TME and, as such, 
ongoing immunosuppression at the tumour site. In addition to suppressing T cell activation 
and proliferation in response to peptide antigens (94), there is also evidence that the 
production of ROS and NO by MDSCs can affect the integrity of TCR-MHC complexes involved 
in T cell priming (95).   
Antibody-depletion of the MDSC population enhances both innate and adaptive immune 
responses in murine models of lung cancer (92). Furthermore, chemotherapeutic agents, such 
as gemcitabine and 5-fluorouracil (5-FU), can exert immunomodulatory effects by decreasing 
the number of MDSCs in situ (96,97).  
1.2.8 Neutrophils 
As an important part of the innate immune response, neutrophils (CD15+/CD16+) react 
rapidly to bacterial pathogens, migrating to areas of inflammation in response to chemokines 
such as IL-8 and CXCL-2 (98). They constitute approximately 70 % of circulating white blood 
cells (WBCs) and with basophils and eosinophils form the granulocyte population of WBCs. 
Basophils and eosinophils are involved in allergic reactions and host defence against parasites.  
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One of the main functions of the neutrophil is to engulf microbes, bacteria and other 
extracellular pathogens through phagocytosis: PRRs on the surface of the cell recognise 
PAMPs or antibodies bound directly to the pathogen. Such pathogens are then engulfed by 
the neutrophil and incorporated into the cell as a phagosome (98). The contents of the 
phagosome can then be destroyed by merging with enzyme-containing lysosomes within the 
cell or by the production of ROS (98). Neutrophils can also function through degranulation and 
through neutrophil extracellular traps (NETs): extracellular networks of DNA which can bind to 
trap pathogens and contain anti-microbial molecules such as proteolytic enzymes. 
In the same way that the TME can manipulate the phenotype of TAMs, tumour-associated 
neutrophils (TANs) exhibit pro-tumour characteristics (99). TGF-β blockade in in vivo models of 
mesothelioma increased infiltration of neutrophils into the TME, with associated ROS-
mediated tumour cell cytotoxicity (100). Interestingly, depletion of neutrophils in the absence 
of TGF-β blockade also enhanced CD8+ T cell activation, suggesting different phenotypes of 
neutrophils in the TME: ‘N1’ (anti-tumour) TANs, in the absence of TGF-β and ‘N2’ (pro-
tumour) TANs, in the presence of TGF-β (100). Assessment of the peripheral blood of patients 
with melanoma reveals that an increasing neutrophil count corresponds with stage of disease. 
These neutrophils inhibit proliferation of melanoma-antigen specific CD8+ T cells through IL-
10 production (101). The ‘N2’ phenotype is associated with the progression of liver 
metastases in mouse models of breast cancer (102).  
The role of neutrophils in CRC is discussed in further detail in section 4.1.6.2. 
1.2.9 B Cells 
B cells (CD19+) form the cornerstone of the humoural adaptive immune response and, as 
such, there is growing recognition of - and investigation into - their role in anti-tumour 
immunity. Following binding of antigen to the B cell receptor, internalisation and processing 
leads to its presentation on MHC class II molecules, which initiates an immune response in a 
number of ways. Firstly, engagement of the MHC-II complex by TCR and co-stimulatory signals 
initiates antigen-specific T cell proliferation and activation. Secondary, stimulatory signalling 
by production of cytokines, such as IL-4, from the T cell initiates differentiation of the B cell 
into a mature plasma cell, capable of producing antigen-specific antibodies. In addition, 
secretion of cytokines such as IFN-γ, TNF-α, IL-2 and IL-12 continue to perpetuate an immune 
response though mechanisms such as further differentiation of TH1 cells. Once tumour cells 
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are opsonised by antibody (bound to specific surface antigens), death can be mediated 
through either phagocytosis or ADCC.  
Effector functions of B cells may also differ as a consequence of alternative stimulation. B cells 
co-cultured with TH1 cells, for example, produce higher levels of IFN-γ and IL-2, whereas those 
cultured with TH2 cells produce greater levels of IL-2, IL-6 and IL-10 (103). Thus, in a similar 
fashion to other immune cells (T helper cells, neutrophils, macrophages), B cells can exh ibit 
both pro- and anti-tumourigenic properties. Given that tumour-specific antibodies can be 
detected in the blood of cancer patients (104), suppressive mechanisms must also exist, in 
that the presence of such antibodies does not result in spontaneous tumour rejection (or 
prevention of tumour development). Tumour inoculation of breast cancer cells in vivo has 
been shown to initiate a humoural response with increased antibody production (105). 
Despite this, the presence of B cells inhibited T cell -mediated anti-tumour responses. One 
possible explanation may be increased competition between B cells and APCs, which is 
abrogated in a B cell-depleted environment, where anti-tumour responses were restored 
(105).  
Co-culturing human B cells and CD4+ T cells ex vivo has demonstrated that B cells can induce 
the differentiation and expansion of a potently immunosuppressive Treg population (106). 
There is also data supporting a regulatory B cell phenotype, which suppress IFN-γ production 
(and hence T cell responses to antigen) through the production of IL-10 (107). As such, B cell 
depletion in murine models of melanoma enhanced tumour-antigen-specific T cell responses 
(107).  
1.3 Cytokines and Chemokines 
Cytokines are proteins secreted by cells which are involved in al l aspects of biological function, 
including cell-to-cell communication, immune activation and inhibition. They can be broadly 
divided into pro-inflammatory and suppressive cytokines. Other categories also exist: 
interleukins, involved in cellular interactions between leucocytes; haematopoietic cytokines, 
involved in blood cell formation (e.g. GM-CSF, G-CSF) and those cytokines involved in humoral 
immunity, such as IL-4. For the purposes of this thesis, only the following examples have been 
discussed in specific detail.   
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1.3.1 Pro-Inflammatory Cytokines 
1.3.1.1 Interferons 
IFNs are broadly categorised into three groups: type I (including IFN-α and IFN-β), type II (IFN-
γ) and type III (the IFN-λ family, including IL-28 and IL-29). They exert their individual functions 
through receptive IFN-stimulated genes (ISGs).  
IFN production is stimulated by the engagement of PRRs (such as TLRs) with PAMPs from 
viruses (and other pathogens). TLR-7 and -8, for example, recognise PAMPs from RNA viruses 
such as vesicular stomatitis virus (VSV) and influenza, whereas TLR-9 recognises DNA viruses 
such as herpes simplex virus (HSV). TLR-4 initiates production of type I IFNs following 
activation by the LPS from bacterial membranes (108).  
Type I IFNs are predominantly - but not exclusively - released as part of an anti-viral response 
by lymphocytes including T cells and NK cells. Immune cells produce both IFN-α and -β, while 
other cells such as fibroblasts and epithelial cells produce IFN-β. These bind to the type I IFN 
cell-surface receptor, which engages with a part of the intracellular Janus Kinase-Signal 
Transducer and Activator of Transcription (JAK-STAT) pathway (109). Subsequent 
phosphorylation and activation of the JAK-STAT pathway initiates transcription of ISGs (110). 
As well as release of IFN-γ (the actions of which are discussed below), the transcription of 
these ISGs results in proteins that can inhibit various stages of viral entry, cell infection and 
replication. ISGs also stimulate an immune response by increasing the ability of APCs to prime 
adaptive immune responses through increased expression of MHC molecules (111), activation 
of NK cells, stimulation of antibody production by B cells (112) and upregulation of apoptosis-
inducing molecules such as TRAIL (section 1.3.1.2) (113). 
Viruses can manipulate type I IFN signalling pathways to subvert the anti-viral effects of IFNs: 
hepatitis C virus, which is implicated in the pathogenesis of  hepatocellular carcinoma (HCC), 
can inhibit JAK-STAT signalling (114).  
IFN-γ is secreted by NK cells, macrophages, APCs and T cells. Binding of IFN -γ to its receptor 
induces interaction with intracellular JAK1 and JAK2 (109). Hence, it also induces intracellular 
signalling of the JAK-STAT pathway and ISG transcription. In contrast to the production of type 
I IFNs, IFN-γ production from immune cells can be stimulated by IL-12 (secreted by 
macrophages in response to pathogens), IFN-α (as discussed above) and IL-18 (also known as 
IFN-γ inducing factor), secreted by monocytes and macrophages (115–117). Secretion of IFN-γ 
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is inhibited by cytokines such as TGF-β and IL-4 (118). The functions of IFN-γ are incredibly 
wide and various but include upregulation of MHC molecules to enhance antigen presentation 
(111), activating monocyte and macrophage activity against pathogens (79) and perpetuating 
a TH1 response by activating NK cells and T cells (including through the upregulation of APC co-
stimulatory molecules such as CD80 and CD86 (119)).  
In malignant disease, IFNs exert multiple anti-tumour effects though similar pathways: 
upregulation of TRAIL and Fas by IFNs can contribute to cancer cell apoptosis (113,120). 
Similarly, the effects of type I IFNs on the inhibition of cell proliferation and cell cycle stasis 
has been demonstrated in prostate cancer cell lines (121) and melanoma (122). In the TME 
IFNs can induce polarisation of macrophages into an ‘anti-tumour’ phenotype (section 1.2.6). 
Type I IFNs have also been shown to increase the expression of TAAs (123) and maintain T cell 
populations (124), contributing to the priming of an adaptive anti-tumour response. Of note, 
while IFNs generally create an immune-stimulatory environment, this leads to the 
upregulation of checkpoint molecules such as CTLA-4 and PD-1/PD-L1 which can down-
regulate immune responses (125).  
Because of their immune-stimulatory properties, IFNs have been used in cancer 
immunotherapy, particularly in immunogenic malignancies such as renal cell carcinoma (RCC) 
(126) and melanoma (127,128) but their use has declined in recent years due to a 
combination of poor toxicity profile and newer immunotherapy agents (such as the 
checkpoint inhibitors) which offer an increased chance of response and improved outcomes.  
1.3.1.2 TNF-Related Apoptosis-Inducing Ligand 
TRAIL is a member of the TNF family which can initiate apoptosis of tumour cells through 
engagement with death receptors (DR) 4 (also known as TRAIL-receptor 1, TRAIL-R1) and DR5 
(TRAIL-R2) (129). TRAIL is produced by T cells, NK cells, monocytes and DCs. As expected, the 
higher levels of DR4/5 observed in neoplastic cells (compared to normal epithelial cells) 
correspond to greater target cell apoptosis (130) and reduced tumour growth in in vivo 
murine models of breast cancer (129).  
Although TRAIL is expressed constitutively on a range of normal tissues, immune cells may 
only express low levels of the molecule. Upregulation of TRAIL by IL-2 and IL-15 increases NK 
cell-mediated apoptosis of L929 fibrosarcoma cells in vivo (131). Stimulation of monocytes by 
IFN-γ and IFN-α can enhance TRAIL-mediated apoptosis of a range of malignant cell lines, 
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including ovarian, colorectal and prostate carcinoma cells through a similar mechanism (132). 
CD4+ T cells can also exert an apoptotic effect on melanoma cell lines through TRAIL (133). 
TRAIL-mediated apoptosis of tumour cells can also be augmented in in vivo models of breast 
cancer by pre-treatment with chemotherapeutic agents including paclitaxel, vincristine, 
vinblastine, etoposide and doxorubicin which up-regulate DR4/5 death receptors (134). 
Similarly, CPT-11 (irinotecan) can increase TRAIL-mediated apoptosis of colorectal tumour 
cells through the same mechanism (135). 
Although cell death can be initiated through interaction between TRAIL and DR4/DR5, the 
other TRAIL receptors, TRAIL-R3 and TRAIL-R4 (also known as DcR1 and DcR2, respectively), 
appear to inhibit the apoptotic effect of TRAIL, possibly through competitive binding of the 
ligand. As such, expression of TRAIL-R3 confers protection against TRAIL-mediated apoptosis 
of tumour cell lines (136).  
Due to an apparent ability to preferentially target tumour cells for apoptosis, TRAIL-based 
therapeutic agents would be attractive. Although a range of phase I and II trials have been 
completed, (including those of mapatumumab, a monoclonal antibody to TRAIL-R1 (137,138)), 
such therapy has not yet progressed to routine clinical use due to a paucity of patient 
responses. 
1.3.2 Immunosuppressive Cytokines 
1.3.2.1 Transforming Growth Factor-β  
TGF-β is an immune regulatory cytokine produced by a wide range of cells in response to 
stimulation by signals including mitogen-activated protein kinases (MAPK) pathway activation 
and cytokines such as TNF-α and TGF-β itself. Signal transduction through intracellular 
signalling pathways leads to TGF-β target gene transcription in the nucleus, controlling 
multiple different regulatory cell and immune responses, cell proliferation, differentiation and 
apoptosis, amongst others (139). TGF-β is usually associated with inhibition of cell 
proliferation, for example through inhibition of cell cycle progression through G1 by the 
production of proteins which block this process (reviewed in (140)). However, this mechanism 
seems disrupted in malignant disease. Levels of TGF-β are elevated in the serum of patients 
with cancer (141,142) and resistance to TGF-β-mediated cell death may be due to a number of 
mechanisms, including downregulation of TGF-β receptors (143). Thus, the anti-tumour 
effects of TGF-β may be outweighed by resistance mechanisms in the TME and the other 
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effects that TGF-β has in encouraging the epithelial-mesenchymal transition process, tumour 
invasion and metastases (144).   
In contrast, TGF-β has many effects on the function of immune cells which ultimately may 
favour tumour growth. In vitro cultures with exogenous TGF-β inhibit NK cell proliferation and 
production of both IFN-γ and TNF-α (145). It can also downregulate activating NK cell surface 
receptors (146,147) and affect the mobility of DCs to the LN, both increasing the chance of 
metastatic LN spread but also impeding antigen presentation (and T cell expansion) (148). It 
also stimulates differentiation of immune cells from ‘anti -tumour’ to ‘pro-tumour’ 
phenotypes, such as macrophages from M1 to M2 (section 1.2.6) and neutrophils from N1 to 
N2 (section 1.2.8) (81,100). 
Some of the effects of TGF-β on T cell functionality is mediated though it’s inhibitory effects 
on cytokines such as IL-2 (139). It is also implicated in the impairment of effector memory T 
cell function: memory T cells from patients with melanoma re-stimulated ex vivo with antigen 
produced significantly lower amounts of IFN-γ than those cultured in the absence of TGF-β 
(149). As such, in vivo models of prostate cancer using TGF-β-resistant CD8+ T cells 
demonstrated reduced tumour growth and angiogenesis (150). Furthermore, TGF-β is 
responsible for inhibiting TH1 differentiation of CD4+ naïve T cells and stimulating 
differentiation of this population into Tregs. Clinical trials of anti -TGF-β antibodies and small 
molecules are ongoing and seem to have tolerable safety profiles in early-phase trials (151).  
1.3.2.2 Interleukin-10  
IL-10 is produced by cells including Tregs, TH2 T cells, monocytes, B cells and NK cells. Much 
like the IFNs, binding of IL-10 to its receptors (expressed on most cells) induces intracellular 
signalling through the JAK-STAT pathway and transcription of IL-10-dependent genes.    
The exact mechanisms through which each cell type are stimulated to produce IL-10 are 
complex and not clearly delineated but can involve PRRs (such as TLRs) being activated by 
extracellular signals which are transduced into intracellular signalling, such as MAPK activation 
(152). IL-10 production is upregulated in response to inhibitory signals. As such, PD-1 
expression on monocytes increases during chronic human immunodeficiency virus (HIV) 
infection and interaction between PD-1 and PD-L1 stimulates IL-10 production (153). The 
production of IL-10 consequently inhibits the proliferation and cytokine production (IFN-γ and 
IL-2) by CD4+ cells (153).  
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IL-10 is a potent modulator of antigen presentation and exerts many effects through DCs, such 
as inhibiting their production/maturation (154) or decreasing the potential of 
monocytes/macrophages as efficient APCs (155). Additionally, IL-10 downregulates the 
expression of the B7 co-stimulatory molecules on APCs (156) and MHC class II on APCs, 
hampering the efficient presentation of antigen and abrogating proliferation of T cells in 
response to antigen stimulation (157). Consequently, blocking IL-10 signalling with anti-IL-10-
antibody in in vivo murine models of cervical cancer decreases tumour growth (158). IL-10 
also mediates the differentiation of TH2 cells and inhibits cytokines such as IL-2, IL-12 and IFN-
γ and inflammatory cytokines such as TNF-α (159).  
Unsurprisingly, higher IL-10 concentrations have been associated with poor prognosis in 
cancer. Levels of IL-10 in serum have been detected at elevated levels in patients undergoing 
surgery for CRC and were associated with higher stage and predicted recurrence rates 
following surgery (160). Similarly, pre-treatment quantities of IL-10 were lower in melanoma 
patients who went on to have a good response to therapy with B-rapidly-accelerated 
fibrosarcoma (BRAF) inhibitors (BRAFi) (161). 
1.3.3 Chemokines 
Chemokines are a subgroups of cytokines involved in chemotaxis: movement of specific cells 
towards an intended target, including migration of immune cells and the metastasis/invasion 
of tumour cells (reviewed in (162)). Regulated on activation, normal T cell expressed and 
secreted (RANTES, CCL5), for example, is a chemoattractant for T cells expressing the CCR5 
ligand. Consequently, it has been found at higher levels in melanoma tumours infiltrated by T 
cells (163). IL-8 (CXCL-8) is a neutrophil chemotactic factor whereas IP-10 (CXCL-10) and 
monokine induced by gamma-interferon (MIG, CXCL-9) both attract monocytes. The receptor 
for both IP-10 and MIG, CXCR3, is expressed on T cells and is responsible for the chemokine-
mediated migration of immune cells into TMEs where IP-10 and MIG are secreted (164). 
MIG also exerts angiostatic properties and, as such, treatment with MIG has been shown to 
attenuate non-small cell lung cancer (NSCLC) tumour growth in vivo (165). Lower expression 
of IP-10 is associated with poorer prognosis in stage II and III CRC (166). Despite this, 
upregulation of IP-10 in CRC cell lines enhances factors associated with metastasis and 
invasion, such as matrix metalloproteinase (MMP) expression, which degrades the 
extracellular matrix and allows cell migration (165).  
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1.4 Inflammation in Cancer 
Inflammation is the normal physiological process used to fight infection and other biological 
insults or pathogens. It primarily involves the mobilisation of phagocytic immune cells 
(neutrophils and macrophages) through production of chemokines/cytokines, acute phase 
proteins such as CRP, complement and coagulation factors, such as fibrinogen, to sites of 
injury. Inflammation is generally a positive response to an insult: indeed, the biological 
processes involved in acute inflammation have been exploited in the management of early 
cancers, such as in the use of intravesical Bacillus Calmette-Guérin (BCG) for the management 
of superficial bladder tumours. There is, however, an overlap between this normal 
physiological response and many of the factors that can contribute to tumourigenesis. In fact, 
inflammation is known to be associated with the development of tumours and is considered 
to be one of the hallmarks of cancer (1). The link between inflammatory bowel disease and 
CRC, Helicobacter pylori infection and gastric cancer, viral hepatitis and HCC and smoking and 
lung cancer all illustrate the relationship between chronic inflammation and tumourigenesis. 
Inflammation and cancer are linked in many complex ways but there are two pathways which 
broadly delineate this association. Firstly, genetic mutations lead to the development of 
malignant cells, which, in turn, produce cytokines and other molecules creating an 
inflammatory environment (intrinsic pathway). Secondly, an underlying inflammatory 
condition induces oncogenesis and the development of tumours (extrinsic pathway) (167). 
Illustrating this concept, the induction of pancreatitis can lead to the development of 
pancreatic ductal carcinoma in mice bearing mutations in the Rat Sarcoma proto-oncogene 
KRAS (168). Mutations in the ‘rearranged during transfection’ (RET) oncogene, which is 
associated with the development of thyroid cancers, can induce a pro-inflammatory 
environment. Expression of RET in normal thyroid cells upregulates the expression of genes 
encoding a wide variety of inflammatory mediators including the cytokines IL-1 and GM-CSF 
and the immune cell chemokines CXCL-10 and CXCL-12. Additionally, factors associated with 
tumour metastases, such as MMPs, were also upregulated (169).  
The production of chemokines and cytokines, plus activation of certain transcription factors, 
either as the result of inflammatory disease or oncogenesis, contribute further to tumour cell 
development, proliferation and survival. As an example, IL-1α and IL-1β, key pro-inflammatory 
cytokines, have been shown to play an essential role in tumour metastases and neo-
vascularisation in mouse models of melanoma (170). Another inflammatory cytokine, IL-6, 
which can stimulate the production of neutrophils in response to infection, supports tumour 
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cell growth and proliferation through activation of STAT3 (171). Production of IL-6 in this 
model of lung cancer is also upregulated by mutations in the epithelial growth factor receptor 
(EGFR) (171).  
The presence of pro-inflammatory mediators can also contribute to the accumulation of 
genetic mutations which can increase the predilection for malignant transformation. ROS and 
NO released by TILs can cause DNA damage and inhibit the activity of the tumour suppressor 
gene p53, which has a role in the repair of DNA damage (167).  
The interplay between each of these factors: activation of transcription factors which enhance 
cell proliferation, increased chromosomal instability and genetic damage, immune cell 
infiltration and possible underlying mutations in oncogenes culminate in a strongly pro-
tumourgenic environment through manipulation of the normal biological processes involved 
in inflammation.  
1.5 Immune Effects of Anti-Cancer Therapy 
Systemic anti-cancer therapy (SACT) can generate an anti-tumour immune response in a 
number of ways, most simply by initiating tumour cell death and release of TAAs which has 
the potential to prime an adaptive immune response. However, there are other mechanisms 
through which SACT can directly and indirectly modulate the immune system, dependent on a 
number of factors including the type of therapeutic agent, tumour type and baseline immune 
functionality of the patient. Conversely, treatment-mediated tumour cell death, although 
leading to antigen release, subsequently generates a clone of tumour cells resistant to therapy 
and which have the potential to metastasise.  
1.5.1 Chemotherapy 
Although established dogma states that traditional cytotoxic chemotherapy regimens are 
immunosuppressive, it is becoming more obvious that these chemotherapy drugs can actually 
contribute to an anti-tumour response, rather than tumour tolerance. Therefore, in addition 
to specifically targeting the tumour itself, there is more of an appreciation that the immune 
effect of cytotoxic chemotherapy can be exploited for further clinical benefit.  
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1.5.1.1 Taxanes (Paclitaxel and Docetaxel) 
Taxanes are anti-microtubular agents originally derived from the yew tree. They exert an anti -
cancer effect by preventing cell division through their effect on microtubules, which form an 
integral part of the cell cytoskeleton. Docetaxel therapy can decrease the proportion of Tregs 
in peripheral blood of patients receiving treatment for metastatic castrate-resistant prostate 
cancer (172) without any significant change in either the total number of PBMCs or the CD4+ 
population. Similar results are seen in patients receiving docetaxel for metastatic breast 
cancer and those receiving cisplatin and vinorelbine for NSCLC in the adjuvant setting (172).   
Taxanes have been shown to change the cytokine profile in patients receiving treatment for 
breast cancer. Compared to healthy controls, levels of IL-2, IFN-γ and GM-CSF are reduced in 
patients prior to chemotherapy, whereas levels of TNF-α and IL-6 were elevated (173). 
Treatment with either paclitaxel or docetaxel reversed these findings and was associated with 
both an increase in NK cell-mediated cytotoxicity against target tumour cells and enhanced T 
cell proliferation (173). Additionally, cytolytic activity of immune cells, including macrophages, 
against tumours is enhanced following treatment with paclitaxel (174,175). 
1.5.1.2 5-Fluorouracil 
The anti-metabolite 5-FU inhibits the enzyme thymidilate synthase (TS), which is involved in 
DNA synthesis. While taxanes can modulate the immune response by depleting Tregs, 5-FU 
has been shown to diminish populations of MDSCs in vivo (96), without affecting other 
immune cell populations. This may be mediated by low expression of TS by MDSCs; sensitivity 
of tumour cells to 5-FU has been shown previously to be related to TS expression (176,177). 
Depletion of these immunosuppressive cells leads to subsequent enhancement of CD8+ T cell -
modulated anti-tumour immune responses (96). Both 5-FU and irinotecan (CPT-11, which 
disrupts DNA replication through the inhibition of the topoisomerase enzymes), also mediate 
the death of CRC cell lines in vitro by enhancing CTL-mediated tumour cell lysis (178).  
Patients with oesophageal cancer have been found to have greater infiltration of immune 
effector cells into the TME after receiving neoadjuvant chemotherapy (179). Treatment with 
pre-operative 5-FU (and cisplatin) was associated with more CD4+ cells in the tumour bed and 
CD8+ cells in adjacent stroma. This was not associated with a concomitant increase in Tregs 
(179). Infiltration of these immune cells in both the tumour mass and tumour stoma have 
been associated with improved prognosis (180). 
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1.5.1.3 Cyclophosphamide 
Cyclophosphamide is an alkylating agent, which causes DNA damage by cross-linking DNA 
strands and preventing DNA replication. It can deplete Tregs (independent of the total CD4+ 
population) and slow the progression of murine colon cancer tumours in vivo (181). This effect 
is mirrored in patients with advanced cancer, who are shown to have higher numbers of 
circulating Tregs compared to healthy volunteers. Low dose cyclophosphamide reduces the 
number of circulating Tregs, without affecting other immune-cell subsets; this is associated 
with an increase in both NK cell-mediated tumour cell lysis and T cell proliferation ex vivo 
(182). Aside from a reduction in the number of Tregs, thought to be attributable to increased 
apoptosis of cells induced by the drug (183), cyclophosphamide can also reverse Treg-
mediated suppression of CD8+ and CD4+CD25- T cell proliferation (183). Unfortunately, this 
effect has not been borne out in early phase trials of cyclophosphamide given in combination 
with an oncolytic virus: populations of Tregs were not modified with combination therapy and 
there was no suppression in levels of anti-viral titres (184). 
1.5.1.4 Anthracyclines 
Anthracyclines such as doxorubicin and epirubicin exert anti-cancer effects through a range of 
mechanisms, including cross-linking of DNA strands (like alkylating agents), generation of ROS 
that damage DNA, proteins and cell membranes and activation of p53. Doxorubicin has long 
been known to have immunomodulatory effects. It has been observed in vivo that splenocytes 
treated with doxorubicin have greater cytotoxicity against target tumour cell lines compared 
to untreated splenocytes (185). Similarly, PBMCs from patients treated with doxorubicin 
exhibit enhanced cytotoxicity against tumour targets, which is likely mediated by increased IL-
2 and greater numbers of CD8+ T cells (186). Doxorubicin can also activate TLR-3, initiating a 
type I interferon response similar to the anti-viral response, to stimulate the production of IP-
10 (187). 
1.5.1.5 Gemcitabine 
Gemcitabine causes tumour cell death by being incorporated into DNA, preventing cell 
replication and division. As well as having the potential to diminish populations of 
immunosuppressive MDSCs like 5-FU (97), gemcitabine can have differential effects on various 
elements of the immune system. Whilst in vivo treatment with gemcitabine caused the 
expected depletion of both lymphocyte and B cell populations, T cell responses to TAAs were 
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enhanced by therapy (188). Conversely, B cell-mediated antibody production was abrogated 
(188).  
1.5.2 Checkpoint Inhibitors 
In addition to stimulatory signals such as engagement of CD80/CD86, there are a wide variety 
of inhibitory ‘checkpoint’ molecules which act at the immunological synapse to regulate 
immune responses against TAAs. These include the immune checkpoints CTLA-4 (which binds 
to CD80/CD86) and PD-1 and its ligand PD-L1. However, with the expanding interest in 
immunotherapy and immune checkpoint blockade, more attention is being paid to the 
potential of other receptors including LAG-3 and TIM-3. Targeting these molecules effectively 
inhibits the negative-feedback response to immune stimulation, thereby increasing the effect 
against tumours. Use of antibodies against CTLA-4, PD-1 and PD-L1 (and combination 
therapies) have been established in the clinic in diseases including mel anoma (189), lung 
cancer (190,191) and RCC (192) and other targeted antibodies therapies are currently making 
their way through clinical trials. The clinical efficacy of checkpoint inhibitors in melanoma will 
be discussed in more detail in section 5.1.4.3.1.  
 
 
Figure 1.1 Checkpoint inhibition by anti-CTLA-4 and anti-PD-1/-L1 antibodies 
T cells are activated following engagement between the TCR and the MHC/antigen 
complex, as well as co-stimulatory signalling through binding of CD28 and CD80/86. CTLA-4 
competitively binds with CD80/86 to switch off T cell activation. This process is blocked by 
CTLA-4 antibodies (a). Similarly, anti-PD-1 and anti-PD-L1 antibodies block PD-1/PD-L1, 
respectively, at the interface between tumour cells and T cells (b). 
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1.5.2.1 CTLA-4 
Following T cell activation, CTLA-4 expression on the cell surface is upregulated and will 
competitively bind with CD80/86 co-stimulatory molecules on the surface of APCs. As this is 
with higher affinity than CD28, T cell activation is effectively switched off. Anti-CTLA-4 
antibodies, therefore, block this mechanism and the T cell remains activated, with ongoing 
proliferation (193) and amplification of antigen-specific responses (Figure 1.1a). In a small 
number of heavily-pretreated patients with metastatic melanoma receiving the fully 
humanised anti-CTLA-4 antibody ipilimumab, a higher proportion of CD4+/ICOS+ or 
CD8+/ICOS+ cells by week 7 of therapy correlated with disease control. An increase in these 
populations of activated T cells were also associated with greater OS (194). Similarly, 
activation of CD4+ and CD8+T cells was enhanced in patients with melanoma and RCC 
receiving anti-CTLA-4 antibody (195).  
As well as the enhancement of T cell responses, checkpoint inhibition can also affect the 
immunosuppressive action of Tregs, which not only constitutively express CTLA-4 but also PD-
1, PD-L1, TIM-3 and LAG-3. Although there is conflicting data in both animal and human 
models, there is evidence that the suppressive effect of Tregs is dependent, to some extent, 
on the presence of CTLA-4 (60,196). In patients with advanced prostate cancer, treatment 
with ipilimumab increased the proportion of both activated CD4+ effector cells and Tregs 
(193). Similar findings have been seen ex vivo from samples of patients treated with 
metastatic melanoma and RCC: anti-CTLA-4 blockade seem to exert an effect through 
enhanced activation of T cell populations rather than decreased Treg activity (195). Indeed, if 
Treg populations are depleted prior to treatment with anti -CTLA-4 antibody (on this occasion 
with the humanised antibody tremelimumab), there is evidence of increased effector T cell 
proliferation in vitro and in vivo. This corresponds to elevated cytotoxicity against specific 
target cell lines (197). Presumably, in the absence of Treg suppression, activation of CD4+ cells 
triggers increased expression of CTLA-4 as part of normal feedback and thus making target 
tumour cells more susceptible to CTLA-4 blockade (197). This is supported by further in vivo 
data which demonstrates that, in murine models of melanoma, blocking CTLA-4 on both Treg 
and effector T cells prolonged survival and significantly decreased tumour growth (198). 
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1.5.2.2 PD-1/PD-L1 
In contrast, the interaction between PD-1 and PD-L1 is at the interface between immune cells 
and tissues/tumour (rather than CTLA-4 on the T cells and APCs in the LN). T cells, which have 
already been primed against antigens, travel to antigen-positive tissue to exert their effect. 
Following activation, IFN-γ and other pro-immune inflammatory signals upregulate PD-1 and 
PD-L1 (199), thereby abrogating the T cell response at the site of infection/tumour (Figure 
1.1b) . In contrast to CTLA-4, PD-1 is also expressed on B cells and NK cells and so PD-1 
blockade with anti-PD-1 (or PD-L1 antibodies) may have multi-factorial effects including 
antibody production and innate NK cell-mediated cytotoxicity. Expression of PD-1 on tumour-
infiltrating immune cells (200) and PD-L1 on tumour cells are both increased in malignancy 
(199). Indeed, higher PD-L1 expression on tumour cells has been associated with poorer 
prognosis (201). 
In addition to abrogating T cell activity, the engagement of PD-1 on antigen specific T cells and 
PD-L1 on target tumour cells has been shown to amplify apoptosis of CTLs (199). Interestingly, 
the efficacy of anti-PD-1 therapy does not seem to be wholly dependent on PD-L1 expression 
on tumour cells: in in vivo models of CRC, mice with PD-L1 knockout tumours still responded 
to anti-PD-L1 therapy (202). This is particularly pertinent given that current guidance for using 
the humanised IgG4 anti-PD-1 antibody pembrolizumab in patients with NSCLC is based on 
PD-L1 expression in the tumour. As PD-L1 is also expressed on DCs, blocking PD-1 also leads to 
increased T cell activation and cytokine production though stimulation of the TCR by activated 
DCs (203). Constant stimulation of T cells, in either chronic infection or cancer, can lead to 
ongoing PD-1 expression and T cell anergy. Blocking PD-1 or PD-L1 in this context can boost 
proliferation, cytotoxicity and IFN-γ production of this population of previously ‘exhausted’ T 
cells (204), highlighting the potential for anti-PD-1/-L1 therapy in malignant disease.  
1.5.2.3 TIM-3, BTLA and LAG-3 
TIM-3 binds to galectin-9, one of a number of proteins which are responsible for 
transmembrane signalling and cell-cell interactions. It is expressed constitutively on NK cells 
(especially the CD56dim phenotype) (205). As seen with other inhibitory immune checkpoints, 
TIM-3 is upregulated on activated antigen positive CD8+ T cells (206) and CD4+ TH1 cells (207). 
Engagement of TIM-3 and galectin-9 decreases TH1 effector cell proliferation and IFN-γ 
production (207) and therapy with anti-TIM-3 antibody can reduce tumour burden in an in 
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vivo model of murine sarcoma (208). Phase I clinical trials of the anti-TIM-3 antibodies TSR-
022 and LY3321367 are ongoing (NCT02817633, NCT03099109). 
B and T lymphocyte attenuator (BTLA, also known as CD272) is another T cell-associated 
inhibitory molecule. It exerts its inhibitory properties through binding with the TNF receptor 
superfamily member 14, which is expressed on tumour cells such as melanoma (209). Like PD-
1 and CTLA-4, it is expressed following T cell activation but upregulation on TH1 (rather than 
TH2) effector cells is prolonged (210). Similarly to other checkpoint molecules, BTLA-deficient T 
cells exhibit increased activation and proliferation following stimulation with the TCR and anti -
CD3 antibody (210) and BTLA-deficient mice exhibit a greater frequency of autoimmune 
diseases.  
As well as its effect on T cell-mediated immunity through engagement with MHC-II molecules, 
LAG-3 mediates the immunosuppressive function of Tregs, on which it is also expressed. 
Indeed, LAG-3 expression increases on activated Tregs, which then exert a potent 
immunosuppressive effect in a LAG-3-dependent manner. Use of anti-LAG-3 antibodies 
therefore abrogates the effect of Tregs in vitro and in vivo, which is demonstrated by an rise in 
T cell proliferation upon stimulation (211). Early phase clinical trials with IMP321 (a LAG-3 
fusion protein that binds MHC-II) have already been reported, showing a tolerable safety 
profile and, pertinently, an increase in the population of effector memory T cells, in patients 
with metastatic breast cancer (212) and RCC (213). Trials in pancreatic cancer at a lower dose 
of IMP321 have not demonstrated the same effect (214). 
Co-expression of BTLA, TIM-3 and PD-1 on antigen-specific CTLs from patients with metastatic 
melanoma defines a population of exhausted, poorly-functioning T cells which produce 
diminished amounts of IFN-γ, IL-2 and TNF-α compared to T cells expressing only one of these 
inhibitory molecules (215). The additional findings that treatment with combination therapies 
(anti-TIM-3/anti-PD-1, anti-BTLA/anti-PD-1/anti-TIM-3 or anti-LAG-3/anti-PD-1) increase the 
proportion of activated (cytokine-secreting) CTLs would seem to support the rationale for 
combination therapy in the future (206,215,216). Trials of combination therapy with immune 
checkpoint inhibitors, including IMP321 and pembrolizumab in melanoma (NCT02676869) and 
anti-TIM-3 and anti-PD-L1 antibody in advanced solid tumours (NCT03099109) are ongoing.  
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1.5.3 Radiotherapy 
Similar to chemotherapy agents, which induce cell death and promote release of TAAs to 
prime an anti-tumour immune response, radiotherapy may also exert a similar effect at the 
targeted site and at distal sites. This phenomenon, known as the ‘abscopal effect’ is 
demonstrated clinically when treatment of a particular site with radiotherapy leads to 
improvement in non-treated areas. Supporting this, in vivo models of colon carcinoma have 
shown that, following radiotherapy, disease response was associated with elevated immune 
cell infiltration into the tumours, raised IFN-γ production and subsequent enhancement of 
cytotoxic potential of intratumoural CD8+ T cells from the responding tumours (217). In a 
phase II trial of radiotherapy plus GM-CSF (to enhance DC maturation) 26.8 % of patients were 
seen to have abscopal responses in non-irradiated tumour sites (218). The additional increase 
in OS between patients who did or did not have abscopal responses (20.98 months vs. 8.33 
months, respectively) supports the hypothesis that having an effective anti -tumour response 
can be beneficial in the context of radiotherapy.  
In in vivo models of melanoma, the immune effects of radiotherapy have been shown to be 
mediated by IFN-γ: production of this cytokine after radiotherapy increased expression of 
chemokines including CXCL9 (219). Other in vitro studies have confirmed that radiation can 
stimulate an environment which promotes immune cell infiltration: radiotherapy-stimulated 
breast cancer cells produce the chemokine CXCL16, which attracts T and NK cell populations 
expressing its receptor CXCR6 (220). In addition to enhancing T cell infiltration into tumour, 
radiotherapy-induced IFN-γ can stimulate upregulation of MHC-I, which consequently leads to 
increased CTL-mediated tumour cell cytotoxicity (219). As some of the effects of radiotherapy 
are mediated by infiltration of antigen-specific T cells within the TME, the effects of 
radiotherapy on DCs have also been investigated. Indeed, radiotherapy has been shown to 
enhance expression of co-stimulatory molecules on DCs, such as CD80, which, along with 
binding of antigen to the TCR, are needed to stimulate T cell proliferation (221).  
Although radiotherapy can exert a positive effect on the immune microenvironment, 
treatment can also initiate the infiltration of other populations into the TME, such as 
immunosuppressive cytokines, MDSCs and M2 TAMs. Indeed, patients with head and neck 
squamous cell carcinoma are found to have raised levels of circulating Tregs following 
treatment with chemoradiotherapy (222). Interestingly, there is also evidence that Tregs are 
more radio-resistant than conventional CD4+ cells, leading to an apparent increase in 
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irradiated tissues (222,223). Radiotherapy has also been shown to induce the expression of 
TGF-β (224); this is one mechanism through which the adaptive anti -tumour responses and 
the priming of such by tumour cell death is inhibited (225). The increase in TGF-β may be one 
mechanism by which radiotherapy itself upregulates PD-1 and PD-L1 on immune cell 
populations (225). Radiotherapy may also promote immunosuppressive effects by 
encouraging infiltration of M2 TAMs, as shown in in vivo models of astrocytoma, glioma and 
prostate cancer (226). This may be partially attributable to the secretion of chemokines for 
macrophages, such as stromal cell-derived factor-1 (SDF-1, also known as CXCL-12), which has 
a role in angiogenesis and is expressed as a result of tissue hypoxia resulting from 
radiotherapy (227).  
Clinical trials of radiotherapy and checkpoint inhibition are underway (NCT02821182, 
NCT02298946) (228). Combination with anti-PD-1 and anti-PD-L1 inhibitors may be of 
particular interest given that radiotherapy can stimulate T cell infiltration into the tumour, 
which is the site of activity of these immunotherapy drugs.  
1.5.4 Oncolytic Viruses 
Oncolytic viruses (OVs) were initially thought to exert their effect through direct oncolysis of 
malignant cells, which are preferentially infected due to the presence of mutations or factors 
which made them more susceptible to OV-mediated killing. As studies into these agents have 
progressed, it has become clear that the generation of immune responses by OVs may be as 
important (if not more so) in their direct anti-tumour effects. A variety of OVs are currently 
being investigated, including RNA and DNA viruses (such as Respiratory and Enteric Orphan 
virus (reovirus), coxsackie virus and HSV) or genetically-modified viruses such as talimogene 
laherparepvec (HSV encoding GM-CSF, also known as T-VEC and OncoVEXGM-CSF), discussed in 
section 5.1.4.3.2. 
Initial concerns about the potential neutralisation of OVs before they can exert their effects 
seem to be unfounded. In a phase I trial of reovirus, the presence of neutralising antibodies 
(Nab) at baseline did not prevent reovirus from reaching tumour sites (229). In patients with 
advanced CRC receiving adenovirus (coding for CEA), over half the patients had NAb at 
baseline yet, despite increasing levels, there was evidence of an antigen-specific immune 
response to treatment (230).  
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In vitro treatment of monocyte-derived healthy donor (HD) DCs with reovirus can stimulate 
secretion of IFN-α, IL-12 and TNF-α. These activated DCs can stimulate NK cells and T cells, 
leading to increased secretion of IFN-γ by both cell subtypes and more potent cytotoxicity 
against target tumour cells (231). In samples from HDs and patients, CD69 expression on NK 
cells was elevated by exposure to reovirus, with enhanced cytotoxicity as shown by greater 
CD107 expression against relevant tumour cell targets (229,232).  
In addition to their effects on innate immunity, OVs can enhance priming of an adaptive 
immune response (233). Moreover, this effect does not rely on infection of target cells 
followed by cell lysis and release of TAAs. B16ova melanoma cells, which express low levels of 
the reovirus receptor junctional adhesion molecule-A are resistant to reovirus infection. When 
immunocompetent mice were implanted with B16ova tumours and treated with reovirus, 
isolated splenocytes produced IFN-γ when re-exposed to melanoma antigens. This indicates 
the activation of a specific anti-tumour response in the absence of direct cytotoxicity (234).  
Treatment with OVs can generate an immune milieu capable of eliciting an immunogenic and 
cytotoxic response. Following infection with reovirus, both human melanoma cell lines and 
primary melanoma cells produce greater amounts of IL-8 and RANTES which can recruit 
immune cells into sites of inflammation (235,236). Associated with this, NK cells, DCs and CTLs 
(primed against melanoma cell lines) all migrate towards tumour-conditioned media (reoTCM)  
from reovirus-infected melanoma cells in the absence of active virus. Down-regulation of IL-10 
is also observed after therapy in vitro (235).  
Although intravenous (i.v.) delivery of OVs may be the most practical route, some are still 
being administered intratumourally (i.t.) in order to circumvent the issue of NAbs completely. 
The populations of infiltrating cells into the tumour can determine whether a pro- or anti-
tumour immune environment prevails and i.t. therapy offers an elegant system in which to 
study the effects of OVs on the TME. Intralesional injection of T-VEC into melanoma 
metastases has been shown to reduce the populations of immunosuppressive Tregs and 
MDSCs (237). Conversely, there was an increase in melanoma-antigen specific T cells in the 
TME (237). Moreover, i.t. therapy can result in infiltration of immune cells into non-injected 
lesions, which may go some way to explain why i.t. OVs can affect injected and non-injected 
tumours (238,239). Given these findings, further studies into the clinical use of OVs may 
instead focus on intensifying their immune-mediated effects to exploit potential combinations 
with other immunotherapies such as the checkpoint inhibitors.   
 
 
32 
 
Chapter 2 Materials and Methods 
2.1 Buffers and Reagents 
Table 2.1 Buffers and Reagents 
Name Constituents 
Ammonium Chloride 
Potassium (ACK) Buffer 
0.15 M NH4Cl (Sigma Aldrich, St. Louis, USA) + 0.1 mM 
ethylenediaminetetraacetic acid (EDTA, Fisher Scientific, 
Waltham, USA) + 10 mM KHCO3 (Sigma Aldrich) in double-
distilled water (ddH20; pH 7) 
ELISA Blocking Solution 
Phosphate buffered saline (PBS) + 10 % (v/v) foetal calf 
serum (FCS; Life Technologies, Carlsbad, USA). 
ELISA Coating Buffer 100 mM NaHCO3 (BDH Lab Supplies, Poole, UK) in ddH2O 
Fluorescence-Activated 
Cell Sorting (FACS)  Buffer 
PBS + 10 % (v/v) sodium azide (NaN3) (Sigma Aldrich) + 10 % 
(v/v) FCS 
PBS-T PBS + 0.05 % (v/v) Tween-20 (Sigma Aldrich) 
2.2 Cell Culture 
Cell lines were cultured in Sanyo CO2 incubators at 37 °C in a humidified atmosphere of 5 % 
CO2. Cell lines were grown in Dulbecco’s Modif ied Eagle Medium (DMEM; Sigma Aldrich) or 
Roswell Park Memorial Institute (RPMI; Sigma Aldrich) medium and supplemented as shown 
in Table 2.2. FCS and pooled human AB serum (HS; Gemini Bio-Products, Sacramento, USA) 
were heat-inactivated at 56 °C for 30 minutes prior to use. Adherent cell lines were passaged 
when approaching confluence using trypsin (Sigma Aldrich). Cell lines were regularly tested for 
mycoplasma contamination. All work involving blood and viruses was carried out in either 
Nuaire or BioMat2 Category II Microbiological Safety Cabinets decontaminated with 2 % (w/v) 
Virkon (Fisher Scientific) followed by 70 % (v/v) ethanol (Sigma Aldrich). Appropriate personal 
protective equipment was worn. Waste products were decontaminated in either 2 % (w/v) 
Virkon or 20 % (v/v) Distel (Tristel Solutions Ltd, Newmarket, UK).  
All centrifugations were performed at 400 g for 5 minutes with full acceleration and brake, 
unless otherwise stated. 
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Table 2.2 Culture Media 
Cell Line Culture Medium Name 
Mel624 (Melanoma) 
Mel888 (Melanoma) 
SW480 (Colorectal) 
SW620 (Colorectal) 
DMEM + 2 mM L-Glutamine + 10 % (v/v) FCS Complete DMEM 
K562 (Chronic Myeloid 
Leukaemia, CML) 
RPMI + 2 mM L-Glutamine + 10 % (v/v) FCS Complete RPMI 
PBMCs RPMI + 2 mM L-Glutamine + 10 % (v/v) FCS Complete RPMI 
2.3 Reovirus 
Reovirus Type 3 Dearing was provided by Oncolytics Biotech® Inc. (Calgary, Canada). Stock 
titre was determined using a standard plaque assay protocol. Aliquots were stored at 4 °C or   
- 80 °C for longer term storage. 
2.4 Cell Lines 
SW480, SW620, K562, Mel624 and Mel888 tumour cell lines were supplied by the American 
Type Culture Collection (ATCC). K562 cells were selected for use in experiments as the ‘gold 
standard’ NK cell target. 
2.5 Cell Counts 
Cells were observed using Nikon Eclipse TS100 or Olympus CKX31 microscopes and counted 
using a standard haemocytometer and Trypan Blue (Beckman Coulter, Brea, USA) exclusion 
method.  
2.6 Propidium Iodide Staining for Viability 
Where stated, propidium iodide (PI) staining was also used to calculate viability of cells  (240). 
Aliquots of 1x106 PBMCs were washed/centrifuged in PBS and 5µl PI (0.01mg/ml in PBS) was 
added. Data was acquired immediately using a Becton Dickinson TM (BD TM, Franklin Lakes, New 
Jersey, USA) LSRII 4-laser flow cytometer.  
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2.7 Collection of Blood Samples 
Peripheral whole blood was obtained from either HD volunteers or patients undergoing 
treatment at Leeds Cancer Centre, St James’s Hospital, Leeds, UK. Leucocyte cones were 
obtained from NHS Blood and Transplant at Seacroft Hospital, Leeds. Informed consent was 
obtained from all patients and donors in accordance with local institutional ethics review and 
approval. 
2.8 Isolation of Blood Components  
2.8.1 Plasma 
K3-EDTA vacuettes (Greiner Bio-One, Kremsmünster, Austria) containing whole blood samples 
were were centrifuged at 2000 g for 10 minutes with low acceleration and no brake . Plasma 
was then harvested using a sterile Pastette, aliquoted into Eppendorf tubes (Scientific 
Laboratory Supplies, Nottingham, UK) and stored at -80 °C until required. 
2.8.2 Whole White Blood Cells  
Whole WBCs were isolated from blood collected into K3-EDTA vacuettes: blood tubes were 
centrifuged at 2000 g for 10 minutes with low acceleration and no brake and the WBC layer 
harvested. Red cell lysis was performed on ice using ACK buffer (Table 2.1). Cells were placed 
on ice for a maximum of 5 minutes, with close monitoring. Once lysis was complete, cells were 
washed in Hank’s Buffered Salt Solution (HBSS; Sigma Aldrich) and centrifuged at 400 g for 10 
minutes, followed by a further 2 washes and 5 minute spins. If red blood cell contamination 
persisted, ACK treatment was repeated. 
2.8.3 Peripheral Blood Mononuclear Cells 
PBMCs were isolated from blood (collected in EDTA vacuettes) or leucocyte cones using 
density gradient separation. After collection of whole blood samples, the WBC population was 
harvested as described above, without the need for red lysis. WBC were diluted with HBSS 
and overlaid onto Lymphoprep© (Axis Shield, Oslo, Norway) at a ratio of 2:1. Tubes were 
centrifuged at 800 g for 20 minutes with low acceleration and low brake. The PBMC layer was 
harvested, washed in HBSS and centrifuged at 400 g for 10 minutes. Cells were washed in 
HBSS and centrifuged twice more for 5 minutes before cell counts performed. PBMCs were 
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then re-suspended at the required density. Blood from leucocyte cones was directly diluted 
with HBSS and PBMCs isolated as described above.  
2.9 Cryopreservation of Cells 
PBMCs and WBCs were cryopreserved at defined densities in appropriate freezing mixture 
(FM) (Table 2.3). FMs and cryovials (Thermo Scientific, Waltham, USA) were equilibrated to 4 
°C prior to use. FM was added in a drop-wise manner, whilst swirling the cells, to minimise cell 
damage by dimethyl sulphoxide (DMSO; Sigma Aldrich). The procedure was carried out swiftly 
to preserve cell membrane integrity. Cryovials were transferred into Mr FrostyTM (Thermo 
Scientific) freezing containers and stored at -80 °C until transfer to liquid nitrogen (LN2), 
usually within 24 hours. 
Table 2.3 Freezing Mixtures 
Name Constituents 
‘Standard’ FM 90 % (v/v) FCS + 10 % (v/v) DMSO 
10 % DMSO/RPMI 90 % (v/v) complete RPMI + 10 % (v/v) DMSO 
20 % DMSO/RPMI 80 % (v/v) complete RPMI + 20 % (v/v) DMSO 
‘Clinical’ FM 
40 % (v/v) RPMI (including 1 mM sodium pyruvate, Sigma 
Aldrich) + 50 % (v/v) human serum (HS) + 10 % (v/v) DMSO 
2.10 Thawing Cells 
Cells were transported on dry ice from LN2 to a 37 °C water bath. Vials were closely 
monitored and removed when a small ice crystal was still visible. Cells were thawed into 
either PBS or cell culture media, immediately washed with PBS and pelleted by centrifugation.  
2.11 Reovirus Treatment of PBMCs 
PBMCs were re-suspended at 2x106 cells/ml in complete RPMI and incubated ± reovirus (0 or 
1 plaque-forming unit (pfu)/cell) overnight at 37 °C. Next day, PBMCs were harvested and 
washed free of unbound virus. Reovirus-treated PBMCs were used in functional assays 
(below) and cell culture supernatants stored at -20 °C. 
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2.12 Chromium Release Cytotoxicity Assay  
Tumour cell lines, which were used as targets, were labelled with 50 µCi of chromium-51 (51Cr; 
Perkin-Elmer, Waltham, USA) for 1 hour at 37 °C. Excess radiation was removed by 3 large 
volume washes/centrifugations in PBS. PBMCs were re-suspended at 5x106 cells/ml in 
complete RPMI. Triplicate, halving serial dilutions of effector PBMCs were performed in 96-
well U-bottomed plates to ensure decreasing effector:target (E:T) ratios. Control plates for 
maximum and spontaneous target release were set up using 1 % (v/v) Triton-X (Sigma Aldrich) 
or complete RPMI, respectively. 51Cr-labelled targets were then added at 5x103 cells/well. 
Following a 4 hour incubation at 37 °C, plates were centrifuged, supernatants transferred onto 
Luma scintillation plates (Perkin-Elmer) and left to dry overnight. A MicroBeta Jet Scintillation 
counter (Perkin-Elmer) determined 51Cr-release from target cells in counts per minute (cpm). 
The percentage of lysed target cells was calculated using the formula: 
% 𝑙𝑦𝑠𝑖𝑠 =  100 𝑥
(𝑠𝑎𝑚𝑝𝑙𝑒 𝑐𝑝𝑚 −  𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝑐𝑝𝑚)
(𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑐𝑝𝑚 −  𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝑐𝑝𝑚)
 
2.13 CD107 Degranulation Assay 
PBMCs and tumour targets were re-suspended at 5x106 cells/ml in complete RPMI and 
aliquoted into FACS tubes (Sigma Aldrich) at a 1:1 ratio. Following incubation for 1 hour at 37 
°C, 10 μg/ml Brefeldin A (Biolegend, San Diego, USA) was added, in addition to anti-CD107a-
FITC and anti-CD107b-FITC antibodies (Table 2.4). After a further 4 hours at 37 °C, cells were 
washed/centrifuged in FACS buffer (Table 2.1). NK cell identification antibodies (anti-CD3-
PerCP and anti-CD56-PE, Table 2.4) were added and tubes protected from light at 4 °C for 30 
minutes before a final wash in FACS buffer. Cells were fixed in 1 % (v/v) paraformaldehyde 
(PFA; Sigma Aldrich) and protected from light at 4 °C until flow cytometry was performed. 
2.14 Preparation of Cryopreserved Cells for Immunophenotyping 
PBMCs were thawed as previously described (section 2.10) and subjected to 
immunophenotyping immediately (‘same day’) or ‘rested’ at 37 °C overnight at a density of 
2x106 cells/ml in complete RPMI before immunophenotyping (section 2.14.1).  
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2.14.1 Immunophenotyping and Flow Cytometry 
Cells were re-suspended in FACS buffer at 5x106 cells/ml and 5x105 cells used per tube for 
staining with appropriate fluorescently-conjugated antibodies (Table 2.4). Antibody staining 
was performed in darkness for 30 minutes at 4 °C and unbound antibody washed free with 
FACS buffer. Cells were fixed in 1 % (v/v) PFA and kept protected from light at 4 °C until flow 
cytometry was performed. 
Data acquisition was undertaken using a BDTM LSRII 4-laser flow cytometer and analysed using 
BD FACSDivaTM software (version 8.0). Expression of cell surface markers was calculated as the 
percentage positive cells in a given population over the isotype control. Relative median shift 
(RMS), as a function of median fluorescence intensity (MFI) compared to the isotype control 
of each fluorophore, was calculated using the formula: 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑀𝑒𝑑𝑖𝑎𝑛 𝑆ℎ𝑖𝑓𝑡 =  
𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑀𝐹𝐼
𝐼𝑠𝑜𝑡𝑦𝑝𝑒 𝑀𝐹𝐼
 
2.14.2 Intracellular Staining of PBMCs for FoxP3 
Tregs were stained for intracellular FoxP3 using the FoxP3 Staining Buffer Set (Miltenyi 
Biotech, Bergisch Gladbach, Germany) following manufacturer’s instructions. Following 
extracellular staining for cell surface markers (section 2.14.1), cells were washed in FACS 
buffer. Fixation/Permeabilisation solution was added and incubated at room temperature (RT) 
for 30 minutes. Cells were then washed in 1x Permeabilisation Buffer and anti-FoxP3-APC 
antibody (Table 2.4) added. Following a further 30 minutes incubation at RT, cells were again 
washed in 1x Permeabilisation Buffer. Finally, cells were washed in FACS buffer and fixed with 
1 % PFA. Data was acquired immediately using a BDTM LSRII 4-laser flow cytometer.  
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Table 2.4 Fluorescently-labelled Antibodies for Flow Cytometry1 
Target 
Molecule 
Fluorochrome 
Volume used per 
5x105 Cells (µl) 
Species of Origin Clone 
CCR7 PerCP 10 Mouse 150503 
CD107a FITC 5 Mouse H4A3 
CD107b FITC 5 Mouse H4B4 
CD127 BV421 5 Mouse HIL-7R-M21 
CD14 FITC 5 Mouse MφP9 
CD14 V500 5 Mouse MφP9 
CD14 BV510 10 Mouse MφP9 
CD14 PerCP 10 Mouse MφP9 
CD19 BV421 2 Mouse HIB19 
CD19 PE 5 Mouse HIB19 
CD19 APC 5 Mouse SJ25CI 
CD19 PE-Cy7 5 Mouse HIB19 
CD25 PE-Cy7 2 Mouse M-A2512 
CD3 PE-Cy7 5 Mouse SK7 
CD3 PerCP 3 Mouse SK7 
CD3 FITC 5 Mouse SK7 
CD3 BV510 5 Mouse HIT3a 
CD4 BV510 10 Mouse SK3 
CD4 PerCP 5 Mouse SK3 
CD4 APC 5 Mouse SK3 
CD56 FITC 10 Mouse NCAM 16.2 
CD56 PE 2 Mouse AF12-7H3 
CD56 BV421 5 Mouse NCAM 16.2 
CD62L BV605 5 Mouse DREG-56 
CD69 APC 2 Mouse FN50 
CD8 V500 5 Mouse SK1 
CD8 BV421 5 Mouse RPA-T8 
CD8 PerCP 5 Mouse SK3 
CD86 FITC 20 Mouse BU633 
CTLA-4 BV786 10 Mouse BNI3 
FoxP3 APC 20 Mouse 3G34 
HLA-DR PerCP 20 Mouse L243 
PD-1 PE 10 Mouse EH12.1 
PD-1 BV786 10 Mouse G155-178 
PD-L1 FITC 5 Mouse MIH1 
TCRγδ BV421 10 Mouse B1 
 
                                                                 
1 Manufactured by BD Biosciences (San Jose, USA) unless otherwise stated 
2 Biolegend 
3 AbD Serotech (Raleigh, USA) 
4 Miltenyi Biotech (Bergisch Gladbach, Germany) 
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Table 2.4 continued 
Target 
Molecule 
Fluorochrome 
Volume used per 
5x105 Cells (µl) 
Species of Origin Clone 
Isotype IgG1 BV605 5 Mouse X40 
Isotype IgG1 FITC 5 Mouse G18-145 
Isotype IgG1 PE 5 Mouse MOPC-21 
Isotype IgG1 APC 5 Mouse 11711 
Isotype IgG1 BV421 5 Mouse MOPC-21
5
 
Isotype IgG1 PE-Cy7 5 Mouse MOPC-21 
Isotype IgG2a PerCp 5 Mouse G155-178 
Isotype IgG2b BV510 5 Mouse 27-35 
Isotype IgG2a BV786 5 Mouse G155-178 
Isotype IgG1 BV786 5 Hamster G235-2356 
Isotype IgG1 V500 5 Mouse X40 
 
Table 2.5 Immune Cell Identification and Activation Markers 
Cell Population 
Markers + Fluorophores 
Identification Activation 
CD4+ T cells 
(CD3+/CD4+) 
CD3-PE-Cy7, CD4-BV510 
CD69-APC, CCR7-PerCP, 
PD-1-PE, PD-L1-FITC, CTLA-4-BV786 
CD8+ T cells 
(CD3+/CD8+) 
CD3-PE-Cy7, CD8-V500 
CD69-APC, CCR7-PerCP, 
PD-1-PE, PD-L1-FITC, CTLA-4-BV786 
Tregs 
(CD3+/CD4+/CD25high 
CD127low/Fox-P3+) 
CD3-BV510, CD4-PerCP, 
CD25-PE-Cy7, CD127-BV421, 
FoxP3-APC 
CD62L-BV605, 
PD-1-PE, PD-L1-FITC 
NK cells 
(CD3-/CD56+) 
CD3-PE-Cy7, CD56-FITC 
CD69-APC, CCR7-PerCP, 
PD-1-PE, PD-L1-FITC 
NKT cells 
(CD3+/CD56+) 
CD3-PE-Cy7, CD56-FITC 
CD69-APC, CCR7-PerCP, 
PD-1-PE, PD-L1-FITC 
γδ T cells 
(CD3+/TCRγδ+) 
TCRγδ-BV421 CD69-APC, CCR7-PerCP 
Monocytes 
(CD14+) 
CD14-BV510 
CD69-APC, HLA-DR-PerCP, 
PD-1-PE, PD-L1-FITC, CD86-FITC 
B cells 
(CD19+) 
CD19-BV421 
CD69-APC, HLA-DR-PerCP, 
PD-1-PE, PD-L1-FITC, CD86-FITC 
 
 
                                                                 
5 Biolegend 
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2.14.3 Immunophenotyping and Flow Cytometry using DuraClone Tubes 
Cells were re-suspended in FCS at 5x106 cells/ml. Aliquots of 5x105 cells were added to 
custom-made DuraClone Dry Reagent Cocktail FACS tubes (Beckman-Coulter, Brea, California, 
USA, Table 2.6) and incubated in darkness at RT for 15 minutes. Where necessary, anti-CTLA-
4-BV786 antibody (Table 2.4) was added to tubes. Cells in tubes A, B, C and D were washed in 
FACS buffer, fixed in 1 % PFA and kept protected from light until data acquired. Tube E was 
subjected to Fox-P3 staining as described below.  
2.14.4 Intracellular Staining of PBMCs for FoxP3 Using DuraClone Tubes 
Intracellular staining of Tregs for FoxP3 was performed using the PerFix-nc kit (Beckman 
Coulter) following manufacturer’s instructions. After the initial 15 minute incubation 
(section 2.14.3), 5 µl of Buffer R1 (Fixative Reagent) was added to cells and incubated in 
darkness at RT for a further 15 minutes. 300 µl Buffer R2 (Permeabilising Reagent) was then 
added and incubated at RT for 1 hour. Finally, cells were washed in PBS and then in 3 ml 1x 
Buffer R3 before being fixed with 1 % PFA. Data was acquired immediately using a BDTM LSRII 
4-laser flow cytometer.  
2.15 Immunophenotyping of Fresh Whole Blood using DuraClone 
Tubes 
Following blood sample collection (section 2.7), 100 µl of fresh whole blood was added to 
DuraClone tubes (Table 2.6) and incubated in darkness for 30 minutes at RT. Cells were 
incubated for a further 10 minutes at RT following addition of 1x FACS Lysing Solution (BD 
Biosciences). Cells were washed and fixed in 1 % PFA and protected from light at 4 °C until 
flow cytometry was performed. Intracellular staining of Tregs for FoxP3 was performed as 
previously described (section 2.14.4). 
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Table 2.6 DuraClone Dry Reagent Cocktail Panel  
 Cell Marker, Fluorophore and Clone 
Tube Panel BV421 BV510 FITC PE PerCP PECy7 APC AF700 APC-Cy7 
A Isotype IgG1 IgG1 IgG1 IgG2a IgG2a IgG2a IgG2b IgG1 IgG1 
B T cells 
CD3 
(UCHT1) 
CD4 
(13B8.2) 
CD8 
(B9.11) 
CCR7 
(G043H7) 
PD-1 
(Polyclonal) 
CD25 
(B1.49.9) 
CD69 
(TP.55.3) 
PD-L1 
(Polyclonal) 
 
C 
NK/NKT/ γδ 
T cells 
CD3 
(UCHT1) 
CD16 
(3G8) 
TCR γδ 
(IMMU510) 
CCR7 
(G043H7) 
PD-1 
(Polyclonal) 
CD56 
(N901) 
CD69 
(TP.55.3) 
PD-L1 
(Polyclonal) 
 
D 
Monocytes/
B cells 
CD19 
(J3-119) 
HLADR 
(Immu-357) 
CD14 
(RMO52) 
CD11c 
(BU15) 
PD-1 
(Polyclonal) 
CD25 
(B1.49.9) 
CD69 
(TP.55.3) 
PD-L1 
(Polyclonal) 
CD86 
(HA5.2B7) 
E Tregs 
CD3 
(UCHT1) 
CD4 
(13B8.2) 
 
CD62L 
(DREG56) 
PD-1 
(Polyclonal) 
CD25 
(B1.49.9) 
FOXP3 
(259D) 
PD-L1 
(Polyclonal) 
CD127 
(SSDCLY107D2) 
4
1 
 
 
42 
 
2.16 Cytokine/Chemokine Analysis 
2.16.1 Enzyme-Linked Immunosorbent Assay (ELISA) 
Paired antibodies were used as per manufacturers’ instructions or following lab-optimised 
protocols (Table 2.1 and Table 2.7). Briefly, capture antibody (in coating buffer) was added to 
Nunc 96-well Maxisorb flat-bottomed plates (Scientific Laboratory Supplies, Nottingham, UK) 
and stored at 4 °C overnight. Plates were washed 3x in PBS-T and blocking solution was added. 
After 2 hours, plates were washed 3x in PBS-T and triplicate halving dilutions of appropriate 
recombinant cytokine protein were performed to generate a standard curve for analysis. Cell 
culture supernatants were added in triplicate and plates stored overnight at 4 °C. Following 6x 
washes with PBS-T, biotinylated detection antibodies were added and plates were incubated 
in darkness at RT for 2 hours. Plates were washed 6x in PBS-T. Streptavidin conjugate 
(ExtrAvidin®, Sigma Aldrich) was added and plates were incubated for 1 hour at RT. Following 
final washes of 3x PBS-T and 3x ddH20, Sigmafast™ p-nitrophenyl phosphate (pNPP) alkaline 
phosphatase substrate (Sigma Aldrich) was added. Plates were monitored for the 
development of colour and a Multiskan® EX plate-reader (Thermo Scientific) was used to 
measure optical density at a wavelength of 405 nm.  
Table 2.7 Antibodies for ELISA 
Cytokine Capture (µg/ml) Detection (µg/ml) Standard (pg/ml) Manufacturer 
CXCL-10 2  0.05  2000 R&D Systems 
TRAIL 2  0.2 1500 R&D Systems 
GM-CSF 2  1 2000 Peprotech  
IFN-γ 4ǂ 1ǂ 10000* ǂBD Bioscience 
*Peprotech 
     
2.16.2 Luminex Multiplex Assay 
Multiplex human chemokine and cytokine analysis was performed using 21-plex (Table 2.8) 
and 27-plex (Table 2.9) Bio-Plex Pro™ plates (BioRad Laboratories, Hercules, California, USA). 
Standards, samples and coupled beads were prepared prior to use following manufacturer’s 
guidelines. All incubations were performed on a Unimax 2010 platform shaker (Heidolph 
Instruments, Schwabach, Germany) at 450 revolutions per minute (rpm). Plate washes were 
performed on Bio-Plex® handheld magnetic wash plate (BioRad) to prevent loss of beads, 
using the Bio-Plex® Wash Buffer. Lyophilised standard was reconstituted with Bio-Plex® 
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Standard Diluent and stored on ice for 30 minutes before use. Serial dilutions were performed 
on reconstituted standard to generate a standard curve for analysis. Plasma samples were 
thawed and centrifuged at 10,000 g for 10 minutes to remove any cellular debris and diluted 
1:2 with Bio-Plex® Sample Diluent. 50 µl of 1x beads were added to Bio-Plex® 96-well flat-
bottom plates and plates were washed twice with Bio-Plex® Wash Buffer. 50 µl of standard 
and sample were added to each well in duplicate. Plates were sealed to protect from light and 
incubated at RT for 30 minutes. Plates were then washed 3x as previously described, before 
25 µl of 1x detection antibody was added to each well. Plates were incubated for a further 30 
minutes at RT. Following 3x washes, 50 µl of 1x Streptavidin-PE was added to each well. The 
plates were incubated at RT for 10 minutes protected from light. Finally, plates were washed 
3x and 125 µl Bio-Plex® Assay Buffer added to each well. Plates were read immediately on a 
Bio-Plex 100 system and analysed with Bio-Plex Manager™ 4.1 software.  
Table 2.8 21-plex Cytokine and Chemokine Panel  
IL-1α 
Cutaneous T cell-Attracting 
Chemokine (CTACK) 
MIG 
IL-α2 CXCL1 (GRO-α) β-Nerve Growth Factor (NGF) 
IL-2rα Hepatocyte Growth Factor (HGF) Stem Cell Factor (SCF) 
IL-3 Leukaemia Inhibitory Factor (LIF) Stem Cell Growth Factor (SCGF)-β 
IL-12p40 MCP-3 Stromal Cell-Derived Factor (SDF)-1α 
IL-16 M-CSF TRAIL 
IL-18 
Macrophage Migration Inhibitory 
Factor (MIF) 
TNF-β 
 
Table 2.9 27-plex Cytokine and Chemokine Panel 
IL-1β IL-10 IFN-γ 
IL-rα IL-12p70 IP-10 
IL-2 IL-13 MCP-1 
IL-4 IL-15 MIP-1α 
IL-5 IL-17α MIP-1β 
IL-6 Eotaxin PDGF-ββ 
IL-7 Basic-Fibroblast Growth Factor (FGF) RANTES 
IL-8 G-CSF TNF-α 
IL-9 GM-CSF VEGF 
 
2.16.3 TGF-β ELISA 
TGF-β ELISA was performed using R&D Systems Human TGF-β Duoset kit following 
manufacturer’s instructions. Briefly, TGF-β capture antibody was reconstituted to a working 
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concentration of 2 µg/ml in PBS. Supplied 96-well microplates were coated with 100 µl diluted 
capture antibody and incubated overnight at RT. The following day, plates were washed 3x in 
the supplied wash buffer and 300 µl supplied block buffer was added to each well. Plates were 
incubated for 60 minutes at RT before being washed 3x with wash buffer. Plasma samples 
were activated using R&D Systems ELISA Sample Activation Kit. 40 µl thawed plasma (per well) 
was added to 20 µl 1NHCl and incubated for 10 minutes at RT. Samples were then neutralised 
by adding a further 20 µl of 1.2 N NaOH/0.5 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES). 10 µl of activated plasma was then diluted 1:20 with provided Reagent Diluent, 
to a final dilution of 1:40. A standard curve was generated using 2-fold serial dilutions of TGF-
β in Reagent Diluent with a top standard of 2000 pg/ml. Activated plasma samples and 
standards (both in triplicate) were added to the prepared microplates, covered and incubated 
for 2 hours at RT. Following 3x further washes, 100 µl TGF-β detection antibody was added 
before further incubation for 2 hours at RT. Plates were washed again, as previously 
described, before the addition of 100 µl of streptavidin-horseradish peroxidase (HRP). After a 
further 20 minutes protected from light at RT, a final wash was performed. Substrate Solution 
was added to each well, followed by Stop Solution after 20 minutes. A Multiskan® EX plate-
reader (Thermo Scientific) was used to measure optical density at a wavelength of 450 nm.  
2.16.4 IL-10 ELISA 
BD Biosciences’ Human IL-10 ELISA kit was used for measurement of IL-10 in plasma samples, 
following manufacturer’s instructions. For analysis an IL-10 ELISA standard curve was 
generated using serial dilutions of IL-10 to a top standard of 500 pg/ml. In summary, 100 µl of 
plasma was added to the 96-well plate, pre-coated in IL-10 antibody, in triplicate. Plates were 
incubated for 2 hours at RT before being washed 5x with the supplied Wash Concentrate. 100 
µl of Working Detector was added to each well and incubated for 1 hour at RT. Plates were 
washed 7x before adding 100 µl Tetramethylbenzidine (TMB) One-Step Substrate Reagent. 
Plates were incubated for a further 30 minutes, protected from light, at which time 50 µl stop 
solution was added to each well. A Multiskan® EX plate-reader (Thermo Scientific) was used to 
measure optical density at a wavelength of 450 nm.  
2.17 ELISpot Assay 
Prior to the addition of capture antibody, 96-well polyvinylidene difluoride (PVDF) 
Multiscreen® ELISpot plates (Merck Millipore, Darmstadt, Germany) were moistened with 100 
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µl 70 % (v/v) sterile ethanol to allow subsequent penetration by aqueous solutions in the 
remaining steps. Following 3x washes with PBS, IFNγ capture antibody (Mabtech, Nacka 
Strand, Sweden) was diluted to a final concentration of 2 µg/ml in PBS and 100 µl added to 
each well. Plates were incubated for 24 hours at 4 °C and then washed 6x with sterile PBS. 
Plates were blocked with complete RPMI and incubated for 2 hours at 37 °C before either 
being used, or stored at -20 °C until required. Cryopreserved plates were thawed at RT for 2 
hours before use. On the day of the assay, effector cells were thawed as previously described 
(section 2.8 and 2.10), re-suspended at the concentration required for the assay and rested at 
37 °C for 2-4 hours prior to use. Blocking solution was discarded from the plates and complete 
RPMI added to each well to prevent the plates drying out. Immune stimuli were prepared as 
follows and 50 µl of each added to appropriate wells. Cytomegalovirus/Epstein-Barr 
Virus/Influenza (CEF) peptide pool (Cambridge Bioscience, Cambridge, UK) was used as a pan-
immune stimulus and either CEA or MART-1 PepMix™ peptide pools were used as tumour-
specific antigens (both JPT Peptide Technologies, Berlin, Germany); all used at 2 µg/ml. 
Pokeweed mitogen (Sigma Aldrich), was used as a positive control (at 1 µg/ml) and complete 
RPMI was used as a negative control. Effector cells were added to duplicate wells in variable 
concentrations to a final volume of 200 µl/well. Plates were incubated at 37 °C for 24 hours. 
The following day, plates were washed 6x with PBS-T. IFNγ biotinylated detection antibody 
(Mabtech, Nacka Strand, Sweden) was diluted 1:5000 in PBS to achieve a final concentration 
of 0.2 µg/ml. 100 µl was added to each well and plates either kept at 4 °C for 24 hours or RT 
for 4-6 hours, protected from light, before development. Streptavidin alkaline phosphatase 
(Mabtech, Nacka Strand, Sweden) was diluted 1:1000 in PBS and following a further 6x wash 
of the plate in PBS, 100 µl added to each well. Following a final incubation at RT for 2 hours, 
protected from light, 100 µl filtered 5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue 
tetrazolium (BCIP/NBT) substrate (Mabtech, Nacka Strand, Sweden) was added in the dark. 
Once spots became visible (approximately 5-10 minutes), the plate was washed in cold water 
to halt further development. Plates were air-dried overnight and read using the SD32G2 AID 
ELISpot reader (AID Diagnostika, Strassberg Germany) and analysed using AID ELISpot 
software (version 5.0). Each visible spot is representative of one T cell secreting IFN-γ (a spot-
forming unit, SFU). 
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2.18 Sample Collection 
2.18.1 CRC Patient Cohort 
Informed consent was obtained from patients receiving chemotherapy for metastatic CRC. 
Samples were collected from patients at three time points corresponding to chemotherapy 
cycles: baseline (pre-treatment), 6 weeks (following 2 cycles of 3-weekly chemotherapy) and 
12 weeks (after 4 cycles of chemotherapy). Patients were followed up until collection of the 
final blood sample. When analysing the change in immune function over time, only patients 
who had multiple samples taken were included in the analysis. Furthermore, such patients 
were stratified into groups based on the change in NLR over the first 6 weeks of therapy, 
initially denoted as: ‘high-high’ (NLR > 5 at baseline which remained elevated at 6 weeks; 
n=2), ‘high-low’ (NLR > 5 at baseline which had fallen to < 5 by 6 weeks; n=10) and ‘low-low’ 
(baseline NLR < 5 which remains so over the first 6 weeks of chemotherapy; n=17). As there 
were only 2 patients in the ‘high-high’ group, this is not included in the statistical analysis.  For 
simplicity, therefore, results are annotated as either the ‘high’ group (denoting the 10 
patients with a high baseline NLR at baseline but low at 6 weeks) or ‘low’ group (those 17 
patients with an NLR <5 throughout). Following thawing of cryopreserved cells, PBMCs were 
rested overnight. Functional analysis was performed as allowed by the number of viable 
PBMCs. 
2.18.2 Melanoma Patient Cohort 
Informed consent was obtained from patients receiving immunotherapy for metastatic 
melanoma. Samples were collected from patients at three time points corresponding to 
immunotherapy cycles: baseline (pre-treatment), 6 weeks (following 2 cycles of 3-weekly 
ipilimumab or pembrolizumab) and 12 weeks (after 4 cycles of 3-weekly ipilimumab or 
pembrolizumab). When analysing the change in immune function over time, only patients 
who had multiple samples taken were included in the analysis. Following thawing of 
cryopreserved cells, PBMCs were rested overnight. Functional analysis was performed as 
allowed by the number of viable PBMCs. 
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2.19 Statistical Analysis 
GraphPad Prism® (version 7.02) was used for statistical analysis. For the CRC and melanoma 
patient groups, Mann-Whitney U tests were used for comparison of baseline samples. For 
analysis of data over time, Wilcoxon rank test was performed. All graphs show the median 
and interquartile ranges and p<0.05 denotes a significant result (*p<0.05, **p<0.01 
**p<0.001). For the validation experiments, paired t-tests were used for comparison of 
samples. All graphs show the standard error of the mean (SEM) and p<0.05 denotes a 
significant result (*p<0.05, **p<0.01 ***p<0.001).  
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Chapter 3 Immune Assay Validation 
3.1 Introduction 
Investigating the immune response to therapy is an essential component of immunotherapy 
trials, alongside any clinical endpoints. In addition, collecting such data from patients on a 
range of treatment regimens may reveal novel insights into immunomodulatory effects which 
can be exploited when developing new therapies. This may also identify potential immune 
signatures which can be used to monitor biological activity and which may correlate with 
clinical efficacy or toxicity.  
To date, knowledge of patient immune responses following such treatments have been 
confined to general observations; detailed, structured investigations including functional 
assessment of patient samples have not been performed in this setting. Analysis of fresh 
patient blood is the ideal, eliminating the possibility of processing errors and other 
confounding factors. Pragmatically, within a trial setting this is not usually possible for the 
majority of assays, particularly in multi-centre studies when samples are collected at 
numerous time points. In this regard, blood samples could be processed and stored as frozen 
components for batch analysis or for transportation to a centre where all assays can be 
performed. If clinical trial samples are cryopreserved in LN2 for long term storage and 
analysed at a later date, validation of novel assays on these frozen samples is required to be 
able to understand the effects of cryopreservation on immune cell function. In order to 
ensure that the results of such analyses are robust, we developed a panel of immune 
functional assays to interrogate immune responses in detail. Validation of this panel will 
ensure high quality and reproducible results, striking a balance between maintaining the 
functional profile of immune cell populations and being able to recover a high enough yield of 
cells from patient samples to perform a range of analyses.  
3.1.1 Immune Functional Assays 
In order to fully interrogate the response of a patient’s immune system to chemotherapy, 
immunotherapy or other novel therapies, a panel of immune functional assays should 
evaluate different facets of the immune response. The assays developed in our panel were 
used to analyse aspects of the innate immune response, adaptive responses (to both tumour-
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specific antigens and non-specific viral peptides) and other parameters including 
cytokine/chemokine profiles.   
3.1.1.1 Immunophenotyping 
Immunophenotyping is used to evaluate the expression of molecules on cells which can 
determine phenotype and activation. Cells are labelled with antibodies bound to a fluorescent 
molecule which can be detected by specific light emission when passed through (excited by) a 
laser and quantitatively measured by a flow cytometer. Despite this being a widely used 
technique, there is still a need for assay validation and standardisation of 
immunophenotyping protocols: the increased capacity for flow cytometric measurement of 
multiple cell populations using multiple fluorophores has added to the complexity of being 
able to ensure accurate compensation strategies. When deciding on an immunophenotyping 
panel to analyse clinical samples there are many factors to consider, including the emission 
spectra and brightness of each fluorophore and the level of expression of specific proteins 
being investigated: proteins present at very low density, for example, could be more reliably 
detected using brighter fluorophores. Furthermore, comparison of different fluorophores of 
the same clone but from different manufacturers can yield different results when used to 
stain matched peripheral blood samples (241), as can using different clones. Isotype controls 
can be used for each fluorophore to determine the proportion of non-specific antibody 
staining, above which the true positive population can be quantified (i .e. IgG-PE isotype 
compared to CD3-PE staining) (242).  
Small variations in sample preparation could also lead to differences in the results obtained by 
flow cytometry. As an example, Kalina et al. demonstrated that, if using a red cell lysis step in 
the processing of peripheral blood samples, both the brand of lysis buffer and the protocol for 
staining the cells can alter the absolute detected counts (%) and also the MFI of each immune 
cell population (241). Similarly, the MFI of cell populations decreased over time following 
staining, suggesting that samples should be analysed within one hour of the cell staining 
procedure or otherwise be stored at 4 °C in the dark for data collection as soon as possible 
(241).  
Even though some centres have shown that the anti-coagulant used in blood sample 
collection bottles does not affect yield of immune cells (243), differences in the populations of 
cells positive for certain cell surface markers have been demonstrated (244). For example, 
lymphocytes from blood samples anticoagulated with heparin showed increased expression of 
 
 
50 
 
HLA-DR in response to stimulation with cytokines such as IFN-γ. This effect was not seen when 
EDTA was used as an anticoagulant (244). 
3.1.1.2 Innate Immune Assays 
The innate immune response to stimulus is usually very rapid (within hours of activation in 
situ) and precedes an adaptive response. Degranulating NK cells are identified by surface 
expression of CD107 which is strongly correlated with cytotoxicity of tumour-cell targets. It 
can therefore be used as an effective surrogate marker for NK-mediated cytotoxicity. The 
expression of CD107 and the cytotoxicity of NK cells has also been shown to correlate with cell 
surface expression of the activation marker CD69 and production of IFN-γ (245).  
Chromium-release assays measure the ability of effector immune cells to actively kill tumour 
targets. Target cells are labelled with 51Cr, which is non-specifically internalised within the cell. 
Release of 51Cr into the cell culture supernatant following co-culture with PBMCs as a 
consequence of target cell lysis therefore represents the functional cytolytic activity of 
effector cells. These assays are utilised in parallel with CD107 degranulation to assess innate 
responses against tumour targets. Our laboratory has previously shown that NK cells within 
the whole PBMC population are the effector cells responsible for lysis of target tumour cells in 
51Cr assays (229). Hence, it is the NK cell population within PBMCs which has been studied in 
these assays throughout this thesis.   
3.1.1.3 Adaptive Immune Assays 
Adaptive immunity involves a T cell response to a previously encountered antigen. An antigen-
specific T cell pool responds, after expansion of a small number of memory T cells were 
primed against the antigen to eradicate the foreign entity. ELISpot assays can detect T cell 
responses to immune stimuli by the production of cytokines such as IFN-γ (246). They are 
used to assess tumour-specific T cell responses (in malignancy and infectious disease) by 
detecting antigen-specific T cells and have a high degree of concordance with other 
measurements of T cell responses (247). Recall responses to previously encountered antigens 
(such as previous influenza infection) can be detected by ELISpot assay long after the initial 
exposure (248). Pre-incubation of PBMCs with the immune stimulus of interest, to allow for 
processing and presentation of antigen, can be used to increase the measureable T cell 
response (246). Although there might be a concern that using a ‘cultured ELISpot’ assay could 
prime naïve T cells to the antigen of interest, the time period for which the T cells are pre-
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cultured is usually less than 14 days (249). Validation of the concentration of protein or 
peptide of choice is also needed to optimise the result (246). Certain peptides are HLA-
restricted and, as such, are specific to individual patients: they can only be presented to T cells 
on certain HLA molecules. The difficulties inherent in identifying a population of T cells which 
recognise a specific antigen, given the potential for MHC-restriction between donors, can be 
abrogated by using pools of overlapping peptides (249,250). Due to the short nature of these 
individual peptides, minimal processing by APCs is needed (251). Combination of the ELISpot 
with depletion assays can ascertain whether the responses are mediated by CD4+, CD8+ T 
cells or NK cells (249), although this may also be dependent on the length of peptides used. 
Peptides of between 8 and 11 amino acids, for example, are thought optimum for 
engagement with MHC class I molecules on CD8+ T cells (250,252). Since CD4+ T cells can 
respond to longer peptides (252,253) - though not reliably those shorter than 10 amino acids - 
peptide pools of approximately 15 amino acids in length with overlapping sections of 8-11 
amino acids can be used to simulate both groups of T cells. The number of PBMCs used in 
ELISpot assays also has an effect on the number of positive responses yielded, with a higher 
proportion of reactions detected if ≥ 4x105 PBMCs/well are used (254). Due to the variability 
in the responses and the heterogeneity of the assay, the Association for Immunotherapy of 
Cancer Working Group recommends that the assay be performed in triplicate (254). 
3.1.1.4 Cytokines 
The balance of cytokines and chemokines can directly impact the generation and direction of 
an immune response. The cytokine/chemokine profile can reveal additional information as to 
the immune response of a patient to therapy and forms a complementary tool for analysis 
when used alongside other assays. Multiple methods can be used to monitor the levels of 
these solutes, including, for example, ELISA and Luminex; the major advantage of Luminex 
being high-throughput analysis. Another advantage is that the relative amount of sample 
needed is much smaller than would be required for multiple ELISAs, thereby preserving 
precious patient samples. However, there are considerable cost implications. Comparisons 
between ELISA and multiplex bead assays have shown that, for most TH1 and TH2 cytokines, 
there is a high degree of correlation between the two methods of detection (255,256). This 
stands true for stimulated and non-stimulated patient samples. Although there is a high level 
of concordance between the two assays, the absolute values of analyte detected can differ, 
possibly due to differences in the reference standards and the antibodies used in the assay 
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(256). Multiplex bead assays have been shown to be more sensitive when detecting low levels 
of cytokine and chemokines (257) which is essential for patient samples. 
Once again, processing and storage of samples can alter the outcome of the assays. Levels of 
IL-8 in plasma from five-day old platelet concentrates, for example, are far higher than 
concentrates analysed after only two days of storage (258). In contrast, cytokine production 
from PBMCs stored at room temperature was decreased compared to those that were 
analysed fresh (259).  
3.1.2 Sample Collection and Storage 
In order to ensure sample quality and reproducibility of analyses, we validated a number of 
aspects of sample collection, isolation of immune cells, preparation of cells for analyses and 
sample storage. We also focussed on the cryopreservation of immune cells to use i n batch 
analysis of immune function.  
3.1.2.1 Collection of Whole Blood Samples 
There is some concern regarding the viability of cells and the impact of time from blood being 
drawn to being processed. Storage of samples at room temperature for up to 24 hours does 
not seem to affect the cell counts of individual immune cell populations, with the exception of 
NK cells (slight increase by 24 hours) and monocytes (slight decrease by 24 hours) (260). There 
is some variability in the expression of the activation markers CD86 and HLA-DR on the surface 
of monocytes if there is a period of greater than four hours between blood sample collection 
and staining (260). 
Following cryopreservation, cell recovery upon thawing is decreased when the time between 
sample collection and processing/cryopreservation is greater than seven hours and increased 
when processed less than two hours after collection (261). Similarly, samples taken and left 
for over eight hours before being processed not only demonstrated decreased cell viability 
after cryopreservation but T cell responses in IFN-γ ELISpot assays were also diminished (243). 
It has been suggested that samples anticoagulated with EDTA (rather than heparin) have 
greater contamination with granulocytes when kept for 24 hours before lymphocyte 
separation (262), so although yield of PBMCs may be similar, the functional effect of 
granulocyte contamination in this situation cannot be disregarded. In addition, the storage of 
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whole blood samples in EDTA tubes (at RT) can affect antigen-specific responses, with a 
decrease in antigen-specific T cell responses at all time points up to 24 hours (263).  
3.1.2.2 Isolation of PBMCs 
PBMCs can be isolated from fresh whole blood via gradient density separation (using solutions 
such as Lymphoprep™ or Ficoll®) or pre-prepared tubes such as Vacutainer Cell Preparation 
Tube. There is no observed difference between the yield of isolated immune cell sub-
populations using either method (243,264). Neither is there a difference in T cell 
immunological responses (265). However, relatively small variations in the preparation of cells 
can affect the outcome of immune assays. For example, using different media for density 
gradient separation can produce discrepancies in the magnitude of T cell response to recall 
antigens: IFN-γ expression was increased in the population of PBMCs isolated using Ficoll® vs. 
Lymphoprep™ (266).  
Although many functional assays focus on the analysis of PBMCs and cytokine/chemokine 
profiles, granulocytes (the majority of which are neutrophils) form a significant part of the 
immune defence against pathogens. However, assays measuring neutrophil activity can be 
difficult and the use of radio-labelled trafficking or chemotaxis assays can be variable and 
correlate poorly to immune functionality (267). One of the major difficulties with the storage 
or culture of granulocytes in vitro is the cytotoxic and microbiocidal potential of activated 
neutrophils (98,268). If neutrophils are isolated from human whole blood, subsequent lysis 
may be due to the release of lysosomes, which initiate cell death. Reduced granulocyte 
viability is directly proportional to the release of lysosomal enzymes (269). Interestingly, 
inhibition of immune responses (seen in PBMCs isolated from peripheral blood which have 
been left at RT for a prolonged period before being processed), may be, in part, due to 
granulocyte contamination of PBMC isolates (270).  
3.1.2.3 Cryopreservation of PBMCs 
Cryopreservation of cells must be optimised in order to maximise cell recovery and prevent 
damage through osmotic processes during freezing. Everything from the FM used to the speed 
of the freezing process and method of thawing can affect the recovery of immune cells 
following cryopreservation. Crucially, DMSO, used as a cryopreservative, should be added in a 
step-wise manner, to protect the cell from sudden osmotic changes and to maintain cell 
integrity (271).  
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The FM in which cells are cryopreserved can also vary greatly between laboratories. In some 
studies, FMs were chilled (ideally below 4 °C) when preparing to cryopreserve cells. This is 
borne out in studies showing that using warmed solutions decrease T cell responses in 
immune assays (266,272). In contrast, other studies have found that adding warmed FMs 
increases the recovery of cryopreserved PBMCs on thawing (273).    
The method of cryopreservation is also important and can itself yield differences in the quality 
and population of cells once recovered. PBMCs must be frozen in a controlled way to avoid 
formation of intracellular ice crystals, which cause cell membrane disruption and lysis. 
Common methods include either a controlled-rate freezer (CRF) or a manual method using 
equipment such as a Mr Frosty™; both function in a similar way by controlling the rate of 
freezing to 1 °C per minute. When culturing DCs from monocytes, for example, the yield is 
shown to be greater if PBMCs are cryopreserved using a CRF technique rather than a manual 
method (274). Despite some benefits of a CRF, use of a Mr Frosty™ is still accepted as good 
practice in many centres. 
There seems to be no consensus on the freezing density of lymphocytes for cryopreservation 
in the literature to date. Pross and Maroun cryopreserved lymphocytes at densities of 
between 3 and 5x106 /ml (275), whereas Mata et al. (276) and Aziz et al. (277) used freezing 
densities of 1x107 PBMC/ml. Disis et al. found there was no difference in viability of thawed 
PBMCs when cryopreserved in aliquots of 1x107/ml, 2x107/ml or 3x107/ml (278).  
3.1.2.4 Storage of Samples 
For batch analysis, clinical trial samples are stored long term in LN2 until required. Some 
studies have shown that storing samples at -70 °C for ≤ 3 weeks does not affect recoverable 
cell viability (279), while others have shown a decline in thawed PBMC viability when stored at 
-80 °C compared to those stored in LN2, with a higher proportion of apoptotic cells. Of note, 
these samples were thawed and analysed after 14 months, which may explain the poorer 
yield (280). T cell populations within frozen PBMCs also appear to remain constant at time 
points up to 15 months in LN2 (and when stored at -70 °C for ≤ 3 weeks) (279). There is 
conflicting data around the preservation of T cell responses over time. Weinberg et al. 
demonstrated that T cell responses to stimulus such as pokeweed mitogen (in lymphocyte 
proliferation assays) were maintained up to 15 months after storage in LN2 (279). There was, 
however, variability in responses to different stimuli when PBMCs had been stored at -70 °C. 
In contrast, other data suggests that long term storage of cryopreserved PBMC (admittedly 
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from HIV-positive individuals) diminishes both CD4+ and CD8+ T cell responses to a variety of 
peptide stimulants (measured by % IFN-γ expression on cell population of interest), 
particularly in cells stored for greater than one year (281). This loss was, as expected, more 
evident in the CD4+ population. This effect was not seen in the HIV-negative donors (281), 
emphasising the importance of standardising and validation of assays in the patient 
population of interest.  
In addition, any fluctuations in temperature during storage can decrease cell viability, cell 
recovery and T cell responses in assays such as the ELISpot (282,283). Even small changes can 
lead to reduced recovery and jeopardise outcomes from immune assays (282). The source of 
these variations, such as other samples being removed from the same storage facility, should 
be considered when planning long-term storage of clinical samples. Providing that different 
centres adhere to quality assured SOPs the yield and functional immune profile of PBMCs can 
be maintained if cryopreserved samples can be shipped on dry ice and transferred 
immediately to LN2 on arrival at a central laboratory.  
3.1.3 Preparation of PBMCs for use in Immune Assays 
3.1.3.1 Thawing of PBMCs 
Variability in the thawing procedure of cryopreserved cells across different laboratories can 
cause large fluctuations in the viability of PBMCs (254). Despite this, a number of factors do 
not seem to alter the viability of cryopreserved cells on thawing: duration of centrifugation 
following thawing, the volume the samples are resuspended in and the density of thawed cells 
during the washing procedure (278). Interestingly, although there is conflicting data on 
whether there is benefit to cooling FM before cryopreservation of PBMC, washing PBMCs in 
cold medium after thawing has a detrimental effect on cell viability (278,284).  
3.1.3.2 Resting PBMCs versus Immediate Use 
There are questions about whether cells which have been cryopreserved can be used in 
immune assays immediately upon thawing or whether a period of incubation may be 
beneficial to allow cells to recover from the thawing process. This has to be weighed against 
the possible loss of cells following a period of resting before use. As an example, PBMCs from 
a cohort of patients with chronic viral infections (including HBC and HIV) were analysed after 
being rested overnight and compared to PBMCs used immediately. Although viability of the 
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cells decreased, it remained above 90 % in the rested group (median viability 94.8 % vs. 92.5 
%) (285). Interestingly, rested PBMCs contained a greater number of dead cells, whereas a 
higher proportion of apoptotic cells were found in unrested PBMCs. Rested PBMCs, therefore, 
may have reduced viability due to death of apoptotic cells, leaving a purer population of viable 
functional immune cells (285,286). Loss of cells due to apoptosis, rather than necrosis, should 
ensure that the immune milieu of the assay is not skewed by this process. While apoptotic 
cells do not respond to antigenic stimulation (by IFN-γ production), the presence of apoptotic 
cells in a viable T cell population can decrease response of viable T cells to viral antigens (287). 
Resting thawed PBMCs before use increases the number of positive responses to viral 
antigens by CD8+ T cells and consequently resulted in increased expression of cytokines 
including IFN-γ and TNF-α in response to antigen (285,288). This effect has also been 
demonstrated to a lesser extent in CD4+ T cells. This suggests that T cell responses can be 
enhanced by resting PBMCs after thawing and can increase sensitivity in detecting antigen-
specific immune responses without increasing the levels of false positives (as there was no 
response to tumour associated antigens by HD PBMCs) (288).      
Resting PBMCs overnight can enhance pre-existing CD8+ T cell responses to CEF peptides in 
ELISpot assays but has no effect on patients with inherently low CEF responses, or on CD4+ 
responses to antigen (289). Enhancement of responses in this context may be useful if the 
frequency of circulating antigen-specific T cells is low. An enhanced response was not related 
to changes in T cell populations as determined by immunophenotyping, suggesting that these 
findings are due to increased functionality of an already stimulated T cell in response to 
antigen/peptide (289). Resting PBMCs overnight prior to use can also decrease the 
background (non-specific) readings compared to cells used immediately after thawing 
(247,249). In these situations, there should be a balance between maintaining functionality of 
immune cell populations, being able to detect immune responses with a high degree of 
specificity and doing so while being able to preserve the viability of cell populations within 
limited clinical samples, given that resting can lead to the loss of up to 50 % of  the viable 
PBMC population (289). We, therefore, specifically investigated the effect of using thawed 
PBMCs immediately in assays, compared to immune responses in populations of PBMCs 
rested overnight before being used.  
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3.1.4 Using Fresh or Cryopreserved Cells in Immune Assays 
The cryopreservation of PBMCs is required for the practicalities of batched analysis of patient 
samples from multiple clinical sites and potentially multiple trials. Bulk analysis also limits the 
intra- and inter-patient variability, as all samples are analysed at the same time using the 
same reagents, same machine settings, etc. Quality-assurance measures should therefore 
include the time from blood collection to processing/freezing and viability/yield of thawed 
PBMCs (290) in order to ensure that results are reliable and reproducible. We therefore 
specifically investigated the yield of cryopreserved PBMCs and the practicalities of freezing in 
order to maintain cell viability and robust immune responses. 
3.1.4.1 Immunophenotyping 
There is variation in the reproducibility of cellular markers on different immune cell 
populations following cryopreservation. Jeurink et al. demonstrated that cryopreserved 
immune cells within the whole PBMC population were similar to those in fresh samples (286). 
While some groups have shown that the relative populations of CD3/CD4+ and CD3/CD8+ T 
cells within cryopreserved PBMCs correlated with those from paired fresh samples (286,291), 
others have demonstrated that the frequency of T cells fall post-thawing and did not recover 
(292). Lemieux et al. showed that following cryopreservation of PBMCs from HDs, populations 
of NK cells and B cells were unchanged but if cells were rested for 24 hours, there was a 
significant decrease in the frequency of CD3+ T cells and monocytes (292). Previous studies 
have shown that activation markers on NK cells, monocytes and B cells are comparable 
whether PBMCs are used fresh, cryopreserved and rested prior to use or cryopreserved and 
used immediately on thawing (276).  
Tregs are a population of particular interest when evaluating the immune response and 
accurate assessment of Treg activation is essential to determine the immunosuppressive 
potential of this cell population. Depending on the definition of the phenotype of Tregs, there 
can be appreciable differences in the proportion of Tregs between fresh and frozen 
conditions: CD4+CD25+FoxP3+ cells are lower in cryopreserved cells, whereas when defined 
as CD4+CD25+CD127low, the population is equivalent (293). Other, conflicting data shows that 
the population of Tregs within PBMCs can be altered by cryopreservation (294). To this end, 
we investigated the effect of cryopreservation on PBMC populations as assessed by flow 
cytometry, including activation and identification of specific populations of immune cells. 
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3.1.4.2 NK Cell Assays 
Activation and function of NK cells in fresh and frozen PBMCs have been assessed by a variety 
of groups. Although populations of NK cells are not diminished following cryopreservation 
their absolute cytotoxic potential is reduced (286). In contrast, other studies have 
demonstrated that the relative cytolytic activity of NK cells can be maintained between each 
condition (fresh vs. frozen) (271). In data from HD PBMCs, there is evidence of variation in NK 
cell function following incubation prior to use in chromium release assays (used immediately 
on thawing vs. being incubated in culture medium for between 3 and 24 hours) (271). 
Contrary to this, Mata et al. compared NK cell activity in fresh cells, frozen/rested cells and 
frozen/unrested cells. They observed that resting PBMCs after thawing achieved similar 
results than when using fresh cells in immune assays (276). Specifically, NK-mediated 
cytotoxicity against target cells, as well as ADCC and CD107 degranulation, were comparable 
to fresh PBMCs, if cryopreserved cells were thawed and rested overnight prior to use  (276). 
Earlier work by Pross and Maroun supports this finding, showing that cryopreserved NK cells 
rested at 37 °C for at least five hours before use demonstrate activity comparable to that seen 
in fresh lymphocytes (275).   
3.1.4.3 T Cell Assays 
Cryopreserved PBMCs can also be used in the evaluation of adaptive T cell-mediated immune 
responses, such as ELISpot assays. Following thawing of HD PBMCs, viability of the cells may 
be decreased but the size of the CD3+ T cell population is not (286). This is dependent, 
however, on whether the PBMCs have been co-cultured with a stimulator of T cell function, 
such as phorbol myristate acetate (PMA) (286). While it has been shown that cryopreservation 
can diminish T cell responses to viral peptides in ELISpot assays (281), other groups have 
found that responses to recall antigens (including viral peptide pools) are not affected by 
cryopreservation (273,278). Indeed, Kuerten et al. (289) demonstrated that cryopreservation 
did not significantly affect IFN-γ production in response to CEF viral peptides when compared 
to fresh PBMCs. Fluctuations in temperature during the long-term storage of PBMCs can also 
effect T cell responses when cells are thawed for immune assays (283).  
In this regard, we specifically investigated the effect that cryopreservation would have on 
innate and adaptive immune cell analysis, in particular NK cell degranulation/cytotoxicity 
assays and ELISpot assays.  
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3.1.4.4 Measurement of Cytokines/Chemokines 
There are concerns that cryopreservation may activate immune cells and skew the immune 
profile of cells used in immune assays. There is conflicting data in this regard, with some data 
suggesting that levels of IL-10, IL-12, TNF-α, IFN-γ and IL-5 do not vary in cell culture 
supernatants of thawed PBMCs (286). However, analysis of cytokine/chemokine production 
from PBMCs collected from a cohort of children with diabetes showed elevated levels of IL-6, 
IFN-γ, IL-10 and IL-13 following freeze-thawing (295). Exogenous stimulation of PBMCs results 
in variable production of solutes between the fresh and cryopreserved conditions (greater 
IFN-γ and TNF-α and lower IL-10 and IL-13) (295). Other studies have shown decreased levels 
of IL-12 in response to increased IL-10 production from thawed PBMCs (296). The previous 
study also showed differential expression of IL-10 when thawed PBMCs were stimulated with 
phytohaemagglutinin (PHA) (296). However, similar evaluation of PBMCs in another cohort of 
HDs showed no variation in cytokine production (including IL-6, TNF-α and IFN-γ) following 
PHA stimulation, between fresh and cryopreserved PBMCs (297). The disparities in levels of 
each cytokine expressed by cryopreserved cells, with or without stimulation, should be 
evaluated prior to being included in immune panel analysis of clinical trials samples (298).  
In conclusion, variability between assays is decreased when performed by the same operator 
but repeatability can be maintained over different laboratories and different operators if 
standard operating procedures (SOPs) are set and adhered to.  
3.1.5 Rationale for Current Study 
We aimed to develop and validate a panel of reproducible immune assays which could be 
batch analysed and used to evaluate the immune response, in peripheral blood, across a 
spectrum of patient populations. Specifically the aims of this part of the project were:  
1. To optimise viable cell recovery after cryopreservation, including isolation of immune 
cell populations, freezing densities and storage of samples. 
2. To optimise the thawing process of samples in order to be able to use them in 
immune assays. 
3. To explore whether there is a significant change in the response and cell phenotype 
after cryopreservation. 
4. To explore whether there are significant differences in functional assays after 
cryopreservation. 
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3.2 Immune Assay Validation: Results 
3.2.1 Cryopreservation of Clinical Trial Samples to Optimise Cell Recovery 
3.2.1.1 Recovery and viability of PBMCs are maintained if separated from 
granulocytes prior to cryopreservation 
Cryopreservation of immune cells was investigated in order to improve the maximum 
recovery of viable cells following thawing and better understand differential viability and 
recovery of different cell types. Fresh peripheral blood was obtained from HDs and either 
whole WBCs (including granulocytes) or PBMCs (without granulocytes) were isolated, to 
determine whether these would yield different results.  
Cells were cryopreserved at a density of 1x107 PBMCs/ml. On thawing, viable cells were 
counted using Trypan Blue exclusion and the proportion of recovered cells was calculated. 
There was a range of viable cell recovery between HDs (Table 3.1).  
Table 3.1 Yield of viable PBMCs from HDs using Trypan Blue exclusion 
 Cryopreserved Cells Viable Cell Yield Recovery of viable cells 
HD 1 21.3x106 7.52x106 35.3 % 
HD 2 19.5x106 12.64x106 64.8 % 
HD 3 20.9x106 9.52x106 45.5 % 
  
Viability can also be assessed by PI staining. In order to ensure that Trypan Blue exclusion was 
a reliable way to assess the recovery and viability of PBMCs following cryopreservation, PI 
staining was used to assess the proportion of dead cells within the population of viable, 
thawed PBMCs from HD 1-3. PI staining of these PBMCs showed that Trypan Blue exclusion 
had a high degree of fidelity for assessing the viability of PBMCs. Viability of recovered cells in 
each of the three donors was greater than 90 % (91.6 %, 91.3 % and 91 %, respectively; 
Figure 3.1). These data indicate that Trypan Blue is a valid method for evaluating the viability 
of PBMCs isolated from peripheral blood and will therefore be used for the remainder of the 
project.  
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Figure 3.1 Viability of cryopreserved PBMCs verified by PI staining 
HD PBMCs were isolated from whole blood samples as already described and 
cryopreserved in clinical FM at 1x107 PBMCs/ml. Thawed PBMCs were then stained with PI 
before being analysed by FACS. Levels of dead cells in the three donor samples (HD 1-3; (a) 
(b) and (c)).   
 
In order to determine the optimum method of sample preparation from patient blood, we 
sought to compare the isolation and storage of the whole WBC population (including 
granulocytes) with the PBMC population. Whole WBC populations (from HDs) were 
cryopreserved at densities of 0.5x106 cells/ml, 1x106 cells/ml and 2x106 cells/ml in different 
FMs (Table 2.3). Following thawing and counting of viable WBCs, it was clear that the yield of 
viable WBCs was much lower than anticipated (below 20 % in all conditions, Figure 3.2a). 
However, increasing cell density was associated with greater yield. This was significant when 
cells had been preserved in standard FM (0.5x106 WBCs/ml vs. 2x106 WBCs/ml, 2.7 % vs. 17.3 
%, p=0.0066; 1x106 WBCs/ml vs. 2x106 WBCs/ml, 5.7 % vs. 17.3 %, p=0.0104). At a freezing 
density of 0.5x106 WBCs/ml there was a significant difference in cell recovery when preserved 
in standard FM vs. 20 % DMSO/RPMI (2.7 % vs. 9.3 %, respectively, p=0.0099). At a density of 
1x106 WBCs/ml, 20 % DMSO/RPMI was significantly superior to 10 % DMSO/RPMI (12.3 % vs. 
5.0 %, respectively, p=0.0142). Interestingly, as the freezing density increases, the effect of 
different FMs seem to be abrogated, with no significant difference seen between media at 
density of 2x106 WBCs/ml (Figure 3.2a). 
As the whole WBC yield was less than expected, the yield of PBMCs (without granulocytes , 
isolated from HDs) was investigated as an alternative. Higher cell densities of 5x106 PBMCs/ml 
and 1x107 PBMCs/ml were used, given the results of previous WBC experiments. Overall, 
recovery of PBMCs at these specific densities was increased compared to WBCs (Figure 3.2b).  
There was no significant difference between viable cell recovery from these high freezing 
densities (5x106/ml, 1x107/ml) with any FMs. Yield was higher at both cell densities for cells 
(a) (b) (c) 
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preserved in standard FM (10 % DMSO/FCS) suggesting that this could be superior in 
preventing loss of cell viability. 
 
  
Figure 3.2 Recovery of whole WBC and PBMC populations following cryopreservation 
Recovery of viable HD WBCs (a) and PBMCs (b) following cryopreservation. Cell populations 
were frozen at stated densities using different FMs. After thawing the yield of viable cells 
was determined using Trypan Blue exclusion (n=3).  
 
Although some loss of viability is expected when peripheral blood cells are cryopreserved, 
maximising the cell recovery is essential to be able to perform multiple immune assays. As 
yields from fresh HD blood did not meet expected levels, a comparison of PBMCs from HD 
fresh blood and leucocyte cones was performed. Leucocyte cones are a reliable source of high 
quantities of PBMCs and the usual product of use within the laboratory for research purposes. 
Once again higher freezing densities (2x107 PBMC/ml and 4x107 PBMC/ml) were used to 
investigate whether this would yield a greater number of viable PBMCs on thawing 
(Figure 3.3). Recovery of PBMCs from fresh blood was higher when cells had been preserved 
in standard FM compared to 20 % DMSO/RPMI. This was significant at a freezing density of 
4x107 PBMCs/ml (standard FM vs. 20 % DMSO/RPMI 30.93 % vs. 13.33 %, p=0.0156). In 
comparison, there appeared to be no change in the recovery of cells from cones when 
comparing both cell density and FM. 
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Notably, the recovery of viable PBMCs was much lower using fresh peripheral bl ood 
compared to cones under all conditions tested. This was significant at a freezing density of 
4x107 PBMCs/ml in 20 % DMSO/RPMI (fresh blood vs. cones 13.33 % vs. 47.20 %, p=0.0151).  
 
 
Figure 3.3 Recovery of PBMCs isolated from fresh blood and leucocyte cones.  
PBMCs were isolated from HD whole blood and from leucocyte cones. PBMCs were frozen 
at the specified densities in either standard FM or 20% DMSO/RPMI. Following thawing, the 
yield of viable cells was determined using Trypan Blue exclusion (n=3).  
 
Overall, these data suggest that there is trend towards better recovery of viable PBMCs after 
cryopreservation in standard FM. There also appears to be a higher yield when PBMCs are 
preserved at higher densities. There was still a difference between recovery of HD PBMCs and 
those from cones, therefore we investigated different FMs to try and improve recovery of HD 
cells in line with those derived from cones.  
3.2.1.2  ‘Clinical’ freezing mixture increased recovery of cryopreserved PBMCs 
In order to optimise the cryopreservation process, recovery of HD PBMCs cryopreserved in 
standard FM (which had been shown to be superior to other mixtures), was compared to that 
of PBMCs cryopreserved in clinical FM (Table 2.3). The latter has been shown by collaborators 
to yield an optimum number of viable cells after cryopreservation and may be more 
appropriate for functional immune analysis at a later stage (personal communication). 
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Recovery of viable PBMCs was not significantly different when cells were cryopreserved in 
standard or clinical FM (Figure 3.4). There was also no significant difference in cell recovery 
between freezing densities.   
 
 
Figure 3.4 Recovery of PBMCs following cryopreservation in standard or clinical FM 
Cell populations were frozen at stated densities using different FMs. After thawing, the 
yield of viable cells was determined using Trypan Blue exclusion (n=3).  
 
This data collectively suggests that to optimise immune cell recovery following 
cryopreservation, PBMCs should be isolated from granulocytes before being frozen in clinical 
FM at a density of 1x107 PBMCs/ml. By freezing at this density, the yield of thawed PBMCs will 
be maximised, while also allowing cells to be frozen in smaller batches so cells are not wasted 
on thawing.   
3.2.2 Functional Analysis of Clinical Trial Samples: Comparing Fresh and 
Cryopreserved Cells. 
Clinical trial samples need to be cryopreserved in LN2 for long-term storage prior to analysis 
and functional assays require validation for cells which have been cryopreserved.  
3.2.2.1 Cytotoxicity of PBMCs against target tumour cells is maintained following 
cryopreservation 
PBMCs were isolated from cones and either used fresh or cryopreserved for a minimum of 8 
weeks prior to analysis. Reovirus (1 pfu/cell) was used as an immune stimulant to activate 
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PBMCs overnight prior to setting up chromium release assays to assess cytotoxicity against 
three target cell lines (K562, SW620, Mel888). Figure 3.5 shows that both fresh and frozen 
PBMCs were activated by reovirus, resulting in increased target cell cytotoxicity in comparison 
to unstimulated PBMCs. This was true for all three target cell lines (e.g. reovirus activation at 1 
pfu/cell vs. 0 pfu/cell for cryopreserved PBMCs against SW620 cells, 62.3 % vs. 23.0 %, 
respectively, p=0.0146; for fresh PBMCs against SW620 cells at same ratio, 82.3 % vs. 44.3 %, 
p=0.0204; both at 100:1 effector:target ratio). Although the absolute cytotoxicity of 
cryopreserved cells is moderately diminished compared to fresh PBMCs, this data indicates 
that previously frozen PBMCs are still functional and able to respond to an immune stimulus 
following cryopreservation.  
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Figure 3.5 Cytotoxicity of fresh and cryopreserved PBMCs  
PBMCs from cones were either used fresh (a, c, e) or following cryopreservation (b, d, f). 
Cells were treated with 0 or 1 pfu/cell reovirus overnight at 37 °C before being incubated 
with 51Cr-labelled target cells (K562 (a + b), SW620 (c + d) and Mel888 (e + f)). Percentage 
of dead tumour cells was then determined (n=3). For p values see Appendix (Table 8.1). 
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3.2.2.2 Degranulation of immune cells against target tumour cells is maintained 
following cryopreservation 
CD107 degranulation assays were performed in parallel with chromium release assays to 
determine the sub-population of immune cells responsible for target cell death. Target cell 
lines were incubated for 4 hours with PBMCs previously activated ± 1 pfu/cell reovirus 
overnight. PBMCs were either fresh or had previously been cryopreserved. Cell populations 
were defined as described in Table 2.5 and degranulating cells were identified using CD107a/b 
antibodies. NK cells expressed the highest levels of CD107 when compared to NKT and T cells, 
suggesting that these cells are predominantly responsible for lysis of tumour cell targets via 
degranulation (Figure 3.6). 
 
 
 
  
 
Figure 3.6 Degranulation of fresh and cryopreserved immune cell populations against 
tumour cell targets 
Fresh (a) or cryopreserved (b) PBMCs were treated ± reovirus at 1 pfu/cell. Following 
overnight incubation, PBMCs were cultured with target cell lines and anti -CD107 antibodies 
for 4 hours. Flow cytometry was used to determine the proportion of CD107 expression 
within immune cell sub-populations (n=3).  
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Figure 3.7 shows degranulation of NK cells (within the PBMC population) in further detail. 
Treatment of PBMCs with reovirus increased NK cell degranulation when exposed to tumour 
targets. This was significant in all target cell lines when using fresh PBMCs (K562: 54.4 % vs. 
84.1 %, p=0.0007; SW620: 52.2 % vs. 83.6 %, p=0.0121; Mel888: 11.0 % vs. 63.0 %, p=0.0023). 
Activation of cryopreserved NK cells with reovirus was also significant against the K562 and 
Mel888 cell lines (K562: 34.4 % vs. 50.3 %, p=0.001; Mel888: 4.0 % vs. 11.3 %, p=0.0084). 
Although the result did not reach significance with SW620 target cells, the trend persisted, 
with mean CD107 expression 18.7 % (0 pfu/cell) vs. 50.0 % (1 pfu/cell; p=0.0647).  When 
exposed to K562 tumour cells, fresh NK cells expressed significantly more CD107 than 
cryopreserved NK cells, both with and without stimulation with reovirus (0 pfu/cell: 54.4 % vs. 
34.4 %, p=0.0399; 1 pfu/cell: 84.07 % vs. 50.30 %, p=0.0081). Following reovirus activation, 
there was also significantly increased CD107 expression on fresh NK cells exposed to both 
SW620 and Mel888 target tumour cells in comparison to cryopreserved cells (SW620: 83.57 % 
vs. 49.97 %, p=0.0171; Mel888: 63.03 % vs. 11.30 %, p=0.0047).  
 
Figure 3.7 Degranulation of fresh and cryopreserved NK cells against tumour cell targets 
Fresh or cryopreserved PBMCs isolated from cones were treated ± reovirus at 1 pfu/cell. 
Following overnight incubation, PBMCs were cultured with target cell lines and anti-CD107 
antibodies for 4 hours. Flow cytometry was used to determine the proportion of CD107 
expression within immune cell sub-populations (n=3).  
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Overall, absolute levels of CD107 expression were slightly lower in cryopreserved cells 
(Figure 3.7), reflecting the results of the chromium release assays but the effect of virus 
activation was comparable. 
3.2.2.3 Cytokine production induced by virus activation is maintained following 
cryopreservation  
PBMCs from cones were isolated and either used fresh or cryopreserved and thawed prior to 
use. Following an overnight incubation with 0 or 1 pfu/cell of reovirus, cell supernatants were 
collected and analysed by ELISA for cytokine/chemokine production in response to viral 
stimulation.  
Cell-free supernatants were evaluated for presence of CXCL-10, IFN-α, TRAIL and IFN-γ 
(Figure 3.8). GM-CSF, TNF-α, IL-28, IL-29 and IL-10 were also evaluated but little or no 
secretion of these cytokines were detected (data not shown). Analysis showed that there was 
an increase in the release of inflammatory cytokines in response to treatment with reovirus 
from both fresh and cryopreserved PBMCs. Levels of IFN-α were significantly different in both 
conditions (fresh PBMCs: 0 pfu vs. 1 pfu, mean ± SEM 0 pg/ml vs. 3252 pg/ml ± 575 pg/ml, 
p=0.011; frozen PBMCs: 0 pg/ml vs. 2256 pg/ml ± 638 pg/ml, p=0.0385; Figure 3.8a). Using 
fresh PBMCs, release of CXCL-10 and TRAIL were significantly increased after virus treatment 
(CXCL-10: 0 pfu vs. 1 pfu, mean ± SEM 99 pg/ml ± 68 pg/ml vs. 489 pg/ml ± 109 pg/ml, 
p=0.0227; TRAIL: 28 pg/ml ± 28 pg/ml vs. 167 pg/ml ± 37 pg/ml, p=0.0218; Figure 3.8b and 
Figure 3.8c). There was a trend for increased cytokine release in response to virus when using 
cryopreserved PBMCs but this was not significant. Levels of IFN-γ were increased from both 
fresh and cryopreserved PBMCs in response to stimulation with reovirus, though this did not 
reach statistical significance (Figure 3.8d).  
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Figure 3.8 Release of cytokines from fresh and cryopreserved PBMCs in response to viral 
stimulation 
PBMCs were isolated from cones and used fresh or following cryopreservation. PBMCs 
were treated with 0 or 1 pfu/cell reovirus and incubated overnight. Cell–free supernatants 
were collected and cytokine/chemokine release was analysed using ELISA. Graphs show 
secretion of IFN-α (a), CXCL-10 (b), TRAIL (c) and IFN-γ (d) (n=4).  
 
In these conditions, there appears to be an increase in cytokine release from both fresh and 
cryopreserved PBMCs in response to stimuli; however, the response could potentially be 
blunted from cryopreserved cells.  
3.2.2.4 Immunophenotyping of reovirus-activated PBMCs is maintained following 
cryopreservation 
Our lab has previously validated that the expression of various identification and activation 
markers are comparable on fresh and cryopreserved PBMCs (personal communication, data 
not shown). Immune cell populations were identified as shown in Table 2.5 and following 
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immunophenotyping, flow cytometry was used to determine the expression of activation 
markers on the cell surface in response to viral activation. These previous investigations were 
extended to determine whether PBMCs could be used immediately on thawing ( ‘same day’) or 
whether a period of incubation prior to immunophenotyping (‘rested’) could optimise the 
expression of activation markers of interest. The frequency of specific cell populations was 
monitored using identification surface markers. Additionally, cellular activation was measured 
using other markers (such as CD69). Most immune markers, including CD3, CD4 and CD8 were 
reproducible in both conditions (‘same-day’ and ‘rested’) (Figure 3.9a). This also applied to 
smaller immune cell populations, such as NK cells and B cells (Figure 3.9b). The only exception 
to this was in the CD14+ monocyte population. While there was no significant difference in 
untreated monocytes left resting overnight, stimulation of the PBMC population with reovirus 
lead to a significant loss of monocytes: 0pfu vs. 1pfu ‘rested’ 64.5 % vs. 14.6 %, p=0.0154; 1pfu 
‘same-day’ vs. 1pfu ‘rested’ 71.8 % vs. 14.6 % , p=0.0052. 
 
 
 
 
 
 
 
 
 
 
72 
 
 
 
 
Figure 3.9 Frequency of cell populations in cryopreserved PBMCs used immediately on 
thawing (‘same day’) or rested overnight (‘rested’) before immunophenotyping 
PBMCs were isolated from cones, treated with 0 or 1 pfu/cell reovirus and incubated 
overnight before cryopreservation. Following thawing they were either 
immunophenotyped immediately (‘same-day’) or rested overnight and used the following 
day (‘rested’). Expression of cell surface markers CD3, CD4 and CD8 was determined by flow 
cytometry (a). Similarly, the expression of CD56 (NK cells), CD3/CD56 (NKT cells), CD56 
bright and CD56 dim (NK cells), γδ TCR (γδ T cells) and CD19 (B Cells) was determined (b). 
Expression of CD14 was also determined by flow cytometry (c) (n=4). 
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There was evidence of immune cell activation across all cell types in response to reovirus, as 
demonstrated by increased CD69 expression. Once again this was reproducible whether 
PBMCs had been thawed for immediate use in the assay, or rested overnight before 
immunophenotyping (Figure 3.10).  
 
 
Figure 3.10 Expression of the activation marker CD69 on PBMCs activated with reovirus 
PBMCs were isolated from cones, treated with 0 or 1 pfu/cell reovirus and incubated 
overnight before cryopreservation. Following thawing they were either 
immunophenotyped immediately (‘same-day’) or rested overnight and used the following 
day (‘rested’). Expression of CD69 on immune cell sub-populations was determined by flow 
cytometry. Graphs show the percentage of positive cells (n=4). For p values see Appendix 
Table 8.2) 
 
If the percentage of positive cells within a population was universally high (Figure 3.11a) then 
RMS was used to determine the magnitude of expression of that particular marker on all cells . 
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N
K
 c
e
ll
s
N
K
 b
r i
g
h
t
N
K
 d
im
N
K
T
 c
e
ll
s
0
2 0
4 0
6 0
8 0
1 0 0
C D 6 9  e x p re s s io n  a ll c e lls  (s a m e  d a y  v s  re s te d )
%
 P
o
p
u
la
ti
o
n
0 p fu  S a m e  D a y
0 p fu  R e s te d
1 p fu  S a m e  D a y
1 p fu  R e s te d
* * * * * * * * * * * * * * * * * * * *
C
D
4
+
 T
 c
e
ll
s
C
D
8
+
 T
 c
e
ll
s
G
d
T
 c
e
ll
s
M
o
n
o
c
y
te
s
B
 c
e
ll
s
0
2 0
4 0
6 0
8 0
1 0 0
C D 6 9  e x p re s s io n  a ll c e lls  (s a m e  d a y  v s  re s te d )
%
 P
o
p
u
la
ti
o
n
0 p fu  S a m e  D a y
0 p fu  R e s te d
1 p fu  S a m e  D a y
1 p fu  R e s te d
* * ** * * ** * * * * * * * * * * * *
 
 
74 
 
cells, 0 pfu/cell vs. 1 pfu/cell, ‘same day’ 28.9 vs. 33.6, p=0.0078; ‘rested’ 28.5 vs. 40.7, 
p=0.0323, Figure 3.11b).  
 
  
 
 
Figure 3.11 Expression of identification and activation cell surface markers on immune 
cell populations in response to reovirus 
PBMCs were isolated from cones, treated with 0 or 1 pfu/cell reovirus and incubated 
overnight before cryopreservation. Following thawing they were either 
immunophenotyped immediately (‘same-day’) or rested overnight and used the following 
day (‘rested’). Expression of CCR7 on CD4+ T cells was determined by flow cytometry and is 
shown as percentage of positive cells (a) and RMS (b); (n=4).  
 
There was no significant difference in the percentage of CCR7 positive CD8+ T cells, NK cells, 
CD56 bright NK cells, NKT cells and γδT cells investigated in either PBMC condition (‘same-day’ 
and ‘rested’) (data not shown). With the exception of CD4+ T cells (Figure 3.11b), CCR7 
expression measured by RMS did not significantly change on any of the other cell populations, 
in any condition (‘same-day’ vs. ‘rested’, 0 pfu vs. 1pfu, data not shown). 
When assessing the percentage positive population, there was no appreciable difference 
between HLA-DR or CD86 expression on B cells and monocytes treated with reovirus (data not 
shown). Once again this was reproducible whether PBMCs had been rested or not before 
treatment with reovirus (data not shown). Similarly, when expression of HLA-DR was assessed 
by RMS, there was no demonstrable difference between expression of either on B cells or 
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monocytes in any of the tested conditions (data not shown). The same was true for CD86 
expression on B cells. However, there was a significant increase in CD86 expression on 
monocytes which had been activated with reovirus, in both the ‘same -day’ and ‘rested’ 
conditions (0 pfu vs. 1 pfu, ‘same day’ 4.7 vs. 7.9, p=0.0415; ‘rested’ 6.2 vs. 22.5, p=0.0474; 
Figure 3.12). There was no significant difference in expression of CD86 between cells that 
were used same day compared to those rested overnight within the reovirus treatment 
conditions (0pfu and 1pfu). 
 
 
Figure 3.12 Expression of CD86 on monocytes in response to reovirus 
PBMCs were isolated from cones, treated with 0 or 1 pfu/cell reovirus and incubated 
overnight before cryopreservation. Following thawing they were either 
immunophenotyped immediately (‘same-day’) or rested overnight and used the following 
day (‘rested’). Expression of CD86 using RMS was determined by flow cytometry (n=4). 
 
In conclusion, these data indicate that immunophenotyping of cryopreserved PBMCs is 
reliable for the identification and evaluation of activated PBMC sub-populations. Analysis of 
PBMCs by immunophenotyping was reproducible whether cells were used immediately or 
rested overnight. Although the monocyte population was diminished by resting overnight, 
especially when cells were stimulated with reovirus, di fferences in the expression of activation 
markers could still be determined.  
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3.2.3 Functional Analysis of Clinical Trial Samples: Validating ELISpot Assays 
Measurement of adaptive immune responses to antigen stimulation can be determined by 
IFN-γ production by T cells. ELISpot assays are an extremely sensitive assay and IFN-γ 
responses have been shown to correlate with outcome and survival in a range of cancers. 
However, due to the multiple steps involved and the sensitivity of the assay, standardisation 
of the protocol is needed in order to ensure the results are reliable and reproducible.  
3.2.3.1 Pooled viral peptides at optimal concentrations can detect recall T cell 
responses in ELISpot assays 
ELISpot assays can be used to determine T cell responses to TAAs (for example CEA or MART-
1) or the CEF viral peptide pool, as measured by IFN-γ SFUs. Cryopreserved PBMCs were 
thawed and rested for 2 hours prior to use in ELISpot assays. Rested PBMCs were incubated 
overnight on a ELISpot plate with either negative control (complete RPMI, Table 2.2), CEF viral 
peptide pools or TAA peptide pools. When PBMCs were incubated with increasing 
concentrations of CEF peptide pool, there was a clear increase in T cell responses in a dose -
dependent manner compared to the negative control (Figure 3.13). These data indicated that 
CEF peptide should be used at a dose of 2 µg/ml in future experiments. It is also apparent that 
CEF can been used as a reliable positive control in future ELISpot assays.   
 
 
Figure 3.13 IFN-γ T cell responses to viral peptide pool  
PBMCs were isolated from cones and cryopreserved. 
On thawing, they were incubated for 2 hours at 37 °C 
in complete RPMI. Following this, they were incubated 
alone (negative control) or with increasing 
concentrations of CEF peptide at a density of 1x105 
cells per well. Images (in duplicate) show examples of 
the T cell responses to: (a) negative control (b) CEF 
peptide at 0.2 µg/ml and (c) 2 µg/ml. 
 
(a) 
(b) 
(c) 
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3.2.3.2 Incubating PBMCs at high density prior to ELISpot assays does not increase 
T cell responses to peptide pools 
Previous studies have suggested that pre-incubation of cells at high densities for 2 days prior 
to use in ELISpot assays enhanced the detection of T cell responses to antigen/peptide (299). 
We tested this within our system and compared PBMCs thawed for immediate use and PBMCs 
that were cultured at a high density prior to use. 
Incubating thawed PBMCs at 1x107/ml for 48 hours prior to use in the ELISpot assay not only 
resulted in a loss of viable cells (data not shown) but did not enhance the response of T cells 
to peptide pools (Figure 3.14). In fact, pre-incubation in this manner only served to 
dramatically reduce the number of responding T cells. 
 
To confirm this effect is consistent when using cryopreserved PBMCs from patients (rather 
than HDs), ELISpot assays were performed using similar conditions of pre-incubation of 
patient PBMCs. In addition, a comparison of cell densities (1x105 PBMCs/well and 3x105 
PBMCs/well) within the ELISpot wells was performed to determine the optimum cell number 
required for the assay. As before, pre-incubating PBMCs at high density for 48 hours prior to 
use in the assay diminished (rather than enhanced) the detection of T cell responses (as 
shown by a lower number of IFN-γ SFU, Figure 3.15a and Figure 3.15d). Using PBMCs 
immediately following thawing led to the detection of a far higher number of T cell responses 
but at increased cell densities the background levels were elevated enough to conceal the 
individual SFUs (Figure 3.15f). Pre-incubating the cells for 24 hours (vs. 48 hours) prior to 
exposure to peptide pools (at both densities of PBMCs/well) seemed to enhance the detection 
of T cell responses without reaching excessive levels (Figure 3.15b and Figure 3.15e).   
 
 
Figure 3.14 IFN-γ T cell responses to CEF viral peptide 
pool following pre-incubation of PBMCs  
PBMCs were isolated and cryopreserved. On thawing, 
they were incubated at high density (1x107/ml) for 48 
hours at 37 °C in complete RPMI or used immediately. 
Images (in duplicate) show examples of the T cell 
responses to 2 µg/ml CEF peptide when cells were: (a) 
pre-incubated for 48 hours or (b) used immediately. 
(a) 
(b) 
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Figure 3.15 Patient IFN-γ T cell responses to viral peptide pool following high-density pre-
incubation of PBMCs 
PBMCs were isolated from patients with metastatic colon cancer prior to chemotherapy 
and cryopreserved. On thawing, they were incubated at high density (1x107/ml) for 24 or 48 
hours or used immediately. Images (in duplicate) show examples of T cell response to 2 
µg/ml CEF peptide at cell densities of 1x105/well (a - c) and 3x105/well (d - f); (a + d) pre-
incubated for 48 hours, (b + e) pre-incubated for 24 hours or (c + f) used immediately.  
 
To determine the response to TAAs, PBMCs isolated from the blood of melanoma or CRC 
patients were used in an ELISpot assay with MART-1 and CEA peptide pools, respectively, as 
immune stimuli. Cryopreserved PBMCs were thawed and incubated at a density of 1x105 - 
4x105 PBMCs/well with the peptide pool overnight. There was no detrimental effect from 
using higher concentrations of TAA peptide pool (e.g. 1 µg/ml CEA peptide vs. 2 µg/ml CEA 
peptide, Figure 3.16). Increasing cell density beyond 2x105 PBMCs/well did not increase T cell 
responses (data not shown). 
 
 
 
 
 
 
(a) 
(b) 
(c) 
(d) 
(e) 
(f) 
48 hours 
No incubation 
24 hours 
1x105 PBMC/well 3x105 PBMC/well 
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Figure 3.16 Patient IFN-γ T cell responses to CEA  
PBMCs were isolated from patients with metastatic CRC and cryopreserved. On thawing, 
they were incubated at high density (1x107/ml) for 24 or 48 hours or used immediately. 
Example images (in duplicate) show T cell responses (at a density of 1x105 PBMC/well when 
thawed cells were used immediately) to CEA peptide at 1 µg/ml (a) and 2 µg/ml (b). 
 
In conclusion, ELISpot assays are a robust method to detect antigen-specific T cells, either in a 
pan recall response to previously encountered viral peptides or against TAAs when analysing 
PBMCs from cancer patients. Pre-incubating PBMCs at high density for 48 hours, after being 
thawed and prior to use in the assay, does not seem to enhance the detection of T cell 
responses. Pre-incubating cells for 24 hours, however, may mean that differential levels of 
response to antigen could be detected across a heterogenous group of patients.  This method 
of preparing cells for use would be more in keeping with the other assays and allow batch 
analysis after 24 hours incubation. Finally, we have shown that peptide pools derived from 
TAAs can also be used to detect tumour-specific T cell responses in patients.  
 
 
 
 
  
(a) 
(b) 
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3.3 Immune Assay Validation: Discussion 
In clinical trials of novel anti-cancer agents, including immunotherapy, there is growing 
interest in translational biological outcomes. In order to gather data about the effect of these 
therapies on the immune system and the validation of potential biomarkers, large numbers of 
clinical blood samples need to be collected and analysed. In previous clinical trials in our lab, 
PBMCs from donor blood samples have been isolated and analysed on the same day. Aside 
from being very time- and resource-intensive, this can also add variability into sample analysis 
and is impractical for anything other than immunophenotyping panels, where cells can be 
stained and fixed to preserve integrity. Batch analysis of these samples, following 
cryopreservation, in validated immune assays will ensure that information collected is 
accurate, reproducible and meaningful.  
Following cryopreservation and thawing of clinical samples, the recovery (% yield) of v iable 
cells requires assessment. Trypan Blue was routinely used to calculate the proportion of viable 
immune cells in these validation experiments. Verification of this method with PI staining 
illustrated that Trypan Blue exclusion was highly accurate and determined that over 90 % 
were viable cells, a trend seen across different donors (Figure 3.1).  
The yield of immune cells isolated from clinical samples must be maximised, especially if 
patients are undergoing chemotherapy where a drop in cell counts is anticipated. Our data 
shows that when cryopreserved as a whole population, WBCs have a poor rate of recovery on 
thawing (Figure 3.2a). This is likely due to the presence of granulocytes within the population, 
which when thawed, lyse and release products which damage other immune cells , an 
observation which is supported by other published data (269). Conversely, the recovery of 
viable cells is increased when the PBMC population is separated from the granulocytes and 
frozen in isolation (Figure 3.2b). Exposure of the PBMC population to granulocytes, as the 
result of a prolonged period of time between sample collection and PBMC isolation (within 
blood sample collection tubes), has been shown to attenuate T cell responses in subsequent 
immune assays (300). For this reason, blood samples should be processed as soon as possible 
following venepuncture and cryopreserved as PBMCs, rather than mixed whole WBCs, to 
optimise both the yield and functionality of viable cells. We therefore aimed to process all 
clinical samples within 2 hours of venepuncture.   
Traditionally, leucocyte cones from HDs have been used to source PBMC populations for use 
in the lab, due to the high yield of PBMCs from each cone and ease of access. It was notable in 
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our data that the recovery of cryopreserved PBMCs isolated from HD leucocyte cones was 
higher than those isolated from fresh donor blood samples (Figure 3.3). The leucocytes cones 
do not contain granulocytes and, as such, there is no contact with PBMCs ex vivo. Hence, the 
viability of patient clinical samples are likely to have been affected by the presence of 
granulocytes despite being processed as soon as possible. Consequently, the conditions for 
the cryopreservation of PBMCs were optimised using fresh blood samples from this point 
onwards.  
We observed that using a standard FM of 10 % DMSO/FCS yielded a higher proportion of 
viable cells when compared to FM using complete RPMI (Figure 3.2). Other studies 
investigating the optimum FM to use when cryopreserving PBMCs have found little difference 
between the use of RPMI or FCS-based FM (243). In addition, our data indicated that 
increasing the percentage of DMSO in the FM to 20 % did not negatively affect cell recovery, 
unlike other groups such as Nazarpour et al. (Figure 3.2, (272)). This data also showed that the 
use of FM containing pooled human AB serum (clinical FM, Table 2.3) was similar to standard 
FM in terms of the percentage of PBMCs recovered following cryopreservation ( Figure 3.4). 
This is in contrast to data published by Disis et al, who observed diminished viability of PBMC 
following cryopreservation in FM containing HS (278). These studies, however, did not include 
functional analysis of PBMCs cryopreserved in FM containing HS. Personal communication 
with other groups has supported the use of HS-containing FM in maintaining functional 
activity of PBMCs. As such, clinical FM was carried forward and used throughout further 
investigations. 
Cell recovery was enhanced by increasing the freezing density of PBMCs (Figure 3.3 and 
Figure 3.4). There appears to be no consensus on this in published data and other groups have 
used freezing densities of between 3x106 PBMC/ml and 3x107 PBMC/ml to store samples for 
analysis (275,276,278). However, the density of PBMCs should be balanced between 
optimising cell viability and ensuring that all assays can be performed as required, so that an 
appropriate number of vials can be thawed as needed for analysis without unnecessary waste 
of precious clinical samples. As such, following these observations, PBMCs collected during 
subsequent studies were cryopreserved at a density of 1x107 cells/ml in clinical FM: a 
concentration which has been used successfully in a number of othe r studies (282,290) and 
yielded a high percentage of viable cells in our data (Figure 3.4).  
Both 51Cr release and degranulation assays were performed using reovirus as an activation 
stimulus for fresh PBMCs, against tumour targets. Lysis of target cells was significantly 
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increased by activation of PBMCs with reovirus. This effect was shown to be comparable for 
PBMCs which had been cryopreserved prior to use (Figure 3.5).  
Similarly, reovirus increased baseline CD107 expression compared to untreated controls  on T, 
NK and NKT cells to varying extents (Figure 3.6). NK cells constituted the highest proportion of 
degranulating cells compared to NKT and T cells, indicating that this population is responsible 
for lysis of targets observed. CD107 expression and the enhancing effect of reovirus is also 
comparable between fresh and previously frozen PBMCs (Figure 3.6 and Figure 3.7). Published 
data has shown similar findings and therefore support our findings that innate immune cell 
assays can be performed using previously cryopreserved cells (271,276), as they are 
representative of freshly isolated cells in their response to immune stimulus. 
There was evidence of cytokine/chemokine release in response to reovirus in supernatants 
from both cryopreserved and fresh PBMCs (Figure 3.8). This was variable across all 
cytokines/chemokines tested. As seen in innate immune assays, the absolute levels of solutes 
detected when using frozen samples were diminished compared to those found in fresh cell-
culture supernatants but the trends were highly significant and representative of the fresh 
samples. Studies have shown that levels of cytokines produced by thawed PBMCs in culture 
are variable, depending on the cytokine and whether the cells have been re -stimulated or not 
(286,297). Activation of PBMCs during thawing, variations in the initial cryopreservation 
process and death of particular immune cell sub-populations during any point in the freeze-
thaw cycle are just some of the reasons why levels of cytokines may vary.  
Previous work in our laboratory has determined that activation of immune cell subsets after 
cryopreservation is comparable to fresh cells where immunophenotyping was performed 
immediately following collection of the sample (personal communication). This echoes 
findings in other studies, where the sub-populations of immune cells within PBMCs remain 
comparable to those present in the same samples following cryopreservation (301). In our 
investigations, PBMCs stimulated with reovirus before cryopreservation were thawed and 
either analysed immediately or following overnight incubation (‘rested’). In both scenarios, 
the absolute frequencies of populations such as CD4, CD3 and CD8 were reliable and 
comparable (Figure 3.9) with the exception of the CD14+ monocyte population (Figure 3.9c).  
Reovirus could activate all sub-populations of cells analysed: expression of the activation 
marker CD69 was significantly increased with reovirus, whether or not PBMCs had been 
rested after thawing (Figure 3.10). Likewise, CCR7 (Figure 3.11) was up-regulated on some 
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cells following treatment with reovirus. These data collectively show that cryopreserved cells 
are comparable to fresh cells when evaluated by immunophenotyping for cell activation by 
reovirus and that cells can be rested overnight prior to analysis. Although the absolute 
percentages of marker expression are lower in previously frozen samples, the capacity to 
become activated after viral stimulation remained. The observed decrease in cytokine 
production between fresh and cryopreserved PBMCs, although proportional, may explain why  
absolute levels of immune cell activation (such as CD69 expression or NK cell 
degranulation/cytotoxicity) is decreased in previously frozen cells (286) as cellular activation is 
linked to the presence of certain cytokines.  
As part of the panel of assays which evaluate immune responses in patients, ELISpot can be 
used to determine the T cell response to TAAs (anti-tumour response) and viral peptide pools 
(pan-recall response). Using cryopreserved PBMCs, there was a dose-dependent response to 
CEF viral peptide pools, with 2 µg/ml being the optimum concentration that was carried 
forward into the analysis of trial samples (Figure 3.13). There is some suggestion that in order 
to enhance the detection of T cell responses to antigen stimulation, thawed PBMCs should be 
incubated at high density prior to being used in ELISpot assays (299). It is suggested that this 
mimics a tissue-like environment, where T cells are activated through interaction with other 
cell populations, thereby increasing T cell function and antigen recognition. This process can 
also lead to a purer population of functional immune cells, due to the loss of dysfunctional 
cells undergoing apoptosis following thawing (286). In our studies, however, incubating 
PBMCs at high density for 24-48 hours prior to analysis led to attenuated T cell responses 
(Figure 3.14 and Figure 3.15). Variability amongst donors to antigen stimulation, both before 
and after resting, implies that the effect of pre-incubation is not predictable or uniform and 
other groups have also found this to be true (289). Due to the heterogeneity of the response 
to viral and tumour antigens between patients, T cell responses from samples incubated for 
48 hours before use may be too low to detect in some situations (Figure 3.15). Similarly, if 
samples are used immediately upon thawing, then responses in some patients may be too 
numerous to accurately calculate. These data also demonstrate an elevated response when 
the density of PBMCs seeded into each ELISpot well was increased. Furthermore, when using 
TAA peptide pools (CEA and MART-1), pre-incubation of PBMCs following thawing prior to the 
ELISpot assay did not enhance T cell responses (Figure 3.16). Optimising an assay that 
demonstrates such inter-patient variability requires focus on trying to maximise the ‘signal to 
noise’ ratio. As such, the following conditions were shown to be  most effective: a density of 
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2x105 PBMCs/well, following resting of these PBMCs overnight and stimulation of the T cells 
with a concentration of peptide pools at 2 µg/ml.  
In summary, peripheral blood samples from patients can successfully be cryopreserved for 
subsequent batch analysis. Although the magnitude in response to immune stimuli is lower in 
previously cryopreserved cells, this should not affect the overall results when samples are 
analysed over time and where the response to treatment is compared to a baseline sample 
from the same patient. The use of optimised and validated protocols will ensure that the 
viability of cryopreserved samples is maximised and that a high yield of viable cells are 
recovered on thawing. We have also demonstrated procedures for optimising PBMCs for use 
in multiple assays: being able to prepare the cells in similar ways reduces the number of cells 
being wasted and increases the number of experimental conditions possible for each clinical 
sample, thereby maximising the translational output within a given study. The utilisation of 
robust SOPs for the investigation and interrogation of immune response will ensure that these 
assays can be performed on many clinical trial samples, potentially across multiple sites, with 
a high degree of accuracy and reproducibility.    
As part of this project, these assays were used to analyse the immune response to treatment 
in patients receiving first-line chemotherapy for CRC and patients receiving immunotherapy 
for metastatic melanoma (Chapter 4 and Chapter 5).  
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Chapter 4 Neutrophil Lymphocyte Ratio 
4.1 Introduction 
4.1.1 Colorectal Cancer 
CRC is currently the fourth most common in the UK (302), with over 40,000 new cases and 
15,000 deaths per year. The Dukes staging system has traditionally been used to stage CRC 
but the American Joint Committee on Cancer (AJCC) or Tumour Node Metastasis (TNM) 
staging can also be used to help guide management decisions (303). A screening programme 
involving the use of faecal occult blood tests was initiated in 2006 for those aged between 60 
and 74 (304) and participants with an abnormal test are invited for colonoscopy. Of the 11.6 % 
of men and 7.8 % of women in whom CRC is detected, over 70 % will have early stage disease 
(Dukes A or B: LN negative, Table 4.1) (304). The definitive management for potentially 
resectable disease is surgery, after which long-term outcome is dependent on stage, with a 
five-year survival of 85 % - 95 % for stage I disease and to 30 % - 60 % for stage III (Dukes C: LN 
positive disease, Table 4.1). Risk factors for CRC include chronic inflammation (such as 
inflammatory bowel disease), high fat ‘Western’ diet, obesity, alcohol excess and smoking, 
which may explain the increasing incidence in recent years (305). Symptoms may include 
lower abdominal pain, rectal bleeding, iron deficiency anaemia, change in bowel habit or 
weight loss. As the majority of tumours are left-sided (in the sigmoid colon or rectum), most 
are diagnosed on colonoscopy or sigmoidoscopy. For patients who are frail and cannot 
tolerate a colonoscopy, computerised tomography colonoscopy can be offered as a screening 
tool but a definitive tissue biopsy may still be sought to assist with diagnosis and management 
plans (306). Dependent on tumour staging, management with curative intent can also include 
neoadjuvant or adjuvant chemotherapy in addition to surgery. In the presence of 
oligometastatic disease, such as liver or lung metastases, surgical resection can still be utilised 
to improve outcome and prognosis. Local ablative therapies, such as the  use of 
chemoablation, can also be useful in these patients. In the management of metastatic disease, 
performance status, quality of life and potential toxicities should be considered prior to 
commencing palliative chemotherapy. 
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4.1.2 Pathology and Staging of CRC  
Staging of CRC is determined using the TNM model, which also corresponds to tumour stage 
(stage I-IV or Dukes staging A-C, Table 4.1) and can be used to guide management decisions. 
Although the AJCC staging has recently been updated to the 8th Edition, the 7th edition was 
used at the time of our study.  
Table 4.1 TNM and Dukes staging of colorectal cancer (adapted from 7th American Joint 
Committee on Cancer, AJCC) (303) 
Stage Dukes Stage Tumour Tumour stage 
I A T1 Invading submucosa 
  T2 Invading muscularis propria 
II B T3 
Invades through muscularis into pericolonic 
tissues 
  T4a Invades to the surface of the visceral peritoneum 
  T4b 
Invades into or adherent to other organs or 
structures 
  Nodal Status Number of Metastatic Nodes 
III C N1a 1 regional LNs 
  N1b 2-3 regional LN 
  N1c 
Tumour deposits in mesentery or nonperitoneal 
tissue without LNs 
  N2a 4-6 regional LNs 
  N2b ≥ 7 regional LNs 
  Metastases Site 
IV - M1a 
Metastases in one organ or site (liver, lung, non-
regional LN etc.) 
  M1b 
Metastases in more than 1 organ/site or 
peritoneal disease 
 
CRC arises from the bowel mucosa and can be proceeded by a number of mutations which 
contribute to the development of the disease. The World Health Organisation (WHO) 
histological classification describes the different pathological subtypes of tumours of the colon 
and rectum (305). In addition to benign adenomas, neuroendocrine tumours and non-
epithelial tumours (including lymphoma), colonic epithelial tumours can be classified as:  
 Adenocarcinoma  Mucinous Adenocarcinoma 
 Signet-ring cell carcinoma  Small cell carcinoma 
 Squamous cell carcinoma  Adenosquamous carcinoma 
 Medullary carcinoma  Undifferentiated carcinoma 
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In addition, there are a number of genetic mutations which contribute to carcinogenesis and 
the development of colorectal tumours, including the tumour suppressor genes adenomatous 
polyposis coli (APC), p53 and KRAS (307–309). Mutations in APC lead to familial adenomatous 
polyposis: the usual regulatory function of APC in preventing abnormal cellular growth is 
abrogated and this leads to the abnormal development of polyps which can become 
malignant. The function of p53 (also called ‘the guardian of the genome’) is to detect DNA 
damage within the cell and either repair it or initiate apoptosis. Loss of p53 therefore allows 
the proliferation of genetically abnormal cells with high malignant potential and mutations in 
p53 are associated with a range of cancers, including the development of CRC. In contrast, 
activating mutations in KRAS leads to upregulation in intracellular signalling pathways, such as 
MAPK, initiating abnormal cell proliferation and survival. Sequential mutations in APC, KRAS 
and p53 therefore lead to the development of dysplastic adenomas which consequently 
transform into carcinomas (308). Other common mutations detected in CRC include BRAF, 
PIK3CA (which encodes for the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) protein, 
part of the PI3K/AKT signalling pathway) and the WNT signalling pathways (310). An important 
sub-population of CRCs are those tumours which exhibit defects in mismatch repair (MMR) as 
a result of mutations in genes such as MLH1, MSH2 and MSH6. Mutations in these genes allow 
the accumulation of small sections of nucleotide repeat sequences (microsatellites) which 
increase the mutational load of the cell and predispose to the development of microsatellite 
instable (MSI) CRC. These tumours are also known to have a higher incidence of BRAF 
mutations (311). Analysis of CRC samples from different areas of the bowel reveal a pattern of 
different mutational profiles relative to location of the tumour. Analysis of mutational 
signatures of 1443 colonic tumour samples revealed that the incidence of MSI CRC and those 
with BRAF mutations was highest in the ascending colon and reduces along the bowel to the 
rectum (310). The highest incidence of KRAS mutations was found in the caecum (310). More 
recently, CRC has been further delineated into four consensus molecular subtypes (CMS): CMS 
1 (MSI with BRAF mutations and immune infiltrates), CMS 2 (‘canonical’ subtype and the most 
prevalent; may have mutations in WNT pathway), CMS 3 (‘metabolic’ subtype with KRAS 
mutations) and CMS 4 (activation of pathways including TGF-β signalling and VEGF; 
inflammatory aetiology with poor a prognosis) (312).   
Understanding the molecular basis of CRC helps us to appreciate  that it is not a singular 
disease and focuses management. As an example, MSI CRC is the only molecular subtype 
which responds to immunotherapy. Conversely, tumour with mutations in KRAS do not 
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respond to therapy with EGFR inhibitors. As EGFR is found on the cell surface and is upstream 
of the MAPK pathway (which includes RAS), activating mutations of the KRAS isoform 
stimulates this intracellular signalling pathway in the absence of EGRF activation. Blocking 
EGFR in this situation is therefore ineffective.  
4.1.2.1 Immune Response and Microsatellite Instability 
MSI is found in up to 15 % of CRC and is due to MMR (313). This is due to either germline 
mutations in MMR genes or hypermethylation and epigenetic silencing of genes such as 
MLH1, MSH2 and MSH6. During DNA replication, mismatches between the two strands of 
DNA can occur (for example due to erroneous insertion of nucleotides in the daughter DNA 
replication strand causing frameshift mutations) (314). MMR proteins recognise the mismatch 
(such as pairing guanine with thymine instead of cytosine) and form a complex (usually by 
binding to other MMR proteins) which excises, resynthesises and replaces the abnormal 
section of DNA (314). Abnormalities in the MMR gene lead to an accumulation of 
microsatellites: small sections of nucleotide repeats which are usually present throughout the 
genome but in the case of tumours deficient in MMR (dMMR), lead to increased mutational 
load and are associated with a number of cancers. Germline mutations in MMR genes are 
specifically associated with familial CRC such as hereditary nonpolyposis CRC (also known as 
Lynch Syndrome) (315). CRCs with dMMR/MSI have a number of molecular and pathological 
features: i) a tendency for proximal tumours diagnosed at a younger age and earlier stage; ii) 
an increased association with mutations in the BRAF tumour suppressor gene (particularly in 
sporadic dMMR cancers) and iii) higher grade at presentation and increased lymphocytic 
infiltration of tumours when compared to microsatellite stable (MSS) CRCs proficient in MMR 
(pMMR) (311). Although some studies have shown that dMMR tumours have a poorer 
prognosis than pMMR tumours (316), this conclusion may have been due to co-existing BRAF 
mutations within the dMMR group. In the combined analysis of 3063 patients with metastatic 
CRC (mCRC) from four large clinical trials, patients with dMMR demonstrated worse 
progression-free survival (PFS) and OS compared to those with pMMR (hazard ratio (HR) 1.33 
and 1.35, respectively) (316). However, within this large patient cohort, nearly 35 % of 
patients with dMMR also had sporadic mutations in BRAF. As such, there was no significant 
difference in OS for patients with BRAF mutations and either pMMR or dMMR (OS 11.3 
months vs. 11.7 months, respectively) (316). In a systematic review of 32 studies reporting 
outcomes in 7,642 patients with stage I-IV disease, MSI CRC was been shown to have a better 
prognosis than MSS CRC, with a HR for OS of 0.65 (95 % confidence interval (CI) 0.59 to 0.71) 
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(317). When considering these data, it is also worth noting that there is no standardised 
method to determine dMMR/MSI status.  
There is also evidence that dMMR/MSI can predict response to chemotherapy, particularly in 
the adjuvant setting. If CRC with dMMR has a better prognosis (as suggested by data from a 
systematic review which included early stage patients (317)), the benefits of adjuvant 
chemotherapy may be diminished, particularly in light of evidence that MSI CRC may be 
resistant to 5-FU (318,319). Although tumours with dMMR can have a better outcome than 
those with pMMR, the current standard-of-care does not differentiate when decisions are 
made regarding adjuvant chemotherapy. While there is also some evidence for a benefit in 
giving adjuvant 5-FU-based chemotherapy to patients with dMMR, this may be limited to 
patients with germline tumours (Lynch Syndrome), rather than sporadic mutations in MMR 
genes (320).  
Although CRC tumours express inhibitory checkpoint ligands, early phase clinical trials of both 
anti-PD-1 and anti-PD-L1 antibodies have so far proved disappointing in unselected patients 
with mCRC (321,322). These results have been echoed in trials of anti-CTLA-4 antibody in 
mCRC patients (323). However, there is emerging evidence that checkpoint antibody therapy 
may have efficacy in patients with MSI tumours, including the mCRC cohort (324). Although 
tumour cell PD-L1 positivity has been shown to predict response to anti -PD-1 therapy, lower 
levels of expression in unselected patients may explain why these therapies are not effective 
in all cases of CRC (325). However, as tumours with dMMR/MSI express higher levels of PD-L1, 
this may be exploited in the use of immunotherapy in these CRCs. Given that the immune 
milieu may have already primed an anti-tumour immune response in these cancers, it seems 
rational that checkpoint inhibitors may further enhance this effect.  
4.1.3 Management of Localised Disease 
The primary modality for treatment of localised disease remains surgical resection. For 
patients with borderline resectable disease (high TNM tumour status, close resection 
margins), the National Institute for Health and Care Excellence (NICE) guidelines recommend 
consideration of neo-adjuvant chemotherapy (306). Evidence regarding this is conflicting: 
some published data supports the use of the anti-EGFR-antibody cetuximab with 5-FU and 
irinotecan chemotherapy (FOLFIRI) in patients with KRAS wild-type (WT) tumours (326). 
Although OS was not increased in this randomised study, response rates (RRs) were increased 
in the group of KRAS-WT patients who received cetuximab. In contrast, more recent data has 
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suggested that the addition of cetuximab to doublet chemotherapy (either FOLFIRI or 5-
FU/capecitabine with oxaliplatin) in the neoadjuvant setting decreases PFS (14.1 months in 
cetuximab group vs. 20.5 months in chemotherapy alone group) (327).    
Following surgery, patients with Dukes C disease or Dukes B with high risk features such as 
vascular invasion or presentation with perforated tumour, are considered for adjuvant 
chemotherapy (306). In patients with resected stage II disease, or those who are over 70 years 
of age, the addition of oxaliplatin to 5-FU (or the oral pro-drug capecitabine) offers no 
increased benefit in terms of DFS or OS (328–330). In patients with LN-positive disease, the 
addition of oxaliplatin to 5-FU in the adjuvant setting prolongs DFS (331–334). 
4.1.4 Management of Advanced Disease 
4.1.4.1 Chemotherapy 
The management of mCRC is based around combinations of the cytotoxic agents oxaliplatin, 
5-FU and irinotecan (335). Doublet 5-FU-based treatment has been shown to be superior to 
single-agent chemotherapy (336,337) but initial choice of regime (irinotecan/5-FU, FOLFIRI or 
oxaliplatin/5-FU, FOLFOX) may depend on a number of factors including potential toxicities, 
patient co-morbidities and end-organ function. There is also evidence that patients receiving 
FOLFOX with disease control and who have a normal platelet count (higher platelet counts 
being associated with poorer prognosis (338)) can receive intermittent chemotherapy with a 
treatment break at 12 weeks (339). In a trial of nearly 800 patients, first-line chemotherapy 
with FOLFOX was shown to be superior to FOLFIRI in terms of time to progression (TTP), RR 
and median OS (340). Conversely, an (albeit smaller) phase III trial of patients randomised to 
FOLFOX followed on progression by FOLFIRI and vice versa, reported similar PFS in both 
treatment arms (341). In the group receiving first-line FOLFIRI, median PFS was 21.5 months 
vs. 20.6 months in the FOLFOX group. Similarly on second-line therapy, those receiving 
FOLFOX had a median PFS of 14.2 months compared to 10.9 months for those patients 
receiving FOLFIRI (341). Although this may suggest a preference for FOLFIRI upfront, neither 
difference in PFS was significant and current NICE guidelines suggest that either regime may 
be used first-line (306). Additional evidence from clinical trials following progression on first-
line chemotherapy supports the use of doublet therapy over single agent 5-FU in patients with 
a satisfactory performance status and adequate organ function (342). In patients who had 
progressed on 5-FU-based combination therapy, single agent irinotecan increased OS 
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compared to best supportive care but, surprisingly, was also shown to improve quality of life 
and most disease-related symptoms (343).   
4.1.4.2 Biological Therapy 
The anti-EGFR-antibodies cetuximab or panitumumab can be used in KRAS-WT patients in the 
metastatic setting in combination with either FOLFOX or FOLFIRI (306). The addition of 
cetuximab significantly increases RR in patients with KRAS-WT tumours and reduces risk of 
disease progression (HR 0.57; p=0.00163) (344). Similarly, combination therapy with 
cetuximab plus FOLFIRI increases PFS, RR and OS (median OS 23.5 vs. 20.0 months, HR 0.796, 
p=0.0093) compared to FOLFIRI alone in patients without KRAS mutations as first line therapy 
for mCRC (345). Similar results have been demonstrated in second-line therapy: patients 
treated with cetuximab and irinotecan following progression on oxaliplatin and 5-FU 
demonstrated an increased PFS and RR compared to irinotecan alone (median PFS 4.0 vs. 2.6 
months; HR 0.692) (346). The addition of panitumumab to irinotecan as second-line therapy 
has also been shown to improve PFS but without an increase in OS (347). Interestingly, there 
is also some evidence that adding cetuximab to irinotecan can re-sensitise patients who have 
previously progressed on irinotecan-based treatment regimes, with greater TTP and RR 
observed. Despite this, there was only a modest gain in median survival of just over 1.5 
months (348). 
Although there is some evidence for the addition of the anti -VEGF anti-angiogenic antibody 
bevacizumab in the management of mCRC, results from clinical trials have been relatively 
modest and there is currently no predictive biomarker to select patients likely to respond to 
anti-VEGF therapy. The addition of bevacizumab to first-line FOLFOX has been shown to 
increase both PFS and OS by 1.4 months (349). Combining bevacizumab with FOLFIRI 
demonstrated slightly more promising results, with a 4.4 month improvement in PFS and an 
increase in survival of 4.4 months (350). Similarly, the use of bevacizumab second-line 
following progression on FOLFIRI was shown to extend survival by just over two months (12.9 
months for patients receiving FOLFOX plus bevacizumab vs. 10.8 months for FOLFOX alone) 
(351). There is also some evidence that older patients who may not tolerate further triplet 
chemotherapy can benefit from bevacizumab plus capecitabine (352).  
Direct comparisons between these biological therapies have generally favoured the addition 
of anti-EGFR-antibodies, with combinations of FOLFIRI and cetuximab and FOLFOX plus 
panitumumab conferring an increase in OS compared to the same chemotherapy backbone 
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with bevacizumab (353,354). This is likely due to the improved outcomes in KRAS-WT patients 
who were selected in these clinical trials to receive anti-EGFR therapy. The combination of 
both cetuximab and bevacizumab to oxaliplatin and capecitabine (CAPOX) chemotherapy 
leads to shortened PFS compared to CAPOX and bevacizumab alone (355). Bevacizumab 
containing chemotherapy is not currently recommended by NICE (306).  
4.1.4.3 Targeted Therapy 
The use of targeted, oral small molecules in mCRC is still being investigated. Although initially 
promising, clinical trials of the oral anti-VEGF TKI cediranib did not meet the criteria for non-
inferiority compared to bevacizumab when combined with FOLFOX chemotherapy (356). 
Regorafenib is another TKI with multiple targets including VEGF. Monotherapy with 
regorafenib has been shown to increase OS by 1.4 months when compared to placebo in a 
pre-treated population of patients with mCRC (357). Despite the high incidence of adverse 
events (AEs) in patients receiving regorafenib (93 %), 61 % of patients receiving placebo also 
described AEs, a proportion of which may have been attributable to disease burden in this 
patient population. 
4.1.4.4 Immunotherapy 
Although there is evidence regarding the role of both inflammation and immune responses in 
the pathogenesis of CRC, responses of unselected patients in this group have been 
disappointing. Conversely, the use of checkpoint inhibitors in patients with dMMR colonic 
tumours have shown more promise, with an objective RR of 40 % compared to 0 % in patients 
with pMMR tumours (324). The median OS in the pMMR group was five months but was not 
met in the dMMR group. Although currently not used in routine practice, clinical trials to 
confirm the utility of checkpoint inhibitors in dMMR mCRC are ongoing (NCT02060188, 
NCT02563002). Early results are promising (358,359) and evaluation into the use of anti-PD-1 
antibodies in CRC with dMMR by NICE is also underway. The activity of anti -PD-1 inhibitors in 
this subset of CRC is likely attributable to a number of factors including the increased 
infiltration of TILs into the TME of these tumours (360,361). The expression of inhibitory 
molecules such as PD-L1 have also been shown be higher in tumours with dMMR in some 
studies (360,361), although other analyses of CRC tumours have found an inverse relationship 
between the dMMR and PD-L1 expression (362).  
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Although there have been many advances in the treatment of mCRC, current treatment 
strategies still incorporate traditional cytotoxic chemotherapy with either FOLFIRI or FOLFOX, 
sequentially first- and second-line, potentially with the addition of anti-EGFR therapy in 
patients with KRAS-WT tumours. Other therapies, including targeted agents and 
immunotherapy are currently not used in routine clinical practice, meaning that the age-
standardised one year survival for stage IV CRC is still only 44 % for men and 35 % for women 
(302). The success of drugs such as cetuximab and panitumumab being incorporated into 
treatment paradigms is likely due to the availability of a biomarker (KRAS status) to select 
patients who can clearly benefit from therapy. The current project aims to further evaluate 
the effect of standard of care chemotherapy on the immune response in CRC, in the hope that 
this will reveal the potential for further exploration into novel immunotherapeutic strategies.   
4.1.5 Immune Response in CRC 
4.1.5.1 Inflammation in CRC 
There is a strong association between colonic inflammation and the development of CRC. 
Indeed, IL-10 knockout mice, who develop intestinal inflammation and colitis, have a higher 
mutational burden within the colon and are therefore predisposed to the development of 
colonic tumours (363). The role of inflammation in the pathogenesis of CRC is illustrated by 
the results of multiple clinical studies of anti-inflammatory drugs such as aspirin. Data from 5 
randomised trials with a prolonged follow-up of 20 years demonstrated that prophylactic 
aspirin leads to a reduced risk of developing CRC (HR 0.76, (95 % CI 0.6-0.96, p=0.02). There 
was also a confirmed decrease in CRC mortality (HR 0·65, 95 % CI 0·48-0·88, p=0·005) (364). 
Cyclooxygenase-2 (COX-2) is an enzyme that is involved in the production of prostaglandins as 
part of the inflammatory process and it is through the inhibition of COX-2 that aspirin may 
exert it’s anti-inflammatory effect. COX-2 is upregulated in adenocarcinomas of the colon and 
has also been linked to tumour angiogenesis (365).  
Understanding the immune landscape in CRC, the immunogenic features of inflammation and 
the potential prognostic markers in CRC, including the NLR, will help us to understand how the 
modulation of immune function in response to chemotherapy could potentially be exploited 
in the development of novel therapies.  
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4.1.5.2 Immune Infiltrates in the Tumour 
The balance between pro-immune and immunosuppressive infiltrates within the TME can 
have a striking effect on prognosis in CRC. Histopathological staining and co-localisation of 
immune cells can provide information regarding outcome and survival in CRCs (42). 
Specifically, primary tumours from CRC patients without disease recurrence are shown to 
have greater densities of CD3/CD8+ T cells compared to those who subsequently relapsed. 
Granzyme B positivity is also associated with increased survival (42,366). Similarly, immune 
infiltration of CRC tumours (367), increased CTL infiltration and infiltration of CD8+ and 
memory T cells (368) are associated with improvements in DFS and OS. This raises the 
possibility that immune infiltration in the tumour could have potential as a prognostic 
biomarker, perhaps in patients who have early-stage disease being considered for adjuvant 
chemotherapy. Although a TH1 gene expression profile in CRC tumours is predictive of 
improved outcome, no such relationship is seen with a TH2 gene profile, which could be 
postulated to confer a worse outlook (33). 
Immunoscore® is a system for analysing and categorising immune infiltrates in the core (CT) 
and invasive margin (IM) of tumours, through immunohistochemistry of formalin-fixed, 
paraffin-embedded (FFPE) tumour blocks. The density and distribution of CD3+ and CD8+ cells 
within the TME are then analysed and an Immunoscore® generated of between zero and four 
(with zero being the lowest level of immune cell infiltration and cell density and four the 
highest) (369). MSI tumours, which by definition have a higher mutational load and potentially 
higher numbers of tumour neo-antigens to generate an immune response, generally have a 
higher Immunoscore®, increased infiltration of TH1 cells and, pertinently, higher levels of cells 
expressing of PD-1 and PD-L1 (370,371). In keeping with this, MSI tumours also have increased 
expression of immune genes such as those involved in antigen presentation, cytokine 
signalling and IFN-γ pathways, amongst others. Although patients with MSI CRC have an 
improved prognosis, there is data to suggest that this may be a reflection of the immune 
response in these patients: MSI tumours generally have a higher Immunoscore® but an 
improved disease-specific survival was also seen in patients with a score of four compared to 
zero, which included those with MSS tumours (370). Increased PD-1/PD-L1 expression was 
also seen in MSS tumours with a higher Immunoscore®. 
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4.1.5.3 Innate Immunity in CRC 
The presence of intra-tumoural NK cells is associated with an improved prognosis in patients 
with CRC (372–374). In further support of this, NK cell infiltration into CRC tumours has been 
shown to decrease with advancing stage of disease and the presence of metastases (375). 
Patients with CRC also appear to have diminished NK cell function compared to healthy 
controls (376). NKG2D is a stimulatory NK cell receptor whose ligands may be upregulated in 
response to cell stress or malignant transformation (377,378). These cells can then be marked 
for destruction through NK cell-mediated mechanisms. As such, mice who are deficient in 
NKG2D are more susceptible to the development of aggressive tumours, suggesting a strong 
role for NK cell receptors in cancer surveillance (377). There is also evidence, however, that 
this and other NK cell-activating receptors can be down-regulated in CRC, potentially blunting 
the process of immune surveillance (379). In addition, persistent exposure to over-expressed 
NK cell ligands can actually lead to a desensitisation of NK cells to this stimulus, which can 
further disrupt the normal mechanisms of NK cell -mediated tumour cell cytotoxicity (380). NK 
cells from patients with CRC have been found to under-express activating receptors (including 
NKG2D, NKp46 and NKp30) and over-express inhibitory receptors such as NKG2A (381). 
Indeed, the presence of NKp46 has been shown to correlate with increased RFS (381). 
Interestingly, it would appear that the inhibition of NK cell -mediated anti-tumour activity can 
be reversed with a combination of IL-2 and cetuximab, which is used clinically in KRAS-WT CRC 
and can initiate ADCC as an additional anti-tumour response (381). 
4.1.5.4 Adaptive Immunity in CRC 
Pre-treatment immune function has been shown to be prognostic in CRC, with high levels of 
MDSCs and low levels of CD4+ or CD8+ T cells being associated with poorer outcomes and 
decreased PFS (382). Patients with CRC also have a higher frequency of peripheral Tregs than 
either matched healthy controls or patients with non-malignant bowel disease (56). Depletion 
of this population of immunosuppressive cells led to enhancement of existing T cell responses 
(as measured by IFN-γ ELISpot) and also unmasked antigen responses in patients who had 
previously had none (56). This suggests that peripheral Tregs in CRC may suppress anti -
tumour responses.  
FoxP3+ Tregs are higher in malignant colorectal tumours compared to matched PBMCs from 
the same patient group or healthy controls (383). In this study, evaluation of PBMCs following 
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excision of a primary tumour revealed a reduction in the expression of FoxP3 on peripheral 
Tregs, which corresponded to an increase in IFN-γ production to the TAA 5T4 (383). 
Suppression of these antigen-specific T cell responses by Tregs have been linked to tumour 
recurrence, with all patients in this data set with a ‘suppressive’ phenotype having detectable 
recurrent disease 12 months after surgery (although in a very small group of patients; n=4 for 
5T4 responses and n=7 for CEA responses) (383). Conversely, in a similar (larger) group of pre-
operative patients, baseline IFN-γ response to CEA (either before or after the depletion of 
Tregs) correlated with an increased risk of tumour recurrence (384).  
4.1.5.5 Cytokine Production 
In a group of 148 patients with CRC, serum cytokine profiling showed differences between the 
patients and matched healthy controls (385). TH1 cytokines such as IFN-γ were higher in CRC 
patients and there was demonstrable variation in cytokine profile across varying 
clinicopathological features. Patients with metastatic disease (stage IV) had higher serum 
levels of the anti-inflammatory IL-1 receptor agonist (IL-Ra), the TH2 cytokine IL-4, pro-
inflammatory IL-6 and the chemokine IL-8. There was also a suggestion of a more TH2 
environment in patients with metastatic tumours. 
Similarly, in another cohort of patients with CRC, analysis of plasma cytokines and chemokines 
showed an increase in IL-6, IL-8, HGF, M-CSF and VEGF (386). Moreover, specific patterns of 
cytokine release (associated with inflammation and angiogenesis) were found in patients with 
a high NLR (defined in this paper as > 5). These data suggest that the cytokine/chemokine 
profile of CRC patients can vary between those at different stages of disease and with 
different inflammatory milieu, potentially reflecting the pathophysiology of the disease.    
4.1.6 The Neutrophil Lymphocyte Ratio  
As already illustrated, the relationship between inflammation, immune response and 
malignancy is complex. Measurement of the NLR is both simple and reproducible and as such 
it has the potential to be used as a pragmatic surrogate marker for inflammation and immune 
response in cancer. There is evidence that poorer cancer survival can be associated with 
either low lymphocyte counts or high neutrophil counts in the peripheral blood of unselected 
cancer patients (387). The NLR has the potential to become an easily measureable biomarker, 
as it includes parameters which are routinely recorded for patients undergoing 
chemotherapy.  
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For the purposes of this work, NLR was calculated using the formula: 
𝑁𝐿𝑅 =
𝑃𝑒𝑟𝑖𝑝ℎ𝑒𝑟𝑎𝑙 𝐵𝑙𝑜𝑜𝑑 𝑁𝑒𝑢𝑡𝑟𝑜𝑝ℎ𝑖𝑙 𝐶𝑜𝑢𝑛𝑡
𝑃𝑒𝑟𝑖𝑝ℎ𝑒𝑟𝑎𝑙 𝐵𝑙𝑜𝑜𝑑 𝐿𝑦𝑚𝑝ℎ𝑜𝑐𝑦𝑡𝑒 𝐶𝑜𝑢𝑛𝑡
  
If patients only have total WBC and neutrophil count recorded, the derived NLR (dNLR) can 
also be used. The dNLR works on the assumption that the total WBC count is comprised 
predominantly of neutrophils and lymphocytes. Hence, dNLR is calculated using the formula:  
𝑑𝑁𝐿𝑅 =  
𝑃𝑒𝑟𝑖𝑝ℎ𝑒𝑟𝑎𝑙 𝐵𝑙𝑜𝑜𝑑 𝑁𝑒𝑢𝑡𝑟𝑜𝑝ℎ𝑖𝑙 𝐶𝑜𝑢𝑛𝑡
𝑃𝑒𝑟𝑖𝑝ℎ𝑒𝑟𝑎𝑙 𝑊𝐵𝐶 𝐶𝑜𝑢𝑛𝑡 −  𝑃𝑒𝑟𝑖𝑝ℎ𝑒𝑟𝑎𝑙 𝐵𝑙𝑜𝑜𝑑 𝑁𝑒𝑢𝑡𝑟𝑜𝑝ℎ𝑖𝑙 𝐶𝑜𝑢𝑛𝑡
 
There is some recognition that NLR may be more accurate than dNLR; decreasing lymphocyte 
populations in cancer patients may mean that other cells populations, which are not 
neutrophils, can make up the proportion of WBC (388–390).  
Both NLR and dNLR have been found to have prognostic value for patients with a diagnosis of 
cancer, including CRC patients undergoing surgical resection (391) and those with advanced 
CRC, with NLR < 4 and dNLR < 2 being associated with improved OS (388). While prognostic 
biomarkers give information about the course and outcome of a disease independent of 
treatment, predictive biomarkers can be used to stratify patients into groups more likely to 
respond to treatment, such as KRAS status and anti-EGFR therapy in CRC.  
Although the NLR has been shown to be a robust prognostic biomarker in a number of 
different tumour types, it remains unclear whether a high NLR (usually conferring a poorer 
outcome) is due to neutrophilia, lymphopenia, or a combination of the two. As a biomarker it 
is pragmatic, easily measurable and has been validated in many large data sets (392–397) but 
without actually understanding what it means and what it may represent. Although it may 
seem a blunt instrument with which to dissect the complex relationship between cancer, 
chemotherapy and immunity, this project aims to clarify whether the NLR could potentially be 
a surrogate marker for immune responses and how this is modulated in the context of anti-
cancer therapy.  
4.1.6.1 NLR and Prognosis in CRC 
Many scoring systems have been developed to stratify patients into high or low risk 
prognostic groups depending on parameters such as CRP, lactate dehydrogenase (LDH), serum 
albumin, platelet counts and peripheral WBC count (398–401). The NLR has been shown to be 
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an independent prognostic factor in many different malignancies but the exact level at which 
it becomes significant can vary. A meta-analysis of over 40,000 patients showed that an NLR > 
4 was a prognostic factor in a variety of solid tumours, although this varied between the 
groups (HR for OS was 2.35 in mesothelioma compared to 1.43 in HCC and 1.91 for CRC). 
Different values of NLR have also been demonstrated to be significantly associated with PFS 
(cut-off NLR > 3) and DFS (NLR > 5) (395). In metastatic disease, high NLR (defined as > 5) 
corresponded with a poorer OS in patients with untreated mCRC and patients entering phase I 
trials refractory to standard therapies (386). Another systematic review highlighted the 
differences in threshold NLR between different studies of unselected cancer patients, ranging 
from > 3.33 to > 5 (397). In reviewing studies of operable cancer, the most commonly used 
NLR was > 5. NLR was also able to predict survival and recurrence after neoadjuvant therapy 
(397).  
NLR has been associated with factors such as increased incidence of tumour obstruction or 
perforation, later stage tumours (T4b) and raised CEA (394,402). High NLR (in this case > 5) is 
also associated with a more aggressive tumour type, with statistically significant correlations 
with a higher TNM tumour stage, increased nodal involvement and vascular invasion. This 
translated to a decrease in PFS and OS (393). 
The Continuous or Intermittent trial of chemotherapy in mCRC showed that patients who had 
a higher platelet count (potentially an indirect marker of inflammation) benefitted from 
continuous chemotherapy, without a treatment break. Further post-hoc analysis also showed 
a correlation between dNLR and OS (median survival of 18.6 months in patients with dNLR < 
2.2 vs. 12.5 months if dNLR ≥ 2.2) (403). An NLR of greater than 2.2 was also seen to be 
predicative of a poorer survival in a group of unselected patients with CRC prior to treatment 
(404). 
NLR and platelet-lymphocyte ratio (PLR) also appear to have prognostic significance in 
patients with resectable CRC with synchronous liver metastases (338). Elevated NLR and PLR 
were associated with a worse OS and with poorer response to chemotherapy. Interestingly, 
normalisation of these parameters following the first cycle of chemotherapy was associated 
with improved disease control (either stable disease, partial response (PR) or complete 
response (CR)). In early stage CRC, in which surgery alone can be curative, an NLR of greater 
than 2.6 was similarly associated with a poorer OS and PFS (405). These findings were 
mirrored in another study which chose a higher level of NLR ( > 5) to stratify risk (394). An NLR 
of > 5 is prognostic in CRC patients undergoing first line palliative chemotherapy (406), 
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localised CRC and CRC with liver metastases in a systematic review of over 10,000 patients 
(407). 
While there has been a paucity of data comparing NLR in cancer patients to a healthy 
population, Pedrazzani et al. compared NLR from 603 patients with resected CRC to 5270 
healthy controls (402). Surprisingly, although these patients did not have metastatic disease, 
there was a significant difference between the absolute NLR values for those with resected 
CRC compared to healthy controls (3.1 ± 1.8 vs. 1.8 ± 1, respectively; p<0.001) (402). 
Moreover, there was no correlation between age and NLR in either group.  
4.1.6.2 Neutrophils in CRC 
In patients with previously untreated mCRC, a neutrophil count above the upper limit of 
normal (ULN) was associated with a poorer OS. There was a trend to a similar effect with 
decreased lymphocyte count (below lower limit of normal, LLN) but it was not statistically 
significant (386). This implies that the neutrophil count, rather the lymphocyte count, could be 
the prognostic element in the calculation of NLR. Indeed, in a large study of pre -operative 
patients undergoing elective resection for CRC, neutrophil count alone was found to be an 
independent factor for cancer-specific survival (CSS) (408). Similarly, in HCC, it was an elevated 
neutrophil count that correlated with increased risk of HCC recurrence, rather than the 
lymphocyte count (409).  
There is evidence that neutrophils may exert an inhibitory effect on the TME. The activity of 
CTL against tumour targets in vitro can be inhibited by the addition of granulocytes (410). Not 
only is this effect dose-dependent but is independent of normal granulocyte function, with a 
similar phenomenon seen when the cells were heat-inactivated. Similarly, the removal of 
granulocytes in an in vivo model of ultraviolet (UV)-induced tumours lead to inhibition of 
tumour growth, indicating that the tumour may be dependent on granulocyte function (411). 
Interestingly, this was in a sub-group of tumours that had been able to subvert a T cell-
mediated anti-tumour immune response.  
Neutrophils are known to produce a wide range of cytokines and chemokines which modulate 
all aspects of the immune response. These may include both regulatory cytokines such as IL-4 
and TGF- β and pro-inflammatory cytokines such as TNF-α, IL-6 and IL-8 (268). The blockade of 
TGF-β can also lead to an increase in TANs which are more cytotoxic to tumour cells and exert 
a more anti-tumour phenotype (so called ‘N1’ versus the pro-tumourgenic ‘N2’) (100).   
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Neutrophil-derived ectosomes (extracellular vesicles created by ‘budding off’ of the cell 
membrane) have been shown to have immunosuppressive properties, increasing expression 
of TFG-β when cultured with macrophages (412). These ectosomes were also able to block the 
release of TNF-α by macrophages. Although this effect may be utilised successfully in the 
resolution of inflammatory processes, it may exert a harmful pro-tumourgenic effect in the 
TME.  
4.1.6.3 Lymphocytes in CRC 
Pre-operative lymphopenia has been shown to be a poor prognostic factor in terms of OS in 
patients with resected CRC (413). In the palliative setting, lymphopenia can be associated with 
decreased OS and PFS in CRC patients receiving first-line chemotherapy (414). Additionally, 
the risk of developing a low lymphocyte count due to chemotherapy is related to increased 
age (greater than 60 years) and raised CEA (415). Although this data suggests a strong 
association between cancer and lymphopenia, the underlying mechanisms remain unclear.  
Fas to Fas-L on T and NK cells initiates a pro-apoptotic pathway (416). Despite most tumour 
cells expressing Fas, they can be resistant to Fas-L-induced cytotoxicity. Conversely, tumour 
cells may also express CD95L, which has been postulated as a potential immune-evasive 
mechanism (416). In fact, high levels of Fas-L on colorectal tumour cells have been shown to 
be associated with increased tumour stage and liver metastases (417,418) and high serum 
levels of Fas-L with poorer outcome and survival (419). Lymphopenia, therefore, may be 
related to higher levels of Fas-L-expressing tumour cells, initiating apoptosis of T cells. This 
hypothesis has been supported in HCC (420) and in CRC (418), where apoptosis of T cells was 
increased when co-cultured with Fas-L-expressing tumour cells.  
Although the mechanisms determining the presence of lymphopenia in cancer patients are 
multiple, complex and poorly understood, we need to consider whether this is a cause or 
effect phenomenon: is the lymphocyte count diminished because of the tumour or has the 
tumour developed because lymphopenia is indicative of a blunted anti-tumour immune 
response? Analysis of immune responses in patients with changing NLR may help to 
understand this process further.  
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4.1.7 Rationale for Current Study 
It is impossible to fully describe the network of complex relationships between the 
development and pathogenesis of CRC and the different immune responses to both disease 
and therapy as outlined above. However, the differences in immunogenicity and outcome in 
patients with dMMR/MSI colorectal tumours illustrates that modulation of the immune 
response in CRC patients may offer new and more effective therapeutic strategies. The 
challenge, therefore, is to determine whether there are any other CRC patients who may 
benefit from these novel therapies. The aims for this work were specifically: 
1. To determine whether the NLR, which has proven to be a robust prognostic biomarker 
in CRC, actually reflects modulation of the immune milieu in CRC patients by 
comparing functional immune responses in patients with a high NLR and low NLR.  
2. To determine the effect that standard-of-care chemotherapy had on immune 
responses and whether this was reflected in changes in the NLR over treatment.  
3. Investigate whether chemotherapy could modulate the immune response in these 
patients and, if so, could this information reveal the potential for immunotherapeutic 
strategies in patients who previously would not have benefited from such treatment.  
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4.2 NLR Results 
4.2.1 Patient recruitment and demographics 
Thirty patients with CRC were consented to the study between November 2014 and 
November 2016. Samples were initially collected from patients at three time points 
corresponding to chemotherapy cycles: baseline (pre-treatment), 6 weeks (following 3 cycles 
of 2-weekly chemotherapy) and 12 weeks (after 6 cycles of chemotherapy). One patient (NLR-
14) withdrew prior to receiving any chemotherapy or having any translational blood samples 
taken and so was excluded from the analysis. Survival data was also collected. Patient 
recruitment and sample collection is illustrated in Figure 4.1. 
 
 
Figure 4.1 Patient recruitment 
 
Following a preliminary analysis of data (after 22 patients had been consented), there was 
considered to be more interesting findings seen in the first 6 weeks of treatment, as well as 
potentially too many confounding factors to gain reliable data from samples taken at 12 
weeks. These may include dose reductions, dose delays, toxicities from chemotherapy 
(particularly neutropenic infection) and patient drop-out due to illness or PD. Consequently, 
from patient NLR-23 only baseline and 6 week samples were collected. For this reason, most 
of the data presented covers this period, unless there was a strong signal from data at 12 
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weeks. Interestingly, there was enough data by 6 weeks to suggest changes in the immune 
response at this time point, which is earlier than the traditional 12 weeks at which patients on 
chemotherapy would be radiologically re-assessed. Four of twenty-nine patients (14 %) only 
had a single baseline sample collected. From patient 23 onwards, samples were collected only 
at baseline and 6 weeks (after discontinuation of the 12 week sample due to modifications to 
the study protocol).  Seven out of these eight patients (88 %) had both planned samples 
collected. A further two patients with mCRC who consented to sample collection but who 
were not planned to receive chemotherapy were included in some of the baseline analysis to 
increase the proportion of patients in the high NLR group. Sample collection for all patients is 
shown in Appendix Table 8.3. For the purpose of the analysis, high NLR was def ined as ≥ 5 
unless otherwise stated. Demographics for the 29 patients who had at least one sample 
collected are shown in Table 4.2. There was a similar proportion of male and female patients, 
with a median age of 70.5 years in males and 63 years in females. All patients received 5-FU or 
capecitabine as part of their chemotherapy regime; 93 % had combination chemotherapy and 
only 2 of the 29 evaluable patients received an additional biological therapy. Most patients 
received a combination of irinotecan/5-FU, reflecting local practice. As expected, most 
tumours arose in the distal colon, sigmoid or rectum. Most patients (66 %) had liver 
metastases at baseline and 17 % of all patients (28 % of those in whom mutational status was 
known) had mutations in KRAS. The proportion of patients with ≥ 2 metastatic sites was 
greater in the high NLR group (83 % vs. 47 %), as was the proportion of those with liver 
metastases (75 % of those with a high baseline NLR vs. 53 % with low baseline NLR).   
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Table 4.2 Patient Demographics (n=29) 
Patient Demographics (n/%) 
Sex Median Age and Range ECOG Performance Status at Baseline 
Male 14 (48 %) Male 70.5 years (31 – 86 years) 0 10 (34 %) 
Female 15 (52 %) Female 63 years (52 – 76 years) 1-2 19 (66 %) 
  Both 65 years (31 – 86 years) 3-4 0 
Primary Tumour Site First-Line Chemotherapy 
Right sided 7 (24 %) Irinotecan/5-FU 19 (66 %) 
Transverse colon 1 (3.5 %) Oxaliplatin/5-FU 6 (21 %) 
Left sided  20 (69 %) Capecitabine only 2 (7 %) 
Unknown primary site 1 (3.5 %) Irinotecan/5-FU + Monoclonal antibody1 2 (6 %) 
Presence of Liver Metastases Number of Metastatic Sites Mutational Status 
Yes 19 (66 %) 0 0 KRAS 5 (17 %) 
No 10 (34 %) 1 10 (34 %) BRAF 3 (10 %) 
  2 13 (45 %) PI3KCA 1 (3.5 %) 
  ≥3 6 (21 %) Failed testing 1 (3.5 %) 
    No mutations detected2 8 (28 %) 
    Not tested  11 (38 %) 
                                                                 
1 One patient received bevacizumab and one received cetuximab in addition to irinotecan/5-FU 
2 Mutational analysis was performed for patients also enrolled onto the FOCUS4 clinical trial and included MSI/dMMR as well as mutations in KRAS, BRAF, 
PI3KCA, PTEN and NRAS.  
1
04 
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4.2.1.1 Baseline NLR values 
The median NLR was 3.63 (range 1.68 - 25.67). Although there were a greater number of 
patients (59 %) with a low NLR, 41 % of patients had a baseline NLR ≥ 5. The spread of values 
for the baseline (pre-treatment) NLR are shown in Figure 4.2. Of note, the greatest proportion 
of patients had an NLR of between 2 and 4 (48 %).  
 
Figure 4.2 Baseline NLR values  
Range and frequency of the baseline NLR values of all 29 evaluable patients. A high NLR is 
defined as ≥ 5 and low NLR < 5.  
 
4.2.1.2 Baseline peripheral blood immunological parameters 
The immunological blood parameters of patients were ascertained by routine hospital blood 
sampling and are summarised in Table 4.3.   
Table 4.3 Peripheral blood parameters (n=29) 
Peripheral Blood Parameters (n/%) 
Baseline NLR Baseline Platelet Count 
≥5 12 (41 %) ≥ULN 7 (24 %) 
<5 17 (59 %) <ULN 22 (76 %) 
Baseline Neutrophil Count Baseline Lymphocyte Count 
≥ULN 11 (38 %) ≤LLN 8 (28 %) 
<ULN 18 (62 %) >LLN 21/29 (72 %) 
Serum CEA (n=25)  
<5 6 (24 %)   
≥5 19 (76 %)   
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Approximately one third of patients had serum parameters that have been previously 
demonstrated to be associated with a poorer prognosis (339,389,408), with raised neutrophil 
count and/or platelet count seen in 38 % and 24 % of patients, respectively and lymphopenia 
in 28 %. Of note, 76 % of patients had a raised serum CEA, which is slightly higher than has 
been seen in previous trials of chemotherapy in the metastatic setting (403).  
4.2.1.3 Survival outcomes 
No patients were lost to follow-up for survival data. Data was censored on 23rd July 2017. 
Median survival for the whole group was 274 days. Median OS for patients with a high 
baseline NLR was significantly decreased compared to those with a low baseline NLR (6.6 
months vs. 18.8 months respectively, p=0.0024, HR 3.6, 95 % CI 1.25 – 10.35, Figure 4.3). 
Although most patients (10/12) in the high NLR group demonstrated a normalisation in NLR 
over the first 6 weeks of chemotherapy, this did not change survival outcomes (data not 
shown).  
 
 
Figure 4.3 OS curves for patients stratified by baseline NLR 
Patients were grouped according to baseline NLR (high ≥ 5, low < 5, n=29). Survival was 
calculated in days from the first dose of chemotherapy. All patients were evaluable in  the 
survival analysis.  
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4.2.2 Evaluation of Patient Immune Response to Chemotherapy Treatment 
and the Association with NLR: Immunophenotyping 
4.2.2.1 Patient immune system activation is not altered during treatment, 
irrespective of NLR  
The activation potential of patient immune systems were assessed by analysis of cell surface 
markers by flow cytometry. There was no significant difference in baseline levels of activation 
markers in either NLR group (low vs. high), including CD69 (Figure 4.4), HLA-DR, CCR7 and PD-
1/PD-L1 on CD4+ and CD8+ T cells, NK/NKT cells, monocytes or B cells (data not shown, 
Appendix Table 8.4).  
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Figure 4.4 Baseline CD69 expression on immune cell subsets (in high vs. low NLR 
patients). 
Cryopreserved PBMCs were immunophenotyped and CD69 expression on immune cell sub-
populations determined by flow cytometry. The percentage CD69 expression is shown on 
CD4+ T cells (a) CD8+ T cells (b), NK cells (c), NKT cells (d), monocytes (e) and B cells (f) (all 
n=24).  
 
Similarly, when looking at the patient cohort as a whole, there was no observed change in 
expression of any of the aforementioned markers on any of the specific cell populations after 
6 weeks of treatment, including CD69 (Figure 4.5 and Appendix Table 8.5). This is true of both 
NLR groups i.e. NLR ≥ 5 at baseline which had fallen to < 5 by 6 weeks (‘high-low’) and those 
with a baseline NLR < 5, which remained so over the first 6 weeks of chemotherapy ( ‘low-low’) 
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(data not shown). This indicates that at a cellular level, patient immune responses, 
determined by Immunophenotyping, seemingly remain unchanged. 
 
  
  
  
Figure 4.5 CD69 expression on immune cell sub-populations over the first 6 weeks of 
chemotherapy (whole patient cohort) 
Cryopreserved PBMCs were immunophenotyped and CD69 expression on immune cell sub-
populations determined by flow cytometry. The percentage expression of CD69 after the 
first 6 weeks of chemotherapy is shown on CD4+ T cel ls (a), CD8+ T cells (b), NK cells (c), 
NKT cells (d), monocytes (e) and B cells (f) (n=15 for NKT cells, all other graphs show n=16). 
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4.2.2.2 Immune checkpoint molecules increase in response to chemotherapy on 
select immune cell populations. 
PBMCs were evaluated for the immune checkpoint markers PD-1 and PD-L1. There was no 
significant difference in the expression of PD-1 between the high and low NLR groups on any 
of the immune cell subsets evaluated at baseline (Figure 4.6). Similarly, PD-L1 expression did 
not vary (data not shown).  
  
 
 
  
Figure 4.6 PD-1 expression on immune cell sub-populations at baseline (in high vs. low NLR 
patients) 
Cryopreserved PBMCs were immunophenotyped and PD-1 expression on immune cell sub-
populations was determined by flow cytometry. The percentage expression of PD-1 is shown 
on CD4+ T cells (a), CD8+ T cells (b), NK cells (c), NKT cells (d), monocytes (e) and B cells (f) 
(n=24).  
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Furthermore, when looking at the whole patient cohort, there was no significant change in 
the expression of PD-1 on CD4+ or CD8+ T cells or NKT cells after the first 6 weeks of 
chemotherapy (data not shown, Appendix Table 8.5). However, PD-1 expression increased on 
NK cells after the first 6 weeks of chemotherapy (p=0.0143, Figure 4.7a). Upon stratification 
by NLR, this elevation in NK PD-1 expression seemed to be attributable to the patients who 
had a low NLR at baseline (p=0.0488, Figure 4.7b, c). 
 
 
  
Figure 4.7 PD-1 expression on NK cells over time 
Cryopreserved PBMCs were immunophenotyped and PD-1 expression on NK cells was 
determined by flow cytometry. The percentage of positive cells is shown for (a) PD-1 
expression on NK cells after the first 6 weeks of chemotherapy (whole patient cohort), (b) 
PD-1 expression on NK cells of patients with high baseline NLR and (c) low baseline NLR 
(n=16).  
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PD-1 expression significantly increased after the first 6 weeks of chemotherapy on both B cells 
and monocytes (p=0.0417 and p=0.0156, respectively, Figure 4.8), although there was no 
appreciable difference between the high and low NLR groups within these cell types (data not 
shown).  
 
  
Figure 4.8 PD-1 expression on B cells and monocytes over the first 6 weeks of 
chemotherapy (whole patient cohort) 
Cryopreserved PBMCs were immunophenotyped and PD-1 expression was determined by 
flow cytometry. The percentage of positive cells is shown on (a) B cells and (b) monocytes 
at baseline and following 6 weeks of chemotherapy (n=16).  
 
4.2.2.3 Relationship between NLR status and frequency of peripheral Tregs: effect 
of chemotherapy 
Patients with a high NLR at baseline had significantly fewer peripheral FoxP3+ Tregs than 
those with a low NLR (p=0.0288, Figure 4.9a). High NLR patients also had significantly reduced 
expression of CD62L on Tregs (p=0.0165, Figure 4.9b). CD62L (L-selectin) is a homing receptor, 
which, when expressed on the surface of Tregs initiates homing to LNs.  
There was no difference noted in expression of either PD-1 or PD-L1 on Tregs between the 
high and low NLR groups at baseline (Figure 4.9c, d). Similarly, there was no appreciable 
change, following the first 6 weeks of chemotherapy, in either PD-1 or PD-L1 expression on 
Tregs, either in the patient cohort as a whole or when stratified by baseline NLR (data not 
shown).  
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Figure 4.9 Characteristics of FoxP3+ Tregs in patients with high or low baseline NLR 
Cryopreserved PBMCs were immunophenotyped and percentage positive cells determined 
by flow cytometry. Total percentage FoxP3+ Tregs as a proportion of CD4+ T cells are 
shown (a) as well as CD62L expression (b) (n=22). Also displayed is cell surface expression of 
PD-1 (c) and PD-L1 (d) (n=24).  
 
When looking at the patient cohort as a whole, there was a trend to a reduction in FoxP3+ 
Tregs following the first 12 weeks of chemotherapy, which approached statistical significance 
between baseline and 6 weeks (p=0.0597) and baseline and 12 weeks (p=0.0625, 
Figure 4.10a). In addition, Tregs decreased over time in both the high and low baseline NLR 
groups, although due to lower patient numbers within each group this was not significant 
(Figure 4.10b, c, d). The reduction in Tregs was independent of the CD4+ population, as shown 
by the consistent proportion of CD4+ cells over these 12 weeks alongside a decrease in the 
Treg/CD4 ratio (Figure 4.10e, f) 
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Figure 4.10 Changes in the Treg population over the course of chemotherapy 
Cryopreserved cells were immunophenotyped and percentage positive cells in the CD4+ T 
cell population determined by flow cytometry at baseline, 6 weeks and 12 weeks. This is 
shown for all patients (a) (n=16) and stratified into high or low NLR ((b), both groups, n=16). 
This data is shown for individual patients in (c) (n=6) and (d) (n=10). The total CD4+ 
population for all patients is shown (e) as is the Treg/CD4+ ratio (f).  
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4.2.2.3.1 Tregs and survival 
When analysing data from all NLR patients, there was a significantly prolonged OS in those 
who had a higher frequency of peripheral FoxP3+ Tregs than the median (median OS not 
reached vs. 6.6 months, p=0.0054, HR 6.424, 95 % CI 1.796 to 22.98, Figure 4.11).  
 
 
Figure 4.11 Overall survival for all NLR patients stratified by frequency of peripheral blood 
Tregs  
Patients were divided into those with a higher or lower than median frequency of Tregs in 
the CD4+ T cell population. Survival was calculated as days from receiving the first dose of 
chemotherapy. All patients with both measurable baseline Tregs and survival data were 
evaluable in the analysis (n=20).  
 
4.2.3 Evaluation of Patient Immune Responses to Chemotherapy Treatment 
and Association with NLR: Cytokine/Chemokine Profile 
4.2.3.1 NLR is associated with a distinct cytokine/chemokine profile at baseline 
Patient plasma was evaluated for a total of 49 cytokines and chemokines by Luminex or ELISA: 
of these, those which were below the lower detection limits of the assay or where the 
majority of samples tested fell below the lower limit of the standard curve are shown in 
Appendix Table 8.6.  
As Figure 4.12 and Table 4.4 demonstrate, of the chemokines and cytokines analysed, 4 (HGF, 
IL-8, IL-10 and TGF-β) were significantly higher at baseline in the patients with a high NLR in 
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comparison to those with a low NLR (p=0.0287, p=0.0183, p=0.0014 and p=0.0005, 
respectively). Comparatively, 8 cytokines and chemokines were significantly higher at baseline 
in those patients with a low NLR: IL-16 (p=0.0033), CTACK (p=0.0009), Eotaxin (p=0.0208), IP-
10 (p=0.0141), MIG (p=0.0035), RANTES (p=0.0183), SCF (p=0.0029) and TRAIL (p=0.0006) 
(Figure 4.13). There was no significant difference in baseline levels for the remaining 19 
cytokines and chemokines studied (Table 4.4). 
Table 4.4 Baseline levels of chemokines and cytokines on Luminex assay/ELISA stratified by 
baseline NLR 
Baseline Levels 
High NLR > Low NLR Low NLR > High NLR No Difference 
IL-8 IL-16 IFN-α2 Basic FGF 
HGF CTACK IFN-γ G-CSF 
IL-10 Eotaxin IL-2Rα GRO-α 
TGF-β IP-10 IL-3 MCP-3 
 MIG IL-4 MIF 
 RANTES IL-7 MIP-1α 
 SCF IL-9 MIP-1β 
 TRAIL IL-17α PDGF-BB 
  IL-18 SCGF-β 
  SDF-1α  
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Figure 4.12 Cytokine/chemokine levels stratified by baseline NLR (1) 
Cytokine/chemokine analysis of patient plasma was performed and stratified according to 
baseline NLR. Solutes that were significantly elevated in the high NLR group are shown: (a) 
HGF, (b) IL-8 (both n=28), (c) TGF-β, (d) IL-10 (both n=29). 
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Figure 4.13 Cytokine/chemokine levels stratified by baseline NLR (2) 
Cytokine/chemokine analysis of patient plasma was performed and stratified according to 
baseline NLR. Solutes that were significantly elevated in the low NLR group are shown: (a) 
MIG (b) SCF (c) CTACK (d) IL-16 (e) TRAIL (f) Eotaxin (g) IP-10 and (h) RANTES (n=28).  
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Overall, patients with a high baseline NLR appeared to have a more permissive cytokine 
profile, with lower levels of pro-immune cytokines and chemokines whilst also demonstrating 
higher levels of inhibitory cytokines including IL-10 and TGF-β.  
4.2.3.2 Change in NLR over time in response to treatment is associated with a 
distinct chemokine/cytokine profile  
There were 5 cytokines/chemokines that demonstrated a significant difference after the first 
6 weeks of chemotherapy in both the high and low baseline NLR patients (Figure 4.14). Some 
were solutes which had previously been shown to differ significantly at baseline between the 
2 groups. HGF was the only cytokine in which the fold change at 6 weeks was raised in the low 
NLR group when compared to the high NLR patients (p=0.0368, Figure 4.14a). For the 
remaining cytokines, fold change from baseline at 6 weeks was significantly increased in the 
high NLR group when compared to the low NLR patients, namely SCF (p=0.0048), MIG 
(p=0.0485), CTACK (p=0.0319) and IL-16 (p=0.0053) (Figure 4.14b-e).  
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Figure 4.14 Fold change in cytokine/chemokine levels over the first 6 weeks of 
chemotherapy, stratified by baseline NLR  
Data shows fold change of cytokines/chemokines in plasma for NLR patients over the first 6 
weeks of treatment. Graphs show: HGF (a), SCF (b), MIG (c), CTACK (d) and IL-16 (e) (n=22). 
Fold change in solutes is shown for patients with baseline NLR ≥ 5 which fell to < 5 over 6 
weeks (high-low NLR) and those whose NLR remained low over this time period (low-low 
NLR). 
 
Interestingly, when looking at all patients, there was no demonstrable change in IL-10 levels 
over the course of chemotherapy at either 6 weeks or 12 weeks (Figure 4.15a). When this 
data was stratified by NLR and further analysed, there were raised levels of IL-10 seen in the 
group that had a high NLR at baseline, when compared to the low NLR group. These remained 
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elevated over the first 6 weeks of treatment whereas the low NLR group continued to have 
levels of IL-10 that were barely detectable (Figure 4.15b). 
 
 
Figure 4.15 Changes in levels of IL-10 over the course of chemotherapy 
Plasma levels of IL-10 (pg/ml) are shown for all patients over the first 12 weeks of 
chemotherapy (a). The change in IL-10, stratified by baseline NLR, after the first 6 weeks of 
chemotherapy is also shown (b) (n=14). 
 
In contrast, levels of TGF-β fell significantly between baseline and 6 weeks (but not between 
baseline and 12 weeks) across the whole patient cohort (p=0.0135, Figure 4.16a). Subgroup 
analysis showed that TGF-β decreased in both the high and low baseline NLR groups 
(Figure 4.16b) but was significant by 6 weeks in the group with a high NLR at baseline 
(p=0.0234, Figure 4.16c and d) 
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Figure 4.16 Changes in levels of TGF-β over the course of chemotherapy 
Plasma levels of TGF-β (pg/ml) are shown for all patients over the first 12 weeks of 
chemotherapy (a). The change in TGF-β, stratified by baseline NLR, during the first 6 weeks 
of chemotherapy is also shown (b). This data is shown for individual patients in (c) and (d) 
(n=23). 
 
Taken together, these data demonstrate that the immunosuppressive cytokine milieu seen in 
patients with a high NLR at baseline can reverse over the first 6 weeks of chemotherapy, with 
a decrease in TGF-β and increase in other pro-immune cytokines and chemokines including 
MIG. However, some differences between the two groups remained: IL-10 and HGF remained 
high in the group of patients with a high NLR at baseline, despite normalisation of the NLR 
over this time period.  
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4.2.4 Evaluation of Patient Immune Responses to Chemotherapy Treatment 
and Association with NLR: Innate Functional Activity  
4.2.4.1 High NLR at baseline is associated with decreased NK cell functional activity  
When exposed to target tumour cells, degranulation of NK cells (as determined by CD107 
expression) was diminished in patients with a high NLR (≥ 5) at baseline. Although this did not 
reach statistical significance at NLR ≥ 5, as we altered the definition of high NLR, firstly to ≥ 4 
then to  ≥ 3, the difference in NK cell activity became more marked between those patients 
with a high or low baseline NLR (shown for different tumour cell targets in Figure 4.17, 
Figure 4.18, Figure 4.19 (all a-c)). When patients were divided into high NLR ≥ 3 and low < 3, 
the difference in degranulation between high and low was more marked against all tumour 
targets; this was significant (p=0.0104) against K562s (a natural target for NK cells) 
(Figure 4.17c) but was also observed against the CRC tumour cell lines SW480 (Figure 4.18c) 
and SW620 (Figure 4.19c). Additionally, across the whole patient cohort, there was a negative 
correlation between levels of CD107 expression prior to chemotherapy and baseline NLR, 
although statistical significance was not reached (Figure 4.17d, Figure 4.18d, Figure 4.19d).  
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Figure 4.17 Degranulation of patient NK cells, against K562 tumour targets, stratified by 
baseline NLR 
Cryopreserved PBMCs were used in degranulation assays to assess NK cell functional 
capacity against K562 tumour targets. Percentage CD107 expression on NK cells, as 
determined by flow cytometry, is shown for different NLR values: (a) NLR of greater/less 
than 5, (b) NLR greater/less than 4 and (c) NLR of greater/less than 3. The relationship 
between baseline NLR and CD107 expression, across all patients, is also shown in (d) (with 
linear regression) (n=28).   
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Figure 4.18 Degranulation of patient NK cells, against SW480 tumour targets, stratified by 
baseline NLR 
Cryopreserved PBMCs were used in degranulation assays to assess NK cell functional 
capacity against SW480 tumour targets. Percentage CD107 expression on NK cells, as 
determined by flow cytometry, is shown for different NLR values: (a) NLR of greater/less 
than 5, (b) NLR greater/less than 4 and (c) NLR of greater/less than 3. The relationship 
between baseline NLR and CD107 expression, across all patients, is also shown in (d) (with 
linear regression) (n=23).   
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Figure 4.19 Degranulation of patient NK cells, against SW620 tumour targets, stratified by 
baseline NLR  
Cryopreserved PBMCs were used in degranulation assays to assess NK cell functional 
capacity against SW620 tumour targets. Percentage CD107 expression on NK cells, as 
determined by flow cytometry, is shown for different NLR values: (a) NLR of greater/less 
than 5, (b) NLR greater/less than 4 and (c) NLR of greater/less than 3. The relationship 
between baseline NLR and CD107 expression, across all patients, is also shown in (d) (with 
linear regression) (n=27). 
 
When analysed in a similar way (defining high NLR as ≥ 5, ≥ 4 and  ≥ 3), there was also a 
difference in the cytotoxic potential of NK cells (within the PBMC population) prior to 
treatment (as determined by 51Cr release assay), although this did not reach statistical 
significance. Patients with a high NLR prior to chemotherapy trended towards decreased 
levels of target tumour cell death, when compared to those with a low NLR, against K562 
target cells (Figure 4.20a-c), SW480 target cells (Figure 4.21a-c) and SW620 cells (Figure 4.22a-
c). As observed previously when evaluating the degranulation of NK cells, there was a negative 
correlation across the whole patient cohort, between the level of tumour cell  death and 
baseline NLR level tested against all target tumour cells (K562: p=0.0023, r2=0.3272, 
Figure 4.20d; SW480: p=0.14226, r2=0.1705, Figure 4.21d; SW620: p=0.0559, r2=0.1707, 
Figure 4.22d). 
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Figure 4.20 Cytotoxicity of patient NK cells, against K562 tumour targets, stratified by 
baseline NLR.  
Cryopreserved PBMCs were used in 51Cr assays to assess NK cell functional capacity against 
51Cr-labelled K562 tumour targets. Cytotoxicity of PBMCs at an E:T ratio of 100:1 is shown at 
baseline (pre-chemotherapy) for decreasing NLR values: (a) NLR greater/less than 5, (b) NLR 
greater/less than 4 and (c) NLR greater/less than 3. The relationship between baseline NLR 
and cytotoxicity, across all patients, is also shown in (d) (with linear regression) (n=26). 
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Figure 4.21 Cytotoxicity of patient NK cells, against SW480 tumour targets, stratified by 
baseline NLR. 
Cryopreserved PBMCs were used in 51Cr assays to assess NK cell functional capacity against 
51Cr-labelled SW480 tumour targets. Cytotoxicity of PBMCs at an E:T ratio of 100:1 is shown 
at baseline (pre-chemotherapy) for decreasing NLR values: (a) NLR greater/less than 5, (b) 
NLR greater/less than 4 and (c) NLR greater/less than 3. The relationship between baseline 
NLR and cytotoxicity, across all patients, is also shown in (d) (with linear regression) (n=14). 
 
 
 
 
 
H
ig
h
 N
L
R
 >
 5
L
o
w
 N
L
R
 <
 5
0
2 0
4 0
6 0
8 0
1 0 0
B a s e lin e  S W 4 8 0
%
 C
y
to
to
x
ic
it
y
a )
H
ig
h
 N
L
R
 >
 4
L
o
w
 N
L
R
 <
 4
0
2 0
4 0
6 0
8 0
1 0 0
B a s e lin e  S W 4 8 0
%
 C
y
to
to
x
ic
it
y
b )
H
ig
h
 N
L
R
 >
 3
L
o
w
 N
L
R
 <
 3
0
2 0
4 0
6 0
8 0
1 0 0
B a s e lin e  S W 4 8 0
%
 C
y
to
to
x
ic
it
y
c )
0 1 0 2 0 3 0
0
2 0
4 0
6 0
8 0
1 0 0
B a s e lin e  %  K ill in g  v s . N L R
N L R
%
 C
y
to
to
x
ic
it
y
d )
p = 0 .1 4 2 2
(a) SW480: High NLR ≥ 5 (  SW480: High NLR ≥ 4 
(c) SW480: High NLR ≥ 3 (d) SW480: Cytotoxicity vs. NLR 
 
 
129 
 
  
 
 
Figure 4.22 Cytotoxicity of patient NK cells, against SW620 tumour targets, stratified by 
baseline NLR.  
Cryopreserved PBMCs were used in 51Cr assays to assess NK cell functional capacity against 
51Cr-labelled SW620 tumour targets. Cytotoxicity of PBMCs at an E:T ratio of 100:1 is shown 
at baseline (pre-chemotherapy) for decreasing NLR values: (a) NLR greater/less than 5, (b) 
NLR greater/less than 4 and (c) NLR greater/less than 3. The relationship between baseline 
NLR and cytotoxicity, across all patients, is also shown in (d) (with linear regression) (n=22). 
 
4.2.4.2 A lower NK cell functional activity was improved following treatment and 
was associated with a reduction in NLR 
Despite a lower level of CD107 expression on NK cells (in response to a variety of tumour 
targets) in patients with a high pre-treatment NLR, an increase in CD107 expression was 
evident when their NLR dropped in response to treatment (Figure 4.23a-c). This was only 
significant against SW620 target cells (p=0.0041, Figure 4.23c), although the same trend was 
apparent against K562 and SW480 targets.  
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Figure 4.23 Fold change in CD107 expression on patient NK cells in the first 6 weeks of 
chemotherapy stratified by change in NLR 
Cryopreserved PBMCs, taken prior to treatment and following 6 weeks of chemotherapy, 
were used in degranulation assays to assess NK cell functional capacity against: (a) K562 
(n=20), (b) SW480 (n=14) and (c) SW620 (n=18). As determined by flow cytometry, fold 
change in CD107 expression is shown for patients with baseline NLR ≥ 5 which fell to < 5 
over 6 weeks (high-low NLR) and those whose NLR remained low over this time period 
(low-low NLR).  
 
Once again, despite the low levels of cytotoxicity (as determined in 51Cr assays) associated 
with a high baseline NLR, this was enhanced by 6 weeks, as NLR decreased (high-low NLR 
group, Figure 4.24a-c). This was significant against K562 target cells (p=0.0204, Figure 4.24a). 
Statistical analysis was not possible in the SW480 condition as there was only data from 2 
patients in the high-low group (Figure 4.24b).  
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Figure 4.24 Fold change in cytotoxicity (51Cr assays) of patient NK cells in the first 6 weeks 
of chemotherapy stratified by change in NLR  
Cryopreserved PBMCs, taken prior to treatment and following 6 weeks of chemotherapy, 
were used in a 51Cr-released assay against: (a) K562 (n=18), (b) SW480 (n=9) and (c) SW620 
(n=16). Fold change in cytotoxicity is shown for patients with baseline NLR ≥ 5 which fell to 
< 5 over 6 weeks (high-low NLR) and those whose NLR remained low over this time period 
(low-low NLR). 
 
4.2.4.3 Higher CD107 expression on peripheral NK cells prior to treatment is 
associated with a trend towards increased overall survival  
Within the entire patient cohort, those with elevated CD107 expression on NK cells showed a 
non-significant trend to prolonged OS when results were analysed by median CD107 
expression against all tested tumour targets (Figure 4.25). Median OS was not reached in the 
K562 group with CD107+ NK cells  ≥ median vs. 345 days in the comparison group 
(Figure 4.25a). This was also true against SW480 targets (median OS for patients with CD107 
expression < median 162 days) (Figure 4.25b) and SW620 targets, where median OS for 
patients with CD107 expression < median was 344.5 days (Figure 4.25c). 
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Figure 4.25 Overall survival of patients stratified by median CD107 expression on NK cells 
against different target tumour cells 
All patients were stratified according to CD107 expression on NK cells when incubated with: 
(a) K562 (n=26) (b) SW480 (n=21) and (c) SW620 (n=25) target cells. Survival was calculated 
as days from receiving the first dose of chemotherapy. All patients were evaluable in the 
survival analysis. 
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4.2.4.4 High cytotoxic potential of PBMCs prior to treatment is associated with 
increased overall survival 
Overall survival was increased in patients whose PBMCs had a higher level of cytotoxicity (as 
determined by 51Cr-released assay) against both K562 and SW620 target cell lines 
(Figure 4.26). Against K562 cells, OS was significantly increased in patients where NK cell-
mediated cytotoxicity was greater than the median (median OS not reached for high 
cytotoxicity group vs. 344 days, p= 0.0498, HR 2.775, 95 %, CI 0.9496 to 8.108). Against SW620 
cells OS was also significantly increased (median OS not reached for high cytotoxicity group vs. 
359 days, p=0.0404, HR 3.226, 95 % CI 0.9358 to 11.12). There were not enough data points to 
determine survival against SW480 target tumour cells.  
 
 
 
Figure 4.26 Overall survival of patients stratified by median cytotoxicity of NK cells 
against different target tumour cells  
All patients were stratified according to cytotoxicity when incubated with: (a) K562 (n=24) 
and (b) SW620 (n=21) target cells. Survival was calculated as days from receiving the first 
dose of chemotherapy. All patients were evaluable in the survival analysis.   
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4.2.5 Evaluation of Patient Immune Responses to Chemotherapy Treatment 
and Association with NLR: ELISpot 
4.2.5.1 T cell responses reflect innate immune responses within patients 
ELISpot assays were performed to determine the adaptive T cell response of patients 
undergoing treatment and to monitor any changes which may occur in response to therapy. 
Once thawed, PBMCs were incubated with either a CRC TAA (CEA) or viral peptides (CEF) and 
T cell responses were measured by IFN-γ production. As with other previous assays, inherent 
variability between patients was evident. However, IFN-γ production in response to viral and 
TAA peptides seemed to reflect the pattern in responses seen in some of the other immune 
assays (NK cell activation), indicating that despite inter-patient variability, there were similar 
trends in the innate and adaptive arm of an individual patient’s immune response to 
treatment. As an example, in patient NLR-7, there was an increase in IFN-γ production to CEF 
peptide (a marker of non-specific T cell recall response) between baseline (pre-chemotherapy) 
and 6 weeks, which then fell by 12 weeks (Figure 4.27a). This was mirrored in cytotoxicity 
assays, where the PBMCs taken at 6 weeks showed higher levels of tumour cell killing 
compared to baseline and immunophenotyping, where expression of CD69 had increased 
dramatically on both CD4+ and CD8+ T cells by the 6 week sample (Figure 4.27b, c, f, g). 
Although CD107 degranulation was not noticeably higher at 6 weeks, levels increased over the 
12 week period (Figure 4.27d, e). 
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Figure 4.27 Comparison between adaptive T cell responses and innate responses during 
treatment: Patient NLR-07  
Cryopreserved PBMCs were collected from patient NLR-07 and analysed by ELISpot and 
other innate immune assays. IFN-γ production in response to CEF peptide was aligned with 
innate responses in the same samples. (a) T cell responses (and number of SFU) are shown 
for baseline, 6 week and 12 week samples in duplicate. Cytotoxicity of PBMCs (determined 
by 51Cr assay) against SW620 (b) and K562 cells (c) are also shown. CD107 expression 
(determined by flow cytometry) is shown against SW620 (d) and K562 (e). Also shown is 
CD69 expression on CD4+ (f) and CD8+ (g) T cells as determined by flow cytometry.  
 
In contrast, patient NLR-10 did not exhibit any change in T cell responses to CEF peptide (as 
demonstrated by unvarying IFN-γ SFU over a 12 week period). This was also reflected in 
cytotoxicity assays, CD107 degranulation assays and in CD69 expression on CD4+ and CD8+ T 
cells (Figure 4.28).  
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Figure 4.28 Comparison between adaptive T cell responses and innate responses during 
treatment: Patient NLR-10 
Cryopreserved PBMCs were collected from patient NLR-10 and analysed by ELISpot and 
other innate immune assays. IFN-γ production in response to CEF peptide was aligned with 
innate responses in the same samples. (a) T cell responses (and number of SFU) are shown 
for baseline, 6 week and 12 week samples in duplicate. Cytotoxicity of PBMCs (determined 
by 51Cr assay) against SW620 (b) and K562 cells (c) are also shown. CD107 expression 
(determined by flow cytometry) is shown against SW620 (d) and K562 (e). Also shown is 
CD69 expression on CD4+ (f) and CD8+ (g) T cells as determined by flow cytometry. 
 
Finally, in patient NLR-05, there was an increase in T cell ELISpot responses between baseline 
and 6 weeks and also between 6 and 12 weeks of chemotherapy (Figure 4.29). Once again this 
was also evident in the chromium-release assay, with a rise in NK-mediated cytotoxicity over 
the 12 week period of chemotherapy. However, in this patient, CD107 and CD69 expression 
did not mirror these findings. 
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Figure 4.29 Comparison between adaptive T cell responses and innate responses during 
treatment: Patient NLR-05 
Cryopreserved PBMCs were collected from patient NLR-05 and analysed by ELISpot and 
other innate immune assays. IFN-γ production in response to CEF peptide was aligned with 
innate responses in the same samples. (a) T cell responses (and number of SFU) are shown 
for baseline, 6 week and 12 week samples in duplicate. Cytotoxicity of PBMCs (determined 
by 51Cr assay) against SW620 (b) and K562 cells (c) are also shown. CD107 expression 
(determined by flow cytometry) is shown against SW620 (d) and K562 (e). Also shown is 
CD69 expression on CD4+ (f) and CD8+ (g) T cells as determined by flow cytometry. 
 
T cell responses to the TAA peptide CEA were variable across the patient cohort; in some 
patients there was no change in ELISpot assays over the course of chemotherapy,  whereas in 
others a change in IFN-γ production was detected. In patient NLR-18, there was an increase in 
SFU to both CEA and CEF peptide, demonstrating a peak in IFN-γ production (and hence T cell 
response) at the 6 week sample. Interestingly, this was not only mirrored by the increase in 
NK cell degranulation at the same time point but also by the serum CEA level (Figure 4.30). 
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Figure 4.30 Comparison between adaptive T cell responses and innate responses during 
treatment: Patient NLR-18. 
Cryopreserved PBMCs were collected from patient NLR-18 and analysed by ELISpot and 
other innate immune assays. IFN-γ production in response to CEF and CEA peptides were 
compared to CD107 degranulation assays and serum CEA measurement. (a) T cell responses 
(and number of SFU) against CEF peptide are shown for baseline, 6 week and 12 week 
samples in duplicate. Similarly, (b) T cell responses (and number of SFU) against CEA 
peptide are also shown. CD107 expression (determined by flow cytometry) is shown against 
K562 tumour cells (c). Also shown are serum CEA levels (d). 
 
4.2.5.2 A high or low NLR prior to treatment is associated with a distinct adaptive T 
cell response  
Examination of pre-treatment T cell responses to CEF peptides suggested a decreased 
response at baseline in the group of patients with a high NLR (Figure 4.31a), although this 
result was not significant. In addition, mirroring the CD107 and cytotoxicity results, enhanced 
response to CEF peptide at 6 weeks was observed in patients in whom NLR fell by 6 weeks of 
chemotherapy (CEF response increased as NLR decreased) (Figure 4.31b). A positive response 
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to CEF peptide at 6 weeks was defined as the proportion of patients with a 1.5x increase in 
SFU, minus the negative control. 
 
 
 
Figure 4.31 T cell responses to CEF prior to treatment, stratified by NLR  
Cryopreserved PBMCs were incubated with CEF peptide and analysed by ELISpot assays. T 
cell responses (SFU) against CEF peptide, prior to treatment, are shown in patients with 
high or low NLR at baseline (a). Also shown is the positive response to CEF peptide at 6 
weeks for patients with baseline NLR ≥ 5 which fell to < 5 over 6 weeks (high-low NLR) and 
those whose NLR remained low over this time period (low-low NLR) (b).  
 
When looking at response to CEA peptide, there was no appreciable difference prior to 
treatment when stratified by NLR (Figure 4.32a). However, a higher number of positive 
responses to CEA peptide was found in low NLR patients (CEA response increased if NLR 
stayed < 5) (Figure 4.32b). 
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Figure 4.32 T cell responses to CEA prior to treatment, stratified by NLR 
Cryopreserved PBMCs were incubated with CEA peptide and analysed by ELISpot assays. T 
cell responses (SFU) against CEA peptide, prior to treatment, are shown in patients with 
high or low NLR at baseline (a). Also shown is the positive response to CEA peptide at 6 
weeks for patients with baseline NLR ≥ 5 which fell to < 5 over 6 weeks (high-low NLR) and 
those whose NLR remained low over this time period (low-low NLR) (b). 
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4.3 NLR Discussion 
The data presented in this chapter further delineates the immune response in patients with 
CRC on first-line chemotherapy and the relationship between NLR and outcome. NLR has been 
found to be a strong predictive marker in a number of different tumour types and, in CRC, has 
been associated with pathological stage, response to therapy and survival. The underlying 
mechanism for this relationship has not been thoroughly investigated. By interrogating this in 
a CRC patient group, we hoped to reveal underlying immunological correlates which could 
potentially be exploited in the development of novel treatment strategies.  
In order to assess the status of a patient’s immune system both at baseline (prior to 
treatment) and at specific time points during therapy, we performed a number of 
complementary analyses on patient blood samples. The results suggested differences in 
immune profiles of those patients with a high baseline NLR and those with a low baseline, 
such as higher levels of cytokines including IL-10 and TGF-β. Those with a low NLR at baseline 
had significantly higher plasma levels of cytokines such as RANTES, SCF, TRAIL and MIG. There 
was also a suggestion that a higher baseline NLR was associated with diminished innate 
immune responses against tumour cell targets (cytotoxicity and degranulation). With 
chemotherapy, there was a change noted in this immune profile, with a fall in levels of TGF-β 
and Tregs. There was also some evidence that T cell responses towards CEF and TAAs altered 
with chemotherapy.  
There was no obvious change in activation markers such as CD69, CCR7 and HLA-DR on 
immune cell populations including CD4+ and CD8+ T cells, monocytes and B cells ( Figure 4.4 
and Figure 4.5) over the time period assessed. However, the timings of these samples may not 
be optimum to reveal such a response to therapy. Due to ethical constraints samples were 
taken prior to chemotherapy, after 6 weeks and initially also after 12 weeks of chemotherapy; 
dates which corresponded with planned hospital visits. It is possible, therefore, that transient 
changes in activation markers were missed. The early activation marker, CD69, is expressed in 
the first 6-12 hours after T cell stimulation (421). In comparison, HLA-DR and CCR7 are later 
markers of immune function. Increased HLA-DR expression, for example, has been 
demonstrated 48 - 72 hours post ex vivo stimulation of PBMCs (421). Similarly, in vitro 
stimulation of CD4+ T cells has shown that the proportion of CCR7+ cells increases over a 
short number of days but the CCR7- subpopulation increased significantly by three weeks 
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(422). It is possible that taking samples at alternative time points, e.g. prior- and 24 hours 
post-chemotherapy, may have permitted detection of such changes.  
In our data, the proportion of Tregs within the CD4+ population fell through the first 6 weeks 
of chemotherapy and reduced further by 12 weeks (Figure 4.10). This was independent of the 
baseline NLR, although it was interesting that, in contradiction to what may have been 
predicted, peripheral Tregs were present at a higher frequency in the low NLR group 
compared to the high. Established dogma would predict that patients with a high NLR (and, in 
our hands, a seemingly depressed immune response) would have a higher proportion of 
Tregs. However, possible future work could include analysis of paired tumour samples which 
may reveal that decreased peripheral Tregs reflect a higher proportion of Tregs in the TME. It 
should also be noted that there are a number of phenotypic classifications of Tregs, with 
different immunosuppressive properties (naïve, effectors and terminal effectors (50)) which 
may be further subcategorised by the presence or absence of CD45RO, which can also be used 
to differentiate naïve and memory T cell populations (50,423). These phenotypically different 
sub-classifications of Tregs appear to express different levels of IL-10 and TGF-β and changes 
in the populations of each can be variably associated with PFS and OS in NSCLC patients (50). 
These differences, which we have not analysed fully, may influence the apparent increase in 
OS in the population of patients with higher levels of peripheral Tregs (Figure 4.11). Our 
discovery of fewer Tregs in the patients with a high baseline NLR seems discordant with the 
higher concentrations of the cytokines TGF-β and IL-10, which are produced by Tregs (50) and 
contribute to the immunosuppressive milieu. However, other cell types are also known to 
secrete these cytokines and may be the physiological source in situ. 
There was a significant difference in the expression of the LN-homing receptor CD62L on Tregs 
between the high and low NLR groups at baseline: this was diminished in the high NLR group 
(Figure 4.9b). In the context of a decreased Treg population, this may support the hypothesis 
that the population of Tregs we are examining in the periphery do not include the CD62L+ 
Tregs which have already trafficked to LNs or tumour. It is at these sites that Tregs can exert 
their suppressive effects and contribute to immune tolerance to tumour antigens, presented 
by APC (424). Again, this may be a factor when considering the differences in OS in patients 
with varying populations of peripheral Tregs and supports the view that, in addition to the 
evaluation of peripheral blood cells to therapy, the TME should also be studied. In support of 
this data, other groups have found that 5-FU-containing chemotherapy (including FOLFOX and 
FOLFIRI in CRC) is associated with a decreased proportion of Tregs in peripheral blood 
 
 
143 
 
(425,426). In a group of gastric cancer patients receiving neo-adjuvant chemotherapy, a 
reduction in peripheral Tregs over the course of treatment also corresponded to an increased 
OS, supporting the evidence for an improvement in OS even in patients with a high NLR which 
falls over the course of treatment (425).  
We found that there was no appreciable difference between the populations of PD-1+ and 
PD-L1+ Tregs at baseline in either the high or low NLR groups. This was the same in many of 
the other cell populations analysed. However, expression of PD-1 on NK cells, monocytes and 
B cells (Figure 4.7 - Figure 4.8) increased during chemotherapy, with a significant change from 
baseline seen by 6 weeks. While this may suggest a potential use for immunotherapy, the 
efficacy of immune checkpoint inhibitors (anti-PD-1 or anti-PD-L1) should depend on the 
presence of both receptor and ligand within the immune environment (427). Supporting this 
theory, 5-FU chemotherapy has been shown to increase expression of PD-L1 on both 
colorectal and oesophageal cell lines, which was also low pre-chemotherapy (428). It is worth 
noting, however, that these cell lines were microsatellite instable HCT 116 cells, which are 
deficient in MSH1 and as already discussed, are more amenable to immune checkpoint 
inhibitors (324,429). This increase in PD-L1, however, may also indicate a developing immune-
resistance to traditional chemotherapy and provide a further rationale for the use of 
immunotherapy after sequential chemotherapy in gastrointestinal cancers. This upregulation 
of PD-L1 is not limited to 5-FU and CRC however: increased expression has also been noted 
following cisplatin- or carboplatin-based neoadjuvant chemotherapy in urothelial cancer (430) 
and once again may signify a broader mechanism of immune response to chemotherapy-
induced cell death, developing immune tolerance and emerging resistance to chemotherapy. 
Wang et al. (431) have previously shown that the colorectal cell line MC38 is resistant to 
immune checkpoint blockade in vitro but that treatment with oxaliplatin stimulated immune 
cell infiltration into the tumour. Furthermore, treatment with sequential oxaliplatin followed 
by anti-CTLA-4 and anti-PD-1 blockade led to reduced tumour size and increased survival in 
mice implanted with MC38 tumours. This is possibly a consequence of combination therapy 
up-regulating the ligands PD-L1 and PD-L2. As such, there appears to be a rationale for 
potential sensitisation of CRC to immune checkpoint inhibition following chemotherapy.  
We observed that innate immune function was also attenuated in patients who had a higher 
baseline NLR, as evidenced by reduced NK cell function against tumour cell targets 
(Figure 4.17 - Figure 4.22); a negative correlation with baseline NLR and NK cell function was 
evident. Of interest, in patients with a high baseline NLR, these differences seemed to be 
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abrogated following 6 weeks of first-line chemotherapy, corresponding to a fall in NLR: NK cell 
function increases as the NLR decreases (Figure 4.23 and Figure 4.24). All patients involved in 
the current study received chemotherapy containing 5-FU or the pro-drug capecitabine. 
Treatment with 5-FU has previously been shown to increase both the number of peripheral 
NK cells (432–434) and their function (as evidenced by increased expression of cell surface 
CD69). As discussed above, it is likely that any increase in CD69 in our patient cohort was not 
detected due to the timings of sample acquisition. There is a solid body of evidence that, aside 
from their frequency within peripheral blood, NK cells themselves may be dysregulated in the 
context of malignancy. Expression of the activating receptors NKG2D, NKp30 and NKp46 are 
diminished on peripheral NK cells from patients with CRC compared to healthy controls (379). 
Expression of NKG2D is also attenuated in patients with metastatic disease compared to 
healthy controls and both low grade and high grade non-metastatic disease (16). Our results 
showed an increase in levels of TGF-β in patient plasma (Figure 4.12c), which is itself known to 
inhibit NK cell function (145). Interestingly, other groups have also shown a correlation 
between downregulation of NK cell activating receptors and TGF-β (146). Collectively, this 
supports our data which links abrogated NK cell function with poor-prognosis high NLR CRC. 
The role of NK cells in immune surveillance and their potential to control the development 
and growth of malignancy indicates that these findings likely represent a vicious circle of 
dysfunctional NK cells contributing to the development of metastatic disease and NK function 
being further suppressed in the context of higher grade, aggressive, metastatic disease.  
To further our understanding of the immune response and how it relates to NLR status, an 
extensive analysis of the cytokine and chemokine profile of patient plasma was performed. 
Initial comparisons of pre-treatment samples between the high and low NLR groups revealed 
thought-provoking findings. Although a considerable number of chemokines and cytokines 
were suppressed prior to treatment in the context of a high NLR, other solutes, specifically 
TGF-β, IL-10, HGF and IL-8 were elevated in these patients (Figure 4.12 and Figure 4.13). The 
elevated levels of TGF-β and IL-10 that we observed in the high NLR group was not 
unexpected, given the data supporting their role in the suppression of anti -tumour immune 
responses (100,155). Significantly, elevated levels of TGF-β have been observed in patients 
with Dukes stage C and D CRC compared to healthy controls (141). Although our cohort of 
patients all had metastatic disease, our data would support the correlation between high 
levels of immunosuppressive cytokines and increased stage/extent of disease. This was also 
illustrated in the work by Ivanovic et al (435), which showed that plasma levels of TGF-β were 
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elevated in patients with more extensive stage breast cancer. This translated to decreased 
two-year survival in patients with plasma TGF-β1 >3 ng/ml compared to those with levels 
more comparable to the HD group (10 % vs. 52 %, respectively) (435). Reflecting similar 
findings to those already discussed, IL-10 is highly predictive of DFS in patients who have 
resections for CRC (160). The interesting finding in our patient cohort was that, although 
levels of TGF-β fell significantly over the first 6 weeks of chemotherapy, levels of  IL-10 
remained steady (Figure 4.15 and Figure 4.16). This might be unexpected given our 
observation that the peripheral blood Treg population fell with chemotherapy. However, 
although Tregs are a major source of IL-10, other immune cell populations, which did not 
decline with chemotherapy, can also produce IL-10. In the context of HIV infection, it has been 
shown by Said et al. that increased PD-1 expression can induce IL-10 production from 
monocytes (153). Similarly, the elevated PD-1 expression noted in our data may be one of the 
potential triggers for ongoing IL-10 production in response to this inhibitory signal. The 
difference in the plasma levels of these two immunosuppressive cytokines with chemotherapy 
may also go some way to explaining why patients with a high NLR may have different 
outcomes than those with low NLR, even if it normalises with therapy (406).   
Both IL-8 and HGF can be secreted by cancer-associated fibroblasts (CAFs) (436). CAFs are 
fibroblasts that are associated with the TME and secrete a range of cytokines and chemokines 
that can contribute to tumour growth, invasion, metastases, angiogenesis and 
immunosuppression (436). Through activation of the intra-cellular MAPK pathway, HGF 
promotes cell growth, survival and metastasis (437). Production of HGF either by CAFs or 
tumour cells is potentially due to mutations in the HGF promoter gene found in a proportion 
of CRC patients (438). In keeping with our findings of elevated HGF levels in patients with a 
high NLR at baseline, HGF levels in peripheral blood and in colonic tumour tissue were higher 
compared to normal controls (439). Increased levels were also associated with LN and liver 
metastases and tumour size. Furthermore, elevated HGF correlates with serum CEA and 
survival in both early stage (440) and later stage disease (441). As such, the raised levels of 
HGF detected in high NLR patients may contribute to their considerably reduced immune 
activation potential prior to treatment.  
IL-8 plays a role in the chemotaxis of both neutrophils and lymphocytes to sites of 
inflammation or infection (164,442). IL-8 can also stimulate angiogenesis (82,443) and its 
production can be induced in the presence of factors such as hypoxia and acidosis (such as is 
found in the TME of CRC) (443). IL-8 can be produced by tumour cells of various aetiologies, 
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including but not limited to, breast cancer, lung cancer, HCC, melanoma and CRC. 
Furthermore, it is associated with tumour progression, stage and outcome (444)(445)(446). 
Although IL-8 is upregulated in inflammatory bowel disease (such as ulcerative colitis), it is 
significantly more elevated in CRC specimens (447) and is correlated with the presence of liver 
metastases. In vitro, CRC cell lines can produce endogenous IL-8, which, in turn, stimulates 
both angiogenesis and cell growth (448). Interestingly, there is evidence that migration of 
PBMCs, specifically Tregs, into the TME can be induced by IL-6 and IL-8 secretion by tumour 
cells (449). The mechanism of this is thought to be the upregulation of IL-8 receptors, CXCL1 
and CXCL2, on Tregs by IL-6. In summary, increased IL-8 is associated with more advanced 
stages of CRC, which produce further IL-8, supporting angiogenesis and influx of Tregs into the 
TME of patients with a high NLR. This data demonstrates that IL-8 is also associated with 
elevated NLR and immune dysfunction in vitro. 
A large proportion of cytokines/chemokines that we analysed were elevated prior to 
treatment in the low NLR group (Figure 4.13). One of these was IL-16 (also known as 
lymphocyte chemoattractant factor, LCF). As well as migration, IL-16 can also stimulate the 
growth/proliferation of CD4+ cells. In keeping with our findings that a high NLR may 
correspond with a depressed immune response, IL-16 has been shown to be differentially 
expressed in colon cancers. MSI cancers, for example, shown previously to demonstrate a 
more immunogenic phenotype (370,371,429,450) are associated with higher levels of IL-16 
(451).   
The chemokine TRAIL can initiate apoptosis of tumour cells. It is produced by T cells, NK cells, 
monocytes and DCs. Supporting our findings of lower plasma TRAIL in high NLR patients 
(Figure 4.13), a relatively lower expression of TRAIL has been documented in carcinomas 
compared to normal epithelium or adenomas (130). This, along with our findings, may suggest 
a downregulation of TRAIL to avoid apoptosis: in our cohort of high NLR patients, 
downregulation of TRAIL may be one of the mechanisms contributing to the development of 
more aggressive/widespread disease. Interestingly (and relevant to our data), CPT-11 
(irinotecan) can upregulate TRAIL receptors (135) and combination therapy with 5-FU or CPT-
11 can decrease tumour growth in vivo (452). 
Eotaxin, also known as CCL11, an eosinophil chemokine in the same family as RANTES, has 
also been implicated in angiogenesis (453) and metastasis of cancer cells through its effects 
on MMPs (453,454). In our investigation, low NLR patients had more circulating eotaxin 
(Figure 4.13); levels of eotaxin are known to be elevated in the serum of patients with breast, 
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lung and CRC (455,456). Similarly, greater concentrations of eotaxin are detected in 
supernatants of hepatic metastases from CRC tumours, above that found in normal liver (457). 
In keeping with our other findings, decreased levels of eotaxin suggests a depressed immune 
response and potentially decreased immune infiltration into the tumour of high NLR patients.  
RANTES is also a chemokine which induces the recruitment of monocytes and macrophages 
into the TME. Subsequently, such immune infiltrates can undergo differentiation into a more 
tumorigenic phenotype (so-called M2 TAMs and N2 TANs). It may be expected, then, that the 
high NLR population would have a higher plasma levels if we are postulating that the TME is 
more immunosuppressive. Comparable with our findings, Johdi et al. found that levels of 
RANTES are lower in the serum of patients with colorectal polyps and CRC (though not 
significantly so) than healthy controls (456). As with the other pro-inflammatory solutes that 
were found to be lower in the high NLR groups, it is unclear whether this is a result of a more 
immunosuppressive environment (immune tolerance to a tumour which should elicit a brisk 
anti-tumour response) or whether the patients with a high NLR have so because these pro-
immune cytokines are decreased. As part of the process resolving inflammation, RANTES can 
be sequestered by apoptotic neutrophils and T cells through enhanced expression of its 
receptor, CCR5 (458). Upregulation of CCR5 can be seen in the presence of markers of 
immune exhaustion such as PD-1, which was also raised in our patient population (458). The 
processes of sequestering this and other pro-inflammatory cytokines may be further 
stimulated by the presence of IL-10 (459). This may support the idea of some kind of immune 
exhaustion/tolerance in the high NLR patients which contributes to lower plasma levels of 
inflammatory cytokines.  
IP-10 was elevated in the group of patients with low pre-treatment NLR (Figure 4.13). One of 
its many actions is as a chemoattractant for monocytes and T cells (460) and it’s production in 
response to IFN-γ contributes to the migration of activated T cells into sites of inflammation or 
into tumours. Illustrating this, IP-10 is elevated in CRC patients with MSI tumours compared to 
those whose tumour demonstrated MSS (451). This would be in keeping with an enhanced 
immune response in MSI tumours. Although our cohort of CRC patients did not include 
anyone with confirmed MSI tumours, our other findings support a depressed immune 
response in patients with high NLR over a number of different parameters. In this context, the 
lower levels of IP-10 in patients with a high NLR would support our other findings. IP-10, along 
with MIG, which was also decreased in our cohort of high NLR patients, exhibits angiostatic 
features. The anti-tumourigenic properties of both IP-10 and MIG have been attributed to 
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their chemotactic properties: the recruitment of immune cells including T cells and NK cells 
contribute to the anti-tumour effects of other cytokines, such as IL-12.  
Cutaneous T cell-attracting chemokine (CTACK, also known as CCL27), is another T cell 
attractant. It has been described as having a prominent role in inflammation of the skin and, 
as such, has been shown to be encourage chemotaxis of immune cells in models of melanoma 
(461). Following transfection with adenovirus expressing CTACK, the CRC cell line CT26 was 
injected into BALB/c mice, leading to a reduction in tumour growth compared to CRC 
transfected with viral vector alone (462). Although this was not significant, it may indicate that 
the expression of CTACK by CRC cells can contribute to an anti-tumour immune effect and this 
would be supported by our findings of increased levels of CTACK in the patients with a low 
NLR (Figure 4.13). Although there is no published data, it may be worth considering whether 
chemotherapy can increase production of CTACK by tumour cells and increase the chemotaxis 
of immune cells into the tumour.  
While we observed that patients with a low NLR had higher levels of plasma SCF than those 
with a high baseline NLR (Figure 4.13), other groups have demonstrated the contrary. In a 
study of 75 patients, levels of SCF in serum were actually lower in patients undergoing surgical 
resection for CRC compared to healthy controls (463). Although we are postulating that a high 
NLR is associated with a poorer prognosis and that this could correlate with more advantaged 
stage of disease, patients with a high NLR may have a higher neutrophil count. As such, 
patients with a low NLR may be predisposed towards having a low neutrophil count and as 
SCF is a haematopoietic growth factor, it may be that neutropenia in these patients can 
stimulate the production of SCF as a compensatory mechanism. Similar phenomena have 
been seen in mice treated with 5-FU chemotherapy, where SCF was shown to reverse 
thrombocytopenia in treated mice (464).  
Unlike IL-16, MIG and SCF, levels of eotaxin, IL-8 and RANTES did not vary over the first 6 
weeks of chemotherapy (Figure 4.14). Again this may contribute to the ongoing differences in 
prognosis between the high and low NLR groups, despite normalisation of the NLR in the 
former.  
To expand on our understanding of NLR status and response to chemotherapy within the 
innate immune system, the adaptive arm of the immune system was also investigated; T cell 
responses were examined by ELISpot. There was an indication that T cell responses in patients 
with a high baseline NLR were attenuated against the CEF viral peptide pool but this was not 
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statistically significant (Figure 4.31). Interestingly, in those patients where the NLR dropped 
over the first 6 weeks of chemotherapy, T cell responses to non-specific viral peptides 
increased as the NLR decreased. Conversely, in patients with a consistently low NLR, it was the 
responses to CEA which increased (Figure 4.32).  
There is conflicting data as to whether T cell responses against TAAs confer clinical benefit. In 
another cohort of patients with CRC, responses to TAAs were varied, with a greater 
proportion of patients with later stage disease registering a response. In this group, there was 
no survival benefit seen (465). In contradiction to this data, Scurr et al. found that CEA-specific 
responses were associated with a poorer outcome, even when patients were stratified by 
stage (384). Whether a positive CEA response was actually indicative of occult metastatic 
disease in earlier stage patients (not included in our study) is unclear.  
Given the decline in Tregs over time in our data (independent of baseline NLR), an increase in 
IFN-γ effector T cell responses during therapy may have been expected. The findings of Clarke 
et al. further support the role of Tregs in suppressing T cell responses: Treg depletion was 
associated with increased response to the 5T4 tumour antigen (56). 
Overall, the data presented in this chapter suggests a depressed immune response in patients 
with a high baseline NLR, as measured by a number of different parameters. Following 6 
weeks of chemotherapy, however, there appeared to be evidence of elevated immune 
responses comparative to baseline if a patient’s NLR decreased to <5. Despite this, OS in the 
group with a reduction in NLR following chemotherapy is still poorer than those patients 
whose NLR stayed low throughout. Non-specific (CEF) T cell responses in this group seemed to 
increase over time but if this is not tumour-specific (similar to the CEA response in the low-low 
group) this may contribute to the poorer prognosis in this group of patients. These findings 
support further exploration into the role of immunotherapy following chemotherapy in  
patients with CRC given the change in the immune milieu which has been detected. Although 
there may be potential clinical benefit to this strategy in CRC patients with high or low 
baseline NLR, there may be additional advantages in the former group, who traditionally have 
a poorer outcome with standard chemotherapy.  
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Chapter 5 Immune Responses in Melanoma 
5.1 Introduction 
5.1.1 Melanoma  
The incidence of melanoma skin cancer is increasing, with over 15,000 new cases diagnosed in 
2014, making it the fifth most common cancer in the UK (466). As incidence increases with 
age, the burden of disease continues to rise with an ageing population. Despite the rapid 
improvement in treatment options over the last five years, malignant melanoma still accounts 
for nearly 2,500 deaths per year (466). Once LN-positive, five-year survival falls to 
approximately 50 %. When distant metastases are present, prognosis may be only a few 
months (467) and one year survival for stage IV disease is less than 50 % (468).  
Risk factors for the development of melanoma include fair skin which burns easily, red or fair 
hair, UV exposure (previous history of sunburn or use of sunbeds, especially at less than 35-
years of age (469)) and a genetic disposition or family history. Individuals with greater than 50 
moles or with dysplastic (abnormal appearing) naevi are also at increased risk as they may be 
a sign of familial conditions such as atypical mole syndrome or familial atypical multiple mole-
melanoma syndrome. Melanoma is more likely to develop on the trunk or limbs, although 
subtypes include mucosal and uveal melanoma.  
Until recently, the mainstay of treatment was dacarbazine chemotherapy but the emergence 
of novel therapies have altered this paradigm. For the management of melanoma with a 
mutation of the BRAF gene, vemurafenib can increase OS from 9.7 to 13.6 months compared 
to dacarbazine (470). More recently, use of the anti- CTLA-4 antibody ipilimumab and anti- 
PD-1/PD-L1 receptor antibodies (immune checkpoint inhibitors) - used either alone or in 
combination - can increase OS by modulating the immune response (189,471–473).  
5.1.2 Pathology and Staging of Melanoma 
Melanoma arises from melanocytes, the pigmented cells between the epidermis and dermis. 
Pigmentation is due to the production of melanin by melanocytes. Initially melanoma spre ads 
outwards (the radial growth phase) and if detected and treated at this stage, outcomes can be 
excellent. However, once lesions enter a vertical growth phase (VGP) and begin to grow 
downwards into deeper layers of the dermis, the risk of metastatic spread increases, at which 
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point the disease can become essentially incurable (474). Suspicious lesions are subject to the 
‘ABCDE’ assessment: whether they are asymmetrical, with irregular borders, have colour 
change with a diameter over 6 mm or whether they evolve over time (increase in size, bleed, 
itch or form nodules). An excision biopsy of the lesion (with appropriate surgical margins) will 
then determine the diagnosis.  
The pathological subtypes of melanoma include (475): 
 Superficial spreading melanoma (SSM)  Lentigo maligna melanoma  
 Uveal melanoma  Nodular melanoma 
 Mucosal melanoma  Acral lentiginous melanoma 
 Desmoplastic melanoma  
 
As well as pathological classification, staging, especially of localised melanomas includes 
tumour depth (Breslow thickness), number of mitoses (as a measure of tumour proliferation), 
presence of TILs and the presence of ulceration. The extent of disease is determined using 
TNM staging classification (Table 5.1) (476). Measurement of serum LDH is also used in 
metastatic disease and has been shown to be prognostic, with patients having an elevated 
LDH at baseline having a shorter OS (477). Sentinel node biopsy is used to determine the 
presence of micrometastatic LN disease, whereas macrometastatic LN disease is detected 
clinically.  
The histological features of melanoma can significantly impact survival. Ten-year survival for 
T1 disease (less than 1 mm thickness) is 92 %, falling to 50 % for T4 disease (melanoma greater 
than 4 mm thick) (476). Similarly, the presence of ulceration in the primary tumour can reduce 
survival: ulcerated T4 disease (T4b) has a five-year survival of 53 %, whereas non-ulcerated 
disease of the same T stage (T4a) is 71 % (476). OS also diminishes with increasing age: for 
early stage disease (I and II) five-year survival for patients aged between 40 - 49 is over 80 %, 
reducing to 60 % in those over 80 years of age (467).  
  
 
 
152 
 
Table 5.1 TNM staging of melanoma (adapted from 7th AJCC) (476) 
Stage Tumour Thickness (mm) Ulceration/Mitosis 
I T1 ≤ 1 mm T1a Without ulceration and mitosis < 
1/mm2 
   T1b With ulceration or mitosis ≥ 1/mm2 
 T2 1.01 – 2 mm T2a Without ulceration 
II   T2b With ulceration 
 T3 2.01 – 4 mm T3a Without ulceration 
   T3b With ulceration 
 T4 > 4 mm T4a Without ulceration 
   T4b With ulceration 
 Nodes Metastatic Nodes Nodal Burden 
III N1 1 N1a Micrometastasis 
   N1b Macrometastasis 
 N2 2-3 N2a Micrometastasis 
   N2b Macrometastasis 
   N2c In transit metastasis 
 N3  ≥ 4 LN or/and in-transit 
metastases 
 
 Metastases Site Serum LDH 
IV M1a Distant skin, LN or lung  
 
 
Normal  
 M1b Any visceral  Normal 
 M1c  Any distant  Elevated 
 
5.1.3 Management of Localised Disease 
Surgical management is the cornerstone of treatment in localised disease. Surgical margins for 
melanomas with a Breslow thickness of up to 2 mm should be 1 cm (for stage I disease) and 2 
cm for lesions with a thickness of greater than 2 mm (stage II disease) (478,479). Sentinel LN 
biopsy (SNB) is considered for patients with lesions greater than 1 mm thick and, if positive, 
completion lymphadenectomy should be considered (479,480). The presence of ulceration in 
the primary tumour and higher Breslow thickness both confer a higher risk of posi tive SNB 
(481). LN dissection can also be considered for symptom control for patients with palpable 
disease.  
For inoperable local disease of the upper or lower limb, systemic therapy may be considered  
but local chemotherapy (usually melphalan) can be given by isolated limb perfusion (ILP). 
During this procedure, the blood supply to the affected limb is isolated and chemotherapy 
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given in higher doses than would be tolerated systemically. Isolated limb infusion is a similar 
but simpler process, where chemotherapy is administered through radiologically-placed 
catheters, rather than ILP where a perfusion machine (similar to a cardiopulmonary bypass 
machine) is required to keep the limb oxygenated. Using these techniques, CR or PR rates can 
approach 50 %. (reviewed in (482)).  
Adjuvant therapy for melanoma has been the major change over the last few years. In a phase 
III trial of adjuvant ipilimumab, given until PD, five-year recurrence-free survival (RFS) in the 
treatment group was significantly increased (40.8 % vs. 30.3 %) (483). However, serious 
toxicity (grade 3 or 4) was observed in 54.1 % patients and single agent ipilimumab is currently 
not approved for use by the NICE. In contrast, trials of single agent anti-PD-1 inhibitors have 
shown significant benefit without unacceptable toxicity. In patients with resected stage III 
disease, one year of adjuvant pembrolizumab resulted in an increased one year RFS, 
compared to placebo, (75.4 % vs. 61.0 %) (484). In patients with mutations in BRAF, treatment 
with one year of combined therapy following resection (dabrafenib and trametinib) not only 
increased RFS, but also OS (86% in the combination-therapy group vs. 77% in the placebo 
group; 95% CI 0.42 to 0.79; p=0.0006) (485). 
5.1.4 Management of Advanced Disease 
5.1.4.1 Chemotherapy 
Although currently not usually first-line therapy, due to the many other treatment options 
available, chemotherapy with dacarbazine (DTIC) or carboplatin was the mainstay of 
treatment for many years. A small randomised phase III trial (61 patients) did not demonstrate 
a significant improvement in OS when IFN-α was added to DTIC chemotherapy (486). In 
addition, despite trials of combination therapy, RRs rarely exceed 20 %. Trials of carboplatin 
chemotherapy have demonstrated similar disappointing results. In one phase II trial of 
carboplatin, the RR of patients with stage IV disease was 16 % (487) and in another the RR was 
only 11 % with a median OS of 4.7 months (488).  
Temozolomide (TMZ) is an oral analogue of DTIC which has shown some activity in melanoma 
in early phase trials. It has an advantage over DTIC as it can cross the blood brain barrier, so 
has been investigated in patients with melanoma brain metastases (489). In phase III trials, RR 
with TMZ alone was 13.4 % (490). When compared with standard-of-care DTIC, TMZ has been 
shown to be comparable in terms of OS (7.7 months vs. 6.4 months, respectively), although 
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this phase III trial did not include patients with central nervous system (CNS) metastases (491). 
In a retrospective study of patients receiving either DTIC or TMZ, the incidence of CNS disease 
was significantly lower in the TMZ group (492). 
5.1.4.2 Targeted Therapy 
5.1.4.2.1 BRAF Inhibition 
The use of targeted treatments has revolutionised the management of mutation-positive 
melanoma. The most common mutation in melanoma is in BRAF, a RAF kinase, which is found 
in approximately 40 % of patients with melanoma. Mutations in BRAF lead to continuous 
activation of the MAPK pathway (493). In the absence of mutations in the pathway, such as 
BRAF, the MAPK pathway is usually activated by cell surface receptors (receptor tyrosine 
kinases, RTKs), such as the EFGR. Mutations in BRAF lead to a nucleotide variation at position 
600 of the kinase. The most common of these (up to 80 %) is V600E, where valine i s 
exchanged for glutamic acid, although other mutations include V600K (lysine in place of 
valine). 
The BRAF inhibitors (BRAFi) include vemurafenib and dabrafenib and can confer dramatic 
benefits to patients with BRAF-mutated melanoma in terms of disease control and OS (494). 
In the BRIM-3 trial of vemurafenib vs. DTIC, there was a significant increase in OS (13·6 
months vs. 9·7 months, respectively) with over 50 % of patients treated with BRAFi having an 
objective disease response (470). Similarly, in another phase III trial comparing DTIC to 
dabrafenib, OS was prolonged in the BRAFi group (15.6 months vs. 18.2 months, respectively) 
(495,496). The most common toxicities of BRAFi include pyrexia, arthralgia, diarrhoea and 
prolonged QT interval on electrocardiogram (470). In a class-effect manner (due to their 
method of action) possible side-effects also include the development of skin lesions such as 
squamous cell carcinoma (SCC) (497). This is due to the effect of BRAFi on WT non-
melanomatous cells: blocking BRAF in this situation may reveal other mutations in the MAPK 
pathway which then drive the development of SCC (498). Despite the good responses 
demonstrated by patients on BRAFi, resistance to therapy will develop in most cases, usually 
due to the development of secondary mutations in the MAPK pathway or by signalling 
through alternative mechanisms, such as the PI3K/AKT pathway or upregulation of other cell -
surface RTKs (499,500). 
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5.1.4.2.2 MEK Inhibition 
MAPK/ERK kinases (mitogen-activated protein kinase kinase; MEK) are further downstream 
from BRAF in the MAPK pathway. Combination therapy with a MEK inhibitor (MEKi) and a 
BRAFi is one way of avoiding resistance to BRAFis: by blocking the MAPK pathway in two 
different ways and, by the same mechanism, decreasing the incidence of BRAFi-associated 
skin lesions such as SCC (501,502). Single agent MEKi has some efficacy in patients with 
mutations in BRAF: in comparison with DTIC, MEKi with trametinib improved PFS from 1.5 to 
4.8 months and 6 month OS from 67 % to 81 % in patients with metastatic melanoma (503). 
Clinical trials of combination therapy with BRAF/MEKi have shown significantly increased OS 
and PFS compared to single agent BRAFi (502,504–506). In these studies RRs for combination 
therapy were over 60 % (502,504,506). 
5.1.4.3 Immunotherapy 
The immune system has been shown to play an important part in the pathogenesis of 
melanoma, with tumours displaying a large proportion of somatic mutations (507) which have 
the potential to act as neoantigens to prime an anti-tumour response. This is illustrated by 
case reports of spontaneous melanoma regression (508,509) but this phenomenon is halted in 
most patients by the activity of immune checkpoints such as anti-CTLA-4 and anti-PD-1. The 
presence of PD-1 expression on TILs correlates with decreased OS and increased Breslow 
thickness (201). There are a number of melanoma TAAs which have been identified, including 
MART-1 and glycoprotein 100 (gp100) (471) which are prevalent in melanoma tumours (510). 
As such, they have the potential to be targeted by antigen-specific T cells, if this population 
can be harnessed therapeutically. Melanoma TILs have been correlated with outcome and the 
presence of positive sentinel node biopsy (481,511). Similarly, antigen-specific T cells are 
found in the peripheral blood of over half of patients with melanoma (512). Being a 
particularly immunogenic tumour, melanoma was one of the first conditions in which 
immunotherapy was thoroughly investigated and brought into clinical use. As well as the 
earlier use of IFN, the field has expanded to include immune checkpoint blockade and novel 
immune therapy such as OVs.  
5.1.4.3.1 Checkpoint inhibitors 
The principle of immunotherapy in melanoma must be that, although any previous immune 
response has not been effective in clearing the tumour, the potential for an anti-tumour 
immune response can be exploited by checkpoint inhibition. Anti-CTLA-4 antibodies, such as 
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ipilimumab and tremelimumab, block the interaction between the inhibitory molecule CTLA-4 
on T cells and CD80/86 on APCs and hence block the downregulation of T cell activation and 
initiate immune-mediated anti-tumour responses.  
A phase III trial demonstrated a significant increase in OS from 6.4 months to 10 months when 
patients were given ipilimumab compared to gp100 (471). Survival at two years was 23.5 %, 
compared to 13.7 % (471). This finding suggests that immunotherapy could potentially lead to 
long-term disease control, even in a small number of patients. Indeed, long-term follow up of 
177 patients treated in multiple clinical trials with ipilimumab showed that the patients who 
had CRs demonstrated ongoing disease control for up to 99 months (ongoing at the time the 
study was published) (513).  
Similarly, the anti-PD-1 antibodies, including nivolumab and pembrolizumab, prevent 
inhibition of T cell activation at the site of the tumour (and elsewhere) and can enhance anti-
tumour T cell responses. Indeed, the expression of PD-L1 on melanoma tumour cells is 
associated with increased Breslow tumour thickness and poorer OS (201). When nivolumab 
was given first-line as a single agent to BRAF-WT patients with metastatic melanoma, there 
was an increase in one year OS compared to DTIC chemotherapy (72.9 % vs. 42.1 %, 
respectively) with an objective RR of 40 % (473). Overall survival in the anti-PD-1 treatment 
group was not reached. Similar findings were observed in a cohort of heavily pre -treated 
patients receiving nivolumab: one year OS was 62 % with a median OS of 16.8 months (472).  
Toxicities of the checkpoint inhibitors are class-driven and usually autoimmune in origin. 
Diarrhoea, nausea, fatigue and rashes are common with both anti-CTLA-4 and anti-PD-1 
antibodies. The concerning toxicities include immune-mediated hepatitis, colitis, pneumonitis 
and hypophysitis leading to symptoms of adrenal insufficiency. Treatment is supportive, with 
the use of high-dose steroids or immunosuppression with agents such as the anti-TNF-α drug 
infliximab (514). In a phase III trial of pembrolizumab vs. ipilimumab (both given 3 weekly), the 
incidence of colitis of grade 3 or greater was reported to be 2.5 % vs. 7 %, respectively (515). 
The frequency of hypophysitis was 0.4 % vs. 1.6 %. Pembrolizumab appears to have a higher 
incidence of hepatitis and pneumonitis (any grade) (515). Consequently, aside from these 
effects, the PD-1 inhibitors seem to be better tolerated. Whether pembrolizumab was given 
every two or three weeks, RRs were similar (approximately 33 %) compared to 11.9 % for 
patients treated with ipilimumab. Survival at one year for 3 weekly treatment was 68.4% in 
patients given pembrolizumab and 58.2% for those treated with ipilimumab (515). Due to this 
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and other studies, anti-PD-1 therapy is generally considered first-line prior to anti-CTLA-4 
agents in BRAF-WT patients.  
Combination therapy with anti-PD-1 and anti-CTLA-4 is only considered in patients with a 
good performance status, due to the increased risk of toxicity. Combination therapy with 
nivolumab and ipilimumab had a 7.7 % risk of severe colitis (compared with 0.6 % for 
nivolumab) and a 55 % incidence of any treatment-related severe adverse event (AE), 
compared to 16.3 % for nivolumab and 27.3 % for ipilimumab alone) (516). Despite this, PFS 
was 11.5 months in the combination treatment group, compared to 2.9 months for 
ipilimumab alone (516).  
5.1.4.3.2 Oncolytic viruses 
OVs infect, replicate in and are cytotoxic to malignant cells. They were initially thought to 
exert their effect primarily through this mechanism of direct oncolysis but through further 
study it has become clear that they can generate an immunogenic anti -tumour response, 
which in some cases is the more potent effect (section 1.5.4).  
T-VEC is a genetically modified HSV encoding the immunomodulatory cytokine GM-CSF. In the 
phase I trial, T-VEC was given i.t. to patients with a range of solid tumours including 
melanoma, breast and gastrointestinal cancers (517). The main toxicities were local 
inflammation, erythema and flu-like symptoms or fever. There was some evidence of clinical 
response, including in melanoma patients and, interestingly, in both injected and uninjected 
lesions (517). The subsequent phase III trial of T-VEC vs. GM-CSF alone confirmed that T-VEC 
has efficacy in metastatic malignant melanoma. These results demonstrated that not only  did 
T-VEC increase disease RRs (26.4 % vs. 5.7 %) but that this translated into improved median 
OS (23.3 months for T-VEC vs. 18.9 months for GM-CSF) (518,519). This further supports the 
concept of OVs having a systemic, rather than simply localised, anti-tumour effect. As such, T-
VEC was the first OV to be recommend by NICE for the management of unresectable disease 
in metastatic melanoma (479). To further exploit the anti-tumour effects of T-VEC 
combination studies with checkpoint inhibition are currently ongoing with encouraging 
preliminary results (520–522). 
5.1.4.3.3 Monitoring response in immunotherapy 
Radiological responses to treatment, especially in the context of clinical trials are usually 
reported according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria. Due 
to the potential for increased tumour burden as a result of immune infiltration 
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(pseudoprogression), rather than true PD, the use of RECIST criteria in trials of 
immunotherapy can have obvious pitfalls. In patients treated with ipilimumab, for example, 
PD at 12 weeks can then lead to shrinkage of measurable lesions and become either PRs or 
even CRs over the following number of months (523). This has led to the development of 
immune-related response criteria (irRC) or immune-RECIST which aim to more accurately 
evaluate responses in patients receiving immunotherapy and prevent early cessation of 
treatment (524). In clinical trials of patients receiving pembrolizumab, 7 % demonstrated 
some type of atypical response, including pseudoprogression and 14 % had PD on classical 
RECIST criteria vs. irRC (525). Patients with seemingly PD by RECIST (but not by irRC) had an 
increased two year OS compared to patients who had PD by both criteria (37.5 % vs. 17.3 %, 
respectively), showing that pseudoprogression does not translate to attenuated responses 
from immunotherapy (525). Amongst other recommendations in these modified response 
criteria, seemingly PD should be re-evaluated on repeated imaging to account for 
pseudoprogression (in the absence of obvious clinical deterioration). In these situations, 
clinical assessment of response is important in clinical decision making.  
5.1.5 Immune Response in Melanoma 
5.1.5.1 Innate Immunity 
When NK cells from HDs are cultured with melanoma cell lines, the expression of activating 
receptors (including NKp30, NKp44 and NKG2D) is diminished, suggesting one method by 
which tumour cells, even with down-regulated MHC-I, can avoid NK cell mediated cytotoxicity 
(18). NK cells exposed to melanoma cells also have diminished cytotoxic potential against 
target tumour cells in a manner dependent on IDO (an immunosuppressive enzyme produced 
by some melanoma cell lines) (18). Interestingly, melanoma cells taken from different 
anatomical sites within the same patient have variable expression of NK-cell ligands and thus 
have different susceptibility to NK-mediated killing (526). Malignant cells from LNs were 
shown to express greater levels of ligands for NKp44 and NKp46 than skin metastases from 
the same patient (526). In in vivo models, mice injected with melanoma cells derived from skin 
had a shorter survival than those receiving cells derived from nodal metastases, in the 
presence of small numbers of NK cells (526). When the mice also received large numbers of 
NK cells, all tumours were controlled and survival was prolonged, underlying the role of NK 
cells in immune-surveillance and the importance of NK ligand expression in the TME.  
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Although NK cells exhibit high levels of cytotoxicity ex vivo, the efficacy of this potential can 
change at E:T ratios more in keeping with that seen in the TME. Indeed, when NK cells are 
cultured with melanoma cell lines at such ratios, the decrease in target tumour cell viability 
was seen to slow and cease after two days (527). This phenomenon was due to upregulation 
of MHC-I molecules on melanoma cells, mediated by NK cell production of IFN-γ, which, in 
turn, inhibited NK cell function (by engaging with inhibitory cell surface receptors). This 
illustrates that, while NK activity may be enough to contain smaller tumours, once the tumour 
burden increases, NK-mediated cytotoxicity is diminished through a number of mechanisms, 
leading to tumour escape (527). As well as lower frequencies of activating receptors, NK cells 
in patients with melanoma express higher levels of inhibitory receptors than HDs (25). For 
example, higher levels of TIM-3, which gradually increased on the population of peripheral NK 
cells with stage of disease, is associated with poor prognostic factors such as ulceration of the 
primary tumour and Breslow thickness > 1mm (25). Although these cells are functionally 
impaired and displayed this exhausted phenotype, TIM-3 antibody blockade increased NK 
cytotoxicity against melanoma cell lines and IFN-γ production (25). Interestingly the BRAFi 
vemurafenib has been shown to modify the immunogenicity of NK cells by increasing 
expression of the ligand for NKp30 but also increasing inhibitory NK cell receptor ligands such 
as MHC-I and decreasing other activating ligands for NKG2D (528). Treatment of melanoma 
cells with vemurafenib also diminishes NK cell degranulation and IFN-γ expression in vitro 
(528), although there is conflicting data around this (529). This data should not be taken in 
isolation, however, given the direct cytotoxic effect of BRAFi on mutated melanoma cells and 
the influence they have over the cytokine profile. As such, the inhibitory effect of MEKi (by the 
modulation of NK activating receptors) can be attenuated by cytokines which would be found 
in the TME such as IL-15 and IL-18 (529).  
5.1.5.2 Adaptive Immunity 
Circulating melanoma antigen-specific CD8+ T cells have been detected in the peripheral 
blood of patients with stage III/IV melanoma; however, they were found to be functionally 
poor (530). Although a majority of cells were phenotypically consistent with memory T cells, 
they were unable to either express CD69 in response to stimulation, effectively lyse 
melanoma cell lines and/or produce IFN-γ and TNF-α (530). Other studies have seemingly 
confirmed this finding in patients with high levels of MART-1-specific CD8+ cells. While the 
presence of antigen-specific memory T cells was not associated with an increased survival, 
patients who had PD in the first two months of chemotherapy (DTIC or TMZ) had a higher 
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proportion of MART-1-positive T cells (531). This was thought, in part, to be attributable to 
both a high antigen load in later-stage disease and loss of HLA-A molecules on matched 
tumour cells, thus inhibiting effective antigen presentation and activation of a CTL response. 
Antigen-specific T cells in peripheral blood express PD-1 and target patient-specific 
neoantigens (532). Examination of the peripheral blood of patients with metastatic melanoma 
has revealed the presence of antigen-specific Tregs which express FoxP3 and secrete IL-10 on 
stimulation with antigen-peptides (such as NY-ESO-1) (533). These Tregs were also able to 
suppress T cell proliferation in vitro.  
It has been postulated that BRAF-mutated melanoma may be more immunogenic than BRAF-
WT; examination of PBMCs from BRAF-mutated melanoma patients has revealed populations 
of BRAF-mutant specific CD4+ and CD8+ T cells (534,535). Treatment with BRAFi could, 
therefore, stimulate a direct cytotoxic effect as well as an immunogenic one by increasing the 
proportion of antigen-positive T cells and diminishing the immunosuppressive influence on 
the background of an already ‘primed’ immune response (536,537). 
The effect of checkpoint inhibition on both the innate and adaptive immune response is 
discussed in detail in section 1.5.2.  
5.1.5.3 Tumour Infiltrates 
The prognostic implication of TILs is well documented in many cancers, i ncluding melanoma, 
where it is seen to be a surrogate marker of an anti-tumour immune response. The phenotype 
of these cells is also important in determining the balance between pro-tumour and an anti-
tumour TME (538). In melanoma, infiltration of TILs is subdivided into absent, non-brisk (local 
infiltration) or brisk (extensive infiltration throughout the VGP). Perhaps as expected, the 
absence of TILs in the primary melanoma have also been shown to predict for positive SNB: a 
brisk TIL infiltrate was associated with a 3.9 % chance of positive SNB, compared to 26.2 % for 
melanomas with absent TILs (481). Data on the prognostic value of TILs in melanoma is 
conflicting, with some studies showing a strong advantage with the presence of brisk TILs in 
VGP (5 year OS 77 % vs. 37 % for absent TILs) (511) and others showing no advantage (five 
year OS 86 % for presence of TILs vs. 90.1 % with absent TILs) (539). The phenotype of TILs is 
obviously important and so even melanomas with a brisk TIL infiltrate may have a poorer 
prognosis if the T cells are exhausted and anergic. As such, the presence of peritumoural T 
cells positive for the activation markers CD25 and OX40 is associated with decreased 
metastatic potential and increased OS (212). Similarly, while the presence of Fox P3+ Tregs in 
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the TME suppress the anti-tumour responses of CD4+ and CD8+ T cells (540), higher 
expression of TH1 cytokines (such as IL-2) in primary melanoma samples are associated with 
tumour regression (541).  
BRAFi can alter immune cell infiltration into melanoma: CD8+ TILs were seen to increase 
following treatment (536) and diminished again on PD (537). Greater infiltration of CTLs is also 
associated with elevated melanoma antigen presentation in tumour biopsies (536). This was 
also true for patients receiving dual BRAFi/MEKi. Interestingly, one patient from this study 
who developed PD on single agent BRAFi and had decreased CTLs on tumour biopsy at that 
time was commenced on dual therapy with the addition of a MEKi. Further tumour biopsy 
demonstrated an increase in CD8+ infiltrate and positive antigen staining (536). As expression 
of TIM-3 and PD-1 rise after BRAFi (presumably as a marker of exhaustion), there is a rationale 
for combined BRAF/checkpoint inhibitor therapy. Phase I/II trials of dual BRAFi/MEKi plus anti-
PD-1 antibody (NCT02130466) or anti-PD-L1 antibody (NCT02027961, NCT01656642) are 
ongoing.  
In a cohort of patients receiving treatment with the anti-PD-1 antibody nivolumab (the 
majority being patients with melanoma), evaluation of archival tissue revealed that PD-L1 
expression on tumour cells was associated with an enhanced tumour immune cell infiltrate 
and increased expression of both PD-1 and PD-L1 on immune cells (325). This correlated with 
both clinical benefit (disease response/stability for > 6 months) and objective response by 
RECIST (325).  
5.1.5.4 Cytokine Production 
The cytokine profile of the TME and the immune response can influence the pathophysiology 
of melanoma and its response to therapy. Cultured melanoma cell lines express low levels of 
IFN-γ, IL-2 and TNF-α but higher levels of IL-8, IL-6 and TGF-β (446). Although normal 
melanocytes can produce low levels of TGF-β, levels of the isoforms TGF-β2 and TGF-β3 
increase in progression from melanocytes to in situ melanomas and finally, to metastatic 
melanoma (542). These findings suggest a possible role for TGF-β in the metastatic potential 
of melanoma, presumably contributing to the suppression of an anti -tumour response. 
Similarly, expression of IL-10 by melanocytes/melanoma cells has been observed to correlate 
to tumour stage (543). Interestingly, increased levels of IL-10 corresponded to a shift between 
the radial and vertical growth phases in melanoma tissue samples (543).  
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Higher serum levels of MCP-1 are associated with a lower RECIST response to treatment with 
BRAFi (161). Once again, as a chemokine for macrophages, this may represent an increase in 
M2 TAMs, which are associated with poorer prognosis (section 1.2.6).  
IL-8 is a potent chemokine for granulocytes (particularly neutrophils) and thus contributes to 
the phagocytosis of pathogens. It is also pro-angiogenic and has been implicated in tumour 
development (544). Transfection of melanoma cells with IL-8 promoted both tumourigenic 
and metastatic potential by upregulating MMP-2 in in vivo models (545). As well as IL-8, levels 
of other angiogenic cytokines, such as VEGF, are noted to be elevated in patients with 
melanoma (546). Higher serum levels of both IL-8 and VEGF are associated with poor 
prognosis and lower PFS (546). Treatment of melanoma cell lines with a MEKi in vitro led to a 
reduction in levels of both IL-8 and VEGF (547). Similarly, in patients treated with BRAFi, IL-8 
decreased significantly over the course of therapy, which, in turn, correlated with a rise in 
CD8+ CTLs in paired tumour biopsies (161). Surprisingly, a larger decline in serum levels of IL-8 
corresponded to a reduction in OS (161). Higher baseline IL-8 levels were associated with 
enhanced tumour burden, potentially identifying a group of patients with a poorer prognosis 
compared to the group with lower baseline IL-8 levels. Although treatment with BRAFi/MEKi 
can potentially initiate anti-tumour responses through the release of TAAs, these data suggest 
that they can also manipulate the TME and systemic immune response in other ways. 
Similarly, a decrease in IL-8 with anti-PD-1 antibody therapy correlates with disease response 
and an early fall in IL-8 (within the first few weeks of therapy) with improved OS (548). 
Interestingly, in the three non-melanoma patients in this study who exhibited 
pseudoprogression on imaging, IL-8 levels remained low (548), suggesting the potential for IL-
8 as a biomarker for checkpoint inhibitor therapy.  
5.1.6 Rationale for Current Study 
The current study aims to further delineate the immune response in patients receiving 
immune checkpoint inhibitors for treatment of metastatic melanoma. We aimed to 
investigate the response of patients receiving first-line treatment, as previous data from early 
phase trials likely included heavily pre-treated patients, in whom immune responses may be 
skewed due to the advanced nature of the disease and previous lines of treatment.  
Peripheral blood from patients receiving first-line checkpoint inhibitors for metastatic 
melanoma (ipilimumab or pembrolizumab) was analysed to determine the immune response 
to these therapies, specifically: 
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1. Further validation of the panel of immune assays, showing that the protocols we have 
developed are robust in different cohorts of patients.  
2. Immune cell activation potential using a novel immunophenotyping panel, NK 
degranulation and 51Cr-release assays and analysis of the adaptive immune response 
through the assessment of IFN-γ production to specific melanoma TAAs and viral 
peptides in ELISpot assays. 
3. Analysis of patterns of cytokine production using Luminex assays. 
4. Comparison of the changes in immune response between patients receiving the anti-
CTLA-4 antibody ipilimumab and the anti-PD-1 antibody pembrolizumab. 
5. Identification of patterns in the immune response between patients with melanoma 
receiving immunotherapy and patients with CRC receiving chemotherapy. 
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5.2 Melanoma Results 
5.2.1 Patient Recruitment and Demographics 
Seven patients due to receive standard-of-care ipilimumab were consented for blood sample 
collection between April 2015 and March 2016. A dose of 3mg/kg was administered every 
three weeks until progression or unacceptable toxicity, for a maximum of four cycles (12 
weeks). Sequential blood samples at baseline, 6 weeks and 12 weeks were collected and 
analysed from three patients (43 %) (Figure 5.1). A further three patients had only baseline 
samples collected. One patient had two samples collected. Where samples were not collected, 
this was usually due to clinical deterioration, patients not returning to clinic or declining blood 
sampling. Only patients who had multiple samples taken (including a baseline sample) were 
included in the analysis of change in immune function over time. 
 
Figure 5.1 Recruitment of patients prior to ipilimumab therapy 
 
During the period of the study, treatment with pembrolizumab became the standard-of-care 
for first line treatment of melanoma as an alternative to BRAFi. Seventeen patients due to 
receive pembrolizumab were consented for blood sample collection between December 2015 
and April 2017. Treatment was administered every three weeks at a dose of 2mg/kg until 
disease progression or toxicity. One patient was subsequently discovered to have an 
additional diagnosis of B cell chronic lymphocytic leukaemia (CLL) and so was excluded from 
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the analysis. Single baseline samples were received from two patients and one patient only 
had samples taken at baseline and 12 weeks. Four patients had samples taken at baseline and 
6 weeks only. A total of nine patients (53 %) had all three planned samples collected 
(Figure 5.2). Once again, where samples were not collected, this was due to clinical 
deterioration or death.  
 
Figure 5.2 Recruitment of patients prior to pembrolizumab therapy 
 
As previously, only patients who had multiple samples taken (including a baseline sample) 
were included in the analysis of change in immune function over time. Sample collection for 
all patients is shown in Appendix Tables 8.7 and 8.8. Patient demographics for those being 
treated with ipilimumab are shown in Table 5.2 (n=3). Patient demographics for those being 
treated with pembrolizumab are shown in Table 5.3 (n=16).   
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Table 5.2 Patient demographics for those receiving treatment with ipilimumab. 
Patient Demographics (n/%) 
Sex Mean Age ECOG Performance Status at Baseline 
Male 3 (100 %) Male 70.3 years 0 1 (33 %) 
Female 0 Female 0 1-2 2 (67 %) 
  Both 70.3 years 3-4 0 
Primary Tumour Site Previous Therapy 
Upper limb 1 (33 %) IFN 1 
Lower limb 1 (33 %) BRAFi 0 
Torso 0 MEKi 1 
Head/Neck 1 (33 %) Temozolomide 0 
Unknown primary 0 Ipilimumab 0 
  No previous therapy 1 
Histology of Primary Tumour Number of Metastatic Sites Mutational Status Breslow Thickness of Primary Tumour 
SSM 1 (33 %) 1 2 (67 %) BRAF 0 ≤ 1 mm 0 
Nodular 0 2 0 NRAS 1 (33 %) 1.01 – 2 mm 1 (50 %) 
Ocular 0 ≥3 1 (33 %) No mutation 2 (67 %) 2.01 – 4 mm 0 
Unknown 2 (67 %)     > 4 mm 1 (50 %) 
1
66 
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Table 5.3 Patient demographics for those receiving treatment with pembrolizumab. 
Patient Demographics (n/%) 
Sex Mean Age ECOG Performance Status at Baseline 
Male 13 (81 %) Male 58.2 years 0 5 (31 %) 
Female 3 (19 %) Female 56.3 years 1-2 11 (69 %) 
  Both 57.9 years 3-4 0 
Primary Tumour Site Previous Therapy 
Upper limb 2 (12.5 %) IFN 0 
Lower limb 6 (37.5 %) BRAFi 4 
Torso 3 (19 %) MEKi 0 
Head/Neck 1 (6 %) Temozolomide 1 
Unknown primary 4 (25 %) Ipilimumab 1 
  No previous therapy 11 
Histology of Primary Tumour Number of Metastatic Sites Mutational Status Breslow Thickness of Primary Tumour 
SSM 6 (37.5 %) 1 4 (25 %) BRAF 6 (37.5 %) ≤ 1 mm 2 (18 %) 
Nodular 5 (31.5 %) 2 8 (50 %) NRAS 4 (25 %) 1.01 – 2 mm 3 (28 %) 
Ocular 1 (6 %) ≥3 4 (25 %) No mutation 6 (37.5 %) 2.01 – 4 mm 2 (18 %) 
Unknown 4 (25 %)     > 4 mm 4 (36 %) 
1
67 
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Peripheral blood subsets and clinical markers are shown in Table 5.4. 
Table 5.4 Patient peripheral blood parameters prior to therapy 
Patient Demographics (n/%) 
 Ipilimumab (n=3) Pembrolizumab (n=16) 
Baseline Platelet Count 
≥ULN 1 (33 %) 1 (6 %) 
<ULN 2 (67 %) 15 (94 %) 
Baseline Neutrophil Count 
≥ULN 1 (33 %) 2 (12.5 %) 
<ULN 2 (67 %) 14 (87.5 %) 
Baseline Lymphocyte Count 
≤LLN 0 2 (12.5 %) 
>LLN 3 (100 %) 14 (87.5 %) 
Serum LDH 
≥ ULN 1 (33 %) 10 (62.5 %) 
< ULN 2 (67 %) 6 (37.5 %) 
 
5.2.1.1 Survival outcomes 
Patients were stratified to determine if any survival advantage was apparent.  No patients 
were lost to follow-up for survival data. Data was censored on 4th September 2017. Median OS 
for the whole group (those treated with ipilimumab and those treated with pembrolizumab) 
was 202.5 days. There was no survival difference seen with either Breslow thickness at 
baseline or BRAF mutational status (data not shown). There was increased survival in patients 
with an LDH level of less than the ULN but likely due to the small number of patients, this did 
not meet statistical significance (Figure 5.3). This had been shown in other analyses of 
patients with melanoma (477,549). 
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Figure 5.3 Overall survival of melanoma patients stratified by baseline LDH levels  
All patients were grouped according to peripheral blood LDH prior to starting checkpoint 
inhibitor (n=19, 16 patients prior to starting pembrolizumab and 3 prior to starting 
ipilimumab).  
5.2.2 Evaluation of Patient Immune Responses During Therapy with Immune 
Checkpoint Inhibitors: Immunophenotyping 
5.2.2.1 Immune cell activation status was altered following pembrolizumab 
treatment 
PBMCs collected from patients being treated with checkpoint inhibitors were 
immunophenotyped using Duraclone tubes to evaluate the effect of ipilimumab or 
pembrolizumab on the immune system. Specific cell populations were analysed for expression  
of both markers of cellular activation and checkpoint receptor molecules. In the 
pembrolizumab-treated group CD69 remained unchanged by treatment on CD4+ and CD8+ T 
cells and B cells (Figure 5.4a-c). However, CD69 expression on the NK and γδT cell populations 
was more pronounced at baseline and declined over time; the decrease was significant 
between baseline and 6 weeks (p=0.0461 and p=0.0398, respectively) (Figure 5.4d, e). 
Furthermore, CD69 expression on γδT cells continued to fall up to 12 weeks (p=0.0078) 
(Figure 5.4e). In contrast, there was no appreciable difference in other activation markers, 
such as HLA-DR and CD86 (monocytes and B cells), CCR7 (NK/NKT cells, γδT cells, CD4+ and 
CD8+ T cells) and CD25 (CD4+ and CD8+ T cells) Appendix Table 8.9. 
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Figure 5.4 CD69 expression on immune cell sub-populations over the course of treatment 
with pembrolizumab  
Cryopreserved PBMCs were immunophenotyped and CD69 expression on immune cell sub-
populations determined by flow cytometry. The percentage expression of CD69 over the 
course of immunotherapy with pembrolizumab is shown on: CD4+ T cells (a), CD8+ T cells 
(b), B cells (c), NK cells (d) and γδT cells (e) (n=13 for B cells, all other graphs show n=14).  
 
In the ipilimumab treated group (n=3), overall, there was no significant difference over the 
course of treatment for any of the markers investigated on any cell populations. This included 
CD69 on CD4+ and CD8+ T cells, NK cells and B cells (data not shown). Additionally, after 
resting overnight, the monocyte population in these three patients was too small to gain any 
meaningful data. 
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5.2.2.2 Checkpoint inhibitors are efficient at blocking target molecules 
Following treatment, immune cells were also analysed for changes in expression of relevant 
immune checkpoint receptors and their respective ligands. As expected, due to binding of 
pembrolizumab to its receptor PD-1, expression fell over the course of treatment (Figure 5.5).  
In patients treated with pembrolizumab, PD-1 expression on CD4+ and CD8+ T cells was 
reduced at both 6 and 12 weeks (CD4+ cells p=0.0002 and p=0.0488, respectively; CD8+ cells 
p=0.0015 and p=0.0117) (Figure 5.5a and b). This was also observed on γδT cells between 
baseline and 6 weeks (p=0.0410) (Figure 5.5c). Treg PD-1 expression was also attenuated over 
the course of treatment (p=0.0215 at 6 weeks and p=0.0098 at 12 weeks) (Figure 5.5d). There 
was no change demonstrated in PD-1 expression on NK cells, NKT cells, B cells or monocytes. 
Similarly, there was no significant change in the proportion of immune cells expressing PD-L1 
over the 12 weeks of treatment. No significant changes were seen in any other cell population 
Appendix Table 8.9. 
  
  
Figure 5.5 PD-1 expression on immune cell sub-populations over the course of treatment 
with pembrolizumab 
Cryopreserved PBMCs were immunophenotyped and PD-1 expression on immune cell sub-
populations determined by flow cytometry. The percentage expression of PD-1 over the 
course of immunotherapy with pembrolizumab is shown on: CD4+ T cells (a), CD8+ T cells 
(b), γδT cells (c) and Tregs (d) (all n=14).  
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In the patients treated with ipilimumab, expression of CTLA-4 on CD4+, CD8+ T cells and NK 
cells also fell over the course of treatment (due to binding of CTLA-4 by ipilimumab). Whereas 
the reduction in PD-1 expression with pembrolizumab treatment was significant, this was not 
the case for CTLA-4 expression with ipilimumab (Figure 5.6) 
  
 
 
Figure 5.6 CTLA-4 expression on immune cell sub-populations over the course of 
treatment with ipilimumab 
Cryopreserved PBMCs were immunophenotyped and CTLA-4 expression on immune cell 
sub-populations determined by flow cytometry. The percentage expression of CTLA-4 over 
the course of immunotherapy with ipilimumab is shown on: CD4+ T cells (a), CD8+ T cells 
(b) and NK cells (c) (all n=3).  
 
 
Finally, when looking at both patient groups, there was no appreciable difference in the 
expression of CTLA-4 on immune cell subsets from patients treated with pembrolizumab. The 
same was true for PD-1 expression in those treated with ipilimumab (data not shown).  
 
 
(c) CTLA-4/NK cells 
(a) (b) CTLA-4/CD4 T cells CTLA-4/CD8 T cells 
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5.2.2.3 Expression of PD-1 on immune cell populations at baseline correlates with 
overall survival 
Overall survival was calculated for all melanoma patients prior to receiving treatment with a 
checkpoint inhibitor (pembrolizumab or ipilimumab). Patients were stratified according to 
baseline PD-1 expression on immune cells and whether this was less than or greater than the 
median levels within the treatment group (Figure 5.7). Greater PD-1 expression on both CD8+ 
T cells ( Figure 5.7a) and B cells (Figure 5.7b) correlated with significantly decreased OS (222 
days vs. median OS not met, p=0.0476, HR 4.19, 95 % CI 1.128 to 15.56 and 174 days vs. 
median OS not met, p=0.0482, HR 4.213, 95 % CI 1.134 to 15.65, respectively). There was no 
relationship between PD-1 expression on CD4+ T cells and OS (data not shown). Conversely, 
PD-1 expression on Tregs conferred an increased OS but this did not reach statistical 
significance (Figure 5.7c).  
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Figure 5.7 Overall survival of all melanoma patients who received an immune checkpoint 
inhibitor, stratified according to baseline PD-1 expression 
Patients were stratified according to the median expression of PD-1 on immune cell 
populations prior to therapy. Survival was calculated as days from receiving the first dose of 
immunotherapy. All patients were evaluable in the survival analysis. This is shown for:  CD8+ 
T cells (a), B cells (b) and Tregs (c) (n=17: 14 patients prior to starting pembrolizumab and 3 
prior to starting ipilimumab).  
 
 
There was no relationship between OS and baseline PD-1 expression on any other immune 
cell populations. Similarly, CTLA-4 expression did not correlate with OS on any of the cell 
populations at baseline (data not shown).  
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5.2.2.4 Immune checkpoint inhibition does not affect Treg frequency, although L-
selectin expression is enhanced 
Treg frequency and other activation markers were analysed for their response to treatment. 
In patients treated with pembrolizumab, there was no significant change in the frequency of 
FoxP3+ Tregs over time, either as a definitive population nor as a proportion of CD4+ T cells 
(Figure 5.8a and b). However, the expression of CD62L on Tregs increased between baseline 
and 12 weeks (p=0.0254) (Figure 5.8c).  
  
 
 
Figure 5.8 Changes in Treg populations in patients over the course of treatment with 
pembrolizumab 
Cryopreserved cells were immunophenotyped for Tregs. The percentage of FoxP3+ Tregs 
(a) and the Treg:CD4 ratio (b) were determined by flow cytometry. The percentage 
expression of CD62L on Tregs was also calculated (c) (all n=14). 
 
 
In patients treated with ipilimumab, there was no change in the population frequency of Tregs 
nor expression of CD62L on Tregs (data not shown).  
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5.2.2.5 Immunophenotyping fresh PBMCs reflects the results of cryopreserved 
PBMCs 
During the latter stages of sample collection, it was possible to perform immunophenotyping 
on freshly isolated (non-cryopreserved) PBMCs from patients being treated with 
pembrolizumab. A total of seven pembrolizumab patients had samples collected and analysed 
as fresh PBMCs.  
As seen when immunophenotyping cryopreserved PBMCs (Figure 5.4), there was a trend 
towards a fall in CD69 expression on CD4+, CD8+ T cells, NKT cells and γδT cells, particularly 
over the first 6 weeks of pembrolizumab therapy (Figure 5.9). When evaluating NKT cells, this 
difference was significant (p=0.0469). There was no significant changes in CD69 expression on 
NK cells, monocytes or B cells (data not shown). 
  
  
Figure 5.9 CD69 expression on fresh immune cell sub-populations over the course of 
treatment with pembrolizumab 
Fresh PBMCs were immunophenotyped and CD69 expression on immune cell sub-
populations determined by flow cytometry. The percentage expression of CD69 over the 
course of immunotherapy with pembrolizumab is shown on: CD4+ T cells (a), CD8+ T cells 
(b), NKT cells (c) and γδT cells (d) (all n=7).  
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In addition to the decrease in CD69, interrogation of fresh blood revealed a significant 
reduction in CD25 expression on both CD4+ and CD8+ T cells between baseline and 6 weeks 
(p=0.0313 and p=0.0156, respectively) (Figure 5.10). Of note, this was not demonstrated in 
cryopreserved cells (Appendix Table 8.9). 
  
Figure 5.10 CD25 expression on fresh immune cell sub-populations over the course of 
treatment with pembrolizumab 
Fresh PBMCs were immunophenotyped and CD25 expression on immune cell sub-
populations determined by flow cytometry. The percentage expression of CD25 over the 
course of immunotherapy with pembrolizumab is shown on: CD4+ T cells (a) and CD8+ T 
cells (b) (n=7).  
 
 
As already demonstrated with cryopreserved PBMCs, treatment with pembrolizumab lowered 
levels of PD-1 on immune cell populations in fresh whole blood. This decrease was significant 
between baseline and 6 weeks on CD4+ T cells, CD8+ T cells, NKT cells, γδT cells and Tregs 
(p=0.0156, p=0.0156, p=0.0156, p=0.0313 and p=0.0156, respectively) (Figure 5.11). Between 
baseline and 12 weeks, there was a significant reduction in PD-1 expression on CD4+ T cells, 
CD8+ T cells, NKT cells and Tregs (all p=0.0313). Additionally, PD-1 expression on NKT cells fell 
significantly between 6 weeks and 12 weeks (p=0.0313). There was no significant change in 
PD-1 expression on NK cells, B cells or monocytes (data not shown).   
B
a
s
e
li
n
e
 
6
 w
e
e
k
s
1
2
 w
e
e
k
s
0
2 0
4 0
6 0
8 0
C D 4 /C D 2 5
%
 P
o
p
u
la
t
io
n
*
B
a
s
e
li
n
e
 
6
 w
e
e
k
s
1
2
 w
e
e
k
s
0
2 0
4 0
6 0
8 0
C D 8 /C D 2 5
%
 P
o
p
u
la
t
io
n
*
(a) (b) CD25/CD4 T cells CD25/CD8 T cells 
 
 
178 
 
  
  
 
 
Figure 5.11 PD-1 expression on fresh immune cell sub-populations over the course of 
treatment with pembrolizumab 
Fresh PBMCs were immunophenotyped and PD-1 expression on immune cell sub-
populations determined by flow cytometry. The percentage expression of PD-1 over the 
course of immunotherapy with pembrolizumab is shown on: CD4+ T cells (a), CD8+ T cells 
(b), NKT cells (c), γδT cells (d) and Tregs (e) (all n=7).  
 
 
As seen when immunophenotyping cryopreserved PBMCs, when fresh PBMCs were analysed, 
there was no significant change in the other activation markers investigated, including PD-L1, 
HLA-DR, CD86 and CD11c on monocytes and B cells and CCR7 on the immune cell populations 
described in Appendix Table 8.9 (data not shown).  
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Also reflecting the results from cryopreserved PBMCs, there was no change in the proportion 
of FoxP3+ Tregs over treatment. In contrast to the cryopreserved PBMCs, no change in CD62L 
positivity was observed in the fresh Treg population (data not shown).  
As shown in previous chapters, analysis of cryopreserved PBMCs is comparable to that of 
fresh immune cell populations. Although there may be some change in the magnitude of the 
positive populations, the pattern of expression between time points seem to be retained.  
 
5.2.3 Evaluation of Patient Immune Responses During Therapy with Immune 
Checkpoint Inhibitors: Cytokine/Chemokine Profile 
5.2.3.1 The cytokine/chemokine profile of patients receiving pembrolizumab 
changes during treatment 
Evaluation of plasma levels of cytokines and chemokines over the course of therapy with 
checkpoint inhibitors revealed a unique profile in patients receiving pembrolizumab. While 
there were increases in a number of pro-immune cytokines and immune cell chemokines, a 
fall in some TH2 cytokines was also demonstrated.  
A total of 48 chemokines and cytokines were evaluated by Luminex in patients receiving 
pembrolizumab. Of these, nine were below the lower detection limits of the assay (Appendix 
Table 8.10). Additionally, in this patient group, there were 29 chemokines and cytokines that 
did not demonstrate an appreciable or significant difference over the 12 week investigational 
period (Appendix Table 8.11). Three of the evaluable cytokines significantly decreased in 
concentration over the first 6 weeks of therapy: the TH1 cytokine IFN-γ and the TH2 cytokines 
IL-4 and IL-5 (p=0.0398, p=0.0381, p=0.0398, respectively) (Figure 5.12).  
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Figure 5.12 Change in IFN-γ, IL-4 and IL-5 levels over the course of treatment with 
pembrolizumab  
Cytokine analysis was performed using Luminex assays and the change in concentration 
(pg/ml) of IFN-γ (a), IL-4 (b) and IL-5 (c) were compared over time (all n=14).  
 
Seven cytokines were seen to elevate over the course of treatment with pembrolizumab. Over 
the first 6 weeks, there was a significant increase in levels of IL-16 (p=0.0327), IP-10 
(p=0.0081), MIG (p=0.0002), SCF (p=0.0498) and SCGF-β (p=0.0171) (Figure 5.13a-e). In 
addition, levels of IL-16 (p=0.0098), MIG (p=0.002), SCF (p=0.0195), IL-3 (p=0.0488) and IL-18 
(p=0.0273) also increased over the 12 weeks of treatment (Figure 5.13a, c, d, f, g).  
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Figure 5.13 Change in chemokine and cytokine levels over the course of treatment with 
pembrolizumab  
Cytokine analysis was performed using Luminex assays and the change in concentration 
(pg/ml) of IL-16 (a), IP-10 (b), MIG (c), SCF (d), SCGF-β (e), IL-3 (f) and IL-18 (g) were 
compared over time (all n=14). 
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5.2.3.2 The cytokine/chemokine profile of patients receiving ipilimumab has 
varying responses to treatment 
The same Luminex panels were used to analyse plasma from the three patients being treated 
with ipilimumab. There were 12 cytokines and chemokines that were not detected or that 
were below the standard curve for these samples (Appendix Table 8.12). Of the remaining 
solutes, none were seen to change significantly over the course of the 12 week treatment 
period. This is likely due to a combination of sample size (n=3) and patient number one 
seemingly being an outlier, when evaluating levels of cytokines such as IFN-γ, IL-4 and IL-5 
(Figure 5.14).  
 
 
 
 
Figure 5.14 Changes in plasma levels of IFN-γ, IL-4 and IL-5 over the course of treatment 
with ipilimumab 
Cytokine analysis was performed using Luminex assays and the change in concentration 
(pg/ml) of IFN-γ (a), IL-4 (b) and IL-5 (c) were compared over time (n=3). 
 
Although there were no significant differences in cytokine and chemokine levels with 
ipilimumab administration, there was a noticeable trend that reflected changes seen in the 
cohort of patients receiving pembrolizumab for some solutes. Of note, levels of IL-3, IL-18, 
MIG and SCF increased between baseline measurement and 12 weeks (Figure 5.15).  
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Figure 5.15 Change in chemokine and cytokine levels over the course of treatment with 
ipilimumab  
Cytokine analysis was performed using Luminex assays and the change in concentration 
(pg/ml) of IL-3 (a), IL-18 (b), MIG (c) and SCF (d) were compared over time (all n=3). 
 
5.2.4 Evaluation of Patient Immune Responses During Therapy with Immune 
Checkpoint Inhibitors: Innate Functional Activity 
5.2.4.1 NK cell function is not significantly altered over time in patients being 
treated with pembrolizumab.  
Although checkpoint inhibitors were initially used to target and moderate T cell activity, 
evidence shows that NK cells can be a potential target also. As such, the effect of checkpoint 
inhibition on NK cell activity was assessed in our patient cohort. NK cell function was 
measured by CD107 degranulation assays against tumour targets. There was a significant 
decrease in CD107 expression on NK cells against K562 tumour cells between baseline and 12 
weeks (p=0.0059) (Figure 5.16a). However, the change in percentage population was modest 
(median CD107 expression at baseline 23 %, at 12 weeks 16.5 %). NK cell degranulation 
B
a
s
e
li
n
e
 
6
 w
e
e
k
s
1
2
 w
e
e
k
s
1 0 0
1 5 0
2 0 0
2 5 0
IL -3
p
g
/m
l
B
a
s
e
li
n
e
 
6
 w
e
e
k
s
1
2
 w
e
e
k
s
0
2 0
4 0
6 0
IL -1 8
p
g
/m
l
B
a
s
e
li
n
e
 
6
 w
e
e
k
s
1
2
 w
e
e
k
s
0
5 0 0
1 0 0 0
1 5 0 0
M IG /C X C L 9
p
g
/m
l
B
a
s
e
li
n
e
 
6
 w
e
e
k
s
1
2
 w
e
e
k
s
0
2 0
4 0
6 0
8 0
S C F
p
g
/m
l
(c) MIG 
(b) IL-18 (a) IL-3 
(d) SCF 
 
 
184 
 
against melanoma target cells (Mel624 and Mel888) did not change significantly over the 12 
weeks of treatment with pembrolizumab (Figure 5.16b, c).  
  
 
 
Figure 5.16 Degranulation of patient NK cells against tumour targets over the course of  
treatment with pembrolizumab 
Cryopreserved PBMCs were used in degranulation assays to assess NK cell functional 
capacity against tumour targets. Percentage CD107 expression on NK cells over treatment, 
as determined by flow cytometry, is shown against: K562s (a), Mel624s (b) and Mel888s (c) 
(n=11). 
 
Chromium-release assays did not demonstrate a significant change over 12 weeks of 
pembrolizumab therapy (Figure 5.17). As seen in the degranulation assays, cytotoxic potential 
of PBMCs was lower against melanoma cells lines (Mel624 and Mel888) when compared to 
the K562 tumour cell line.  
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Figure 5.17 Cytotoxicity of patient NK cells against tumour targets over the course of  
treatment with pembrolizumab 
Cryopreserved PBMCs were used in 51Cr-release assays to assess NK cell functional capacity 
against 51Cr-labelled tumour targets. Cytotoxicity at an E:T ratio of 100:1 is shown over 
treatment is shown against: K562s (a), Mel624s (b) and Mel888s (c) (n=11).  
 
5.2.4.2 Innate immune function in patients treated with ipilimumab mostly reflects 
that of patients treated with pembrolizumab 
In patients receiving ipilimumab, the levels of both NK cell degranulation (Figure 5.18) and 
cytotoxicity of PBMCs (Figure 5.19) were considerably lower against Mel624 and Mel888 
target cells. Against K562 cells, both CD107 expression and PBMC-mediated cytotoxicity 
trended toward a decrease between baseline and 12 weeks but this was not significant 
(Figure 5.18a and Figure 5.19a). Once again, the small patient population (n=3) limited the 
statistical significance of these findings.  
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Figure 5.18 Degranulation of patient NK cells against tumour targets over the course of  
treatment with ipilimumab 
Cryopreserved PBMCs were used in degranulation assays to assess NK cell functional 
capacity against tumour targets. Percentage CD107 expression on NK cells over treatment, 
as determined by flow cytometry, is shown against: K562s (a), Mel624s (b) and Mel888s (c) 
(n=3). 
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Figure 5.19 Cytotoxicity of patient NK cells against tumour targets over the course of  
treatment with ipilimumab 
Cryopreserved PBMCs were used in 51Cr-release assays to assess NK cell functional capacity 
against 51Cr-labelled tumour targets. Cytotoxicity at an E:T ratio of 100:1 is shown over 
treatment is shown against: K562s (a), Mel624s (b) and Mel888s (c) (n=3). 
 
In a pooled analysis of patients who were about to start treatment with either ipilimumab and 
pembrolizumab, there was no appreciable OS benefit according to baseline NK cell activity, 
either by evaluating cytotoxicity or CD107 expression in response to target cells (data not 
shown). Once again, patient numbers were too small to evaluate OS in individual groups (only 
ipilimumab or only pembrolizumab groups).  
 
5.2.5 Evaluation of Patient Immune Responses During Therapy with Immune 
Checkpoint Inhibitors: Adaptive T cell Response 
ELISpot assays were performed to assess antigen-specific T cell responses of patients receiving 
checkpoint inhibitors over a 12 week investigational period. Cryopreserved PBMCs were 
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thawed and incubated with the MART-1 TAA or CEF viral peptide pool. T cell responses were 
measured by production of IFN-γ (SFU). 
5.2.5.1 T cell responses to viral peptides in patients treated with checkpoint 
inhibitors  
A viral peptide pool (CEF) was utilised to determine pan T cell antigen recall responses in these 
patients. As expected, the response of patients was highly variable. One patient had a uniform 
T cell response to CEF peptide over the ipilimumab treatment period (Figure 5.20a) and one 
patient had a similar magnitude of response at baseline and 6 weeks, with a slight decreased 
by the 12 week time point (Figure 5.20b). The third patient treated with ipilimumab had a very 
high response to CEF across all time points, that was too high to count (data not shown).  
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Figure 5.20 T cell responses to CEF viral peptide pool in patients treated with ipilimumab 
Cryopreserved PBMCs were collected from patients treated with ipilimumab and analysed 
by ELISpot. Images, in duplicate, show IFN-γ production in response to CEF peptide for two 
example patients, alongside quantification of SFU over the treatment period: Mel-Ipi-03 (a) 
and Mel-Ipi-04 (b) 
 
Again, as expected, there was also considerable inter-patient variability in the responses to 
viral peptides across patients receiving pembrolizumab therapy. There was no definitive 
pattern across time points, with some patients demonstrating a decrease in response to CEF 
(Figure 5.21a), an increase in response to CEF (Figure 5.21b) or no change during therapy 
(Figure 5.21c). 
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Figure 5.21 T cell responses to CEF viral peptide pool in patients treated with 
pembrolizumab 
Cryopreserved PBMCs were collected from patients treated with pembrolizumab and 
analysed by ELISpot. Images, in duplicate, show IFN-γ production in response to CEF peptide 
for three example patients over the treatment period: Mel-Pem-03 (a) and Mel-Pem-11 (b) 
and Mel-Pem-09 (c).  
5.2.5.2 T cell responses to TAAs in patients treated with checkpoint inhibitors  
MART-1 was used as a representative melanoma TAA to assess tumour-specific T cell 
responses in patients treated with immune checkpoint inhibitors. There was a much less-
pronounced response to MART peptide compared to CEF in all three ipilimumab-treated 
patients. In one patient there was no appreciable T cell response to MART at all (data not 
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191 
 
shown). In the remaining two patients, one had a response which increased during the course 
of ipilimumab therapy (Figure 5.22a) and one had a higher baseline response which 
diminished over the investigational period (Figure 5.22b). Only one patient treated with 
ipilimumab (Mel-Ipi-03) had evaluable responses to both CEF and MART peptides: no change 
over time to CEF but an increased T cell response to MART during treatment (Figure 5.20a and 
Figure 5.22a) 
 
 
 
  
 
 
Figure 5.22 T cell responses to MART-1 TAA in patients treated with ipilimumab 
Cryopreserved PBMCs were collected from patients treated with ipilimumab and analysed 
by ELISpot. Images, in duplicate, show IFN-γ production in response to MART-1 peptide for 
two example patients, alongside quantification of SFU over the treatment period: Mel-Ipi-
03 (a) and Mel-Ipi-07 (b). 
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As previously discussed, the adaptive T cell response of all patients receiving pembrolizumab 
varied greatly across the whole patient group. Correlation with CEF peptide responses also 
varied across the patient group. There were generally a greater number of T cell responses to 
CEF peptide than to MART-1, as would be anticipated. 
As observed with CRC patients on chemotherapy (section 4.2.5), there was some concordance 
between innate and adaptive immune assays within individual patients. As an example, in 
Mel-Pem patient 12, there was an apparent decrease in NK cell activity over the 12 weeks of 
pembrolizumab therapy, as shown by a fall in both cytolytic activity and NK cell degranulation 
against K562 target cells (Figure 5.23a and b). Reflecting this, T cell responses against CEF 
peptide also decreased (Figure 5.23c and d), as did CD69 expression on both CD4+ and CD8+ T 
cells (Figure 5.23e and f). Taken together, these data indicate that the entirety of a patient’s 
immune system (innate and adaptive), may respond in a similar way to disease and treatment 
strategies. 
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Figure 5.23 Comparison between adaptive T cell responses and innate responses during 
treatment: Patient Mel-Pem-12  
Cryopreserved PBMCs were collected from patient Mel-Pem-12 and analysed by ELISpot 
and other innate immune assays over the treatment period. IFN-γ production in response 
to CEF peptide was aligned with innate responses in the same samples. Cytotoxicity of 
PBMCs (determined by 51Cr assay) against K562 cells is shown in (a), CD107 expression 
(determined by flow cytometry) against K562s is shown in (b). T cell responses to CEF 
peptide (c) and number of SFU (d) are also shown. Finally, CD69 expression is shown on 
CD4+ T cells (e) and CD8+ T cells (f) as determined by flow cytometry.  
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5.2.6 Relationship between NLR and Immune Function in Patients Receiving 
Checkpoint Inhibitors 
Given our previous studies (Chapter 4) we sought to investigate any potential relationship 
between NLR and immune function in patients receiving immunotherapy. Although there 
were only a small number of patients within the pembrolizumab treatment group with a high 
baseline NLR (n=4), a further two patients in the ipilimumab group had a baseline NLR of 
greater than 5. As shown in Figure 5.24, when both treatment groups were pooled for 
analysis, there was an increase in OS in the low NLR group (median OS not met in the low NLR 
group vs. 129 days in the high NLR group, HR 0.257, 95 % CI 0.05454 to 1.212). This supported 
our findings in the CRC group, where OS was also diminished in those with a baseline NLR of 
greater than 5 (Figure 4.3). There was no appreciable difference in other functional immune 
assays between melanoma patients with a high or low NLR prior to treatment (data not 
shown).  
 
 
Figure 5.24 Overall survival for melanoma patients prior to checkpoint inhibitor therapy, 
stratified by NLR 
Patients receiving checkpoint inhibitors were stratified according to NLR prior to treatment. 
Survival was calculated as days from receiving the first dose of chemotherapy. All patients 
were evaluable in the survival analysis (n=19; 3 patients prior to ipilimumab and 16 
patients prior to pembrolizumab). 
 
Although there was a smaller number of melanoma patients being treated with 
immunotherapy, there are some signals of immune modulation within the group. This data 
can serve as a useful comparison to the CRC cohort of patients receiving chemotherapy and 
act as a discussion point for further investigation.   
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5.3 Melanoma Discussion 
This work aimed to further define the immune response in patients receiving treatment with 
checkpoint inhibitors for metastatic melanoma. Although the use of immune checkpoint 
inhibitors in melanoma has increased dramatically over the last few years, a limited number of 
studies have looked specifically at immune responses to therapy in vivo.  
Sequential samples were taken from patients receiving either ipilimumab or pembrolizumab 
every 6 weeks between baseline treatment and 12 weeks. Analysis of these samples, using 
our panel of validated immune assays, was able to provide insight into the different immune 
responses to anti-cancer therapy when compared to patients receiving traditional cytotoxic 
chemotherapy. After the project was commenced, pembrolizumab was approved for first-line 
use in patients with metastatic melanoma. As a consequence, treatment options changed in 
favour of pembrolizumab, limiting the number of patients in our ipilimumab group. This 
meant we could only collect a full set of samples from three patients. Subsequently, the focus 
shifted to collecting samples from patients being started on pembrolizumab.  
Although fewer patients were recruited to this study than CRC patients in the previous 
chapter, they represented a range of patients with metastatic disease, across a range of age 
groups with different initial histology and site of origin (where this could be determined). 
Although not significant, these data show that in this group of melanoma patients, a raised 
LDH at baseline conferred reduced survival: median OS was 222 days in patients with an LDH 
over the ULN. Median OS was not met in the patients with an LDH within the normal range 
(Figure 5.3). LDH is associated with prognosis and disease progression in a number of different 
patient groups and forms part of the AJCC staging criteria (476). As an enzyme involved in cell 
metabolism it participates in cell growth and tumour bulk. Supporting our data, in a group of 
97 patients with metastatic melanoma, those with elevated LDH levels had significantly 
poorer OS compared to those who did not (5 months vs. 16 months, p<0.0001) (550). Similar 
findings were shown in a larger cohort of 284 patients receiving treatment as part of early 
phase trials: in this dataset, lower LDH also corresponded to prolonged OS (11.8 vs. 5.8 
months, p=0.0001) (477). Further supporting these findings, in a study of 71 stage IV 
melanoma patients, LDH was found to be a highly specific marker of progressive disease in 
patients receiving systemic therapy (including chemotherapy, immunotherapy and 
radiotherapy) (551). The lack of statistical significance in our cohort likely reflects the smaller 
patient numbers in the study. Interestingly, further studies into the prognostic ability of LDH 
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have shown that even patients with a ‘high normal’ LDH can have poorer outcomes than 
those with a truly low LDH and that even increases in LDH which still fall within the ‘normal’ 
range can affect survival.  
In our patients, the activation status and potential to respond to immune stimuli was assessed 
using various validated assays, each of which examined different aspects of the immune 
system. Immunophenotyping was used to determine the expression of activation markers on 
various cell types. Evaluation of CD69 (an early activation marker) over the course of 
pembrolizumab treatment, revealed a slight decline in expression between baseline and 6 
week samples, which was significant on NK cells and γδT (Figure 5.4). These changes could be 
due to a multitude of factors: the extended period of time between the samples or the 
general natural day-to-day variability in the immune system, without the added complications 
of tumour burden/treatment. It is possible that any stimulatory effect on the immune system 
may have been missed in this window and if samples had been taken at an earlier time point, 
e.g. 24 or 48 hours post-treatment, we may have observed a different result. Unfortunately 
this was not ethically possible as it would have required further patient visits out-with their 
treatment schedule. Reduced peripheral CD69+ T cells may actually represent an increase in 
trafficking of activated T cells out of the periphery, particularly in light of the observed rise in 
levels of chemokines such as MIG and IP-10 (Figure 5.13). CD69 expression on monocytes 
could not be determined due to the small population of cells present following overnight 
resting of PBMCs prior to analysis. Peripheral blood immune cells from patients with 
melanoma have been shown to have downregulation of IFN-stimulated genes when compared 
to healthy controls (552). This corresponded with decreased expression of activation markers 
such as CD69 and illustrated how changes in CD69 can reflect a suppressed immune response. 
It is also supportive of our data, which demonstrated a reduction in both CD69 and CD25 
expression and decreasing levels of IFN-γ over the investigational period (Figure 5.4, 
Figure 5.10 and Figure 5.12, respectively). 
In fresh PBMCs isolated from our patients being treated with pembrolizumab, there was 
reduced expression of CD25 on CD4 and CD8+ T cells between baseline and 6 weeks of 
therapy (Figure 5.10). Diminished CD25 expression on T cells is associated with a higher 
incidence of metastases (553) (although not statistically significant). Conversely, enhanced 
peritumoural infiltration of CD25+ T cells is associated with prolonged patient survival (553). 
Although the fall in CD25 in our samples was unexpected (given that treatment with 
checkpoint inhibitors should increase T cell activation and response), we were unable to take 
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matched patient biopsies for these peripheral blood samples. It may be, therefore, that 
peripheral blood levels of CD25 on T cells was diminished as this population was instead in the 
TME. Interestingly, lower levels of CD25 on CD4+ T cells have also been found in a proportion 
of patients treated with ipilimumab (554).  
The current study did not show a significant change in the levels of Tregs over the course of 
therapy with either ipilimumab or pembrolizumab (Figure 5.8). There is some conflicting 
evidence to the effect of both anti-CTLA-4 and anti-PD-1 antibodies on levels of circulating 
Tregs. In a study of 95 patients receiving ipilimumab, a stable or decreasing peripheral Treg 
population at week 12 was associated with disease control (CR, PR or SD) (555). This was also 
significantly associated with prolonged survival compared to patients in whom Tregs 
increased during the course of treatment (15.8 months vs. 5.3 months, respectively, p=0.03) 
(555). Similarly, in patients treated with the anti-PD-1 antibody nivolumab, disease response 
was associated with a decline in peripheral Tregs (556). Conversely, patients who did not 
respond to therapy had a higher population of circulating Tregs at 12 weeks (556). Although 
some studies have shown a reduction in peripheral Tregs over the course of anti-CTLA-4 
therapy (554,557), others have not (558,559), despite CTLA-4 being constitutively expressed 
on Tregs. While there is conflicting evidence as to whether anti -CTLA-4 therapy affects 
circulating Tregs, the positive effect that checkpoint inhibition has on the immune function of 
T cells is the more pertinent in creating an effective anti-tumour response.  
The data presented in this chapter also demonstrates an increase in CD62L expression on 
Tregs in patients treated with pembrolizumab (Figure 5.8). Although no difference in CD62L 
expression was seen in the small group of ipilimumab patients, analysis of a larger cohort of 
patients treated with high dose ipilimumab and fotemustine showed enhanced CD62L 
expression on CD3+ CD4+ memory T cells, likely representing homing of these cells to LNs 
(560). The observed increase we observed in CD62L+ Tregs (which may be more 
immunosuppressive than CD62Llow Tregs due to their increased ability to home to LNs and 
suppress antigen-specific priming of T cells) may be part of a feedback mechanism reflecting 
heightened immune responses in these patients following pembrolizumab.  
In contrast to other studies, we were unable to demonstrate any significant differences in the 
expression of other immune activation markers such as HLA-DR, which has been shown to 
increase in response to tremelimumab (559) and PD-L1 blockade with atezolizumab (427). 
Additionally, we did not observe changes in other cell surface markers, such as lower CCR7 
expression on peripheral CD4 and CD8+ T cells following ipilimumab therapy that have been 
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seen in larger patient cohorts (561). Fresh immunophenotyping on all samples may have 
revealed these more subtle changes in expression of activation markers: changes in  CD25 
expression were detected in fresh PBMC samples but not in cryopreserved samples 
(Figure 5.10 and Appendix Table 8.9).   
As expected, detection of PD-1 on immune cells was abrogated following treatment with 
pembrolizumab. This was observed irrespective of whether PBMCs had been analysed fresh or 
had been cryopreserved prior to immunophenotyping (Figure 5.5 and Figure 5.11). A similar 
trend for decreased CTLA-4 detection on CD4+, CD8+ T cells and NK cells was seen in patients 
treated with ipilimumab but once again, due to the small number of patients (n=3) and the 
low levels of CTLA-4-positive cells (less than 5 % of T cells and less than 1 % of NK cells), these 
findings were not significant (data not shown). During in vitro studies we were unable to find a 
FACS antibody with a clone that differed from those of the clinical antibodies, so the apparent 
reduction in the expression of these surface molecules may be due to the inability of the flow 
cytometry antibody to bind it’s epitope on the cell surface in the presence of either 
ipilimumab or pembrolizumab. The expression of CTLA-4 and PD-1/PD-L1 on cell subsets can 
be enhanced in malignancy (representing an exhausted and ineffective anti -tumour response) 
(200) and may be associated with changes in disease-related outcomes (201,562–564). As 
such, expression of CTLA-4 and PD-L1 on tumour cells (or tumour-infiltrating immune cells) 
correlates with greater efficacy of PD-1/PD-L1 blockade (321,427,565).  
While there was no demonstrable relationship between PD-1 expression on CD4+ T cells and 
survival, a lower level of PD-1 expression pre-treatment on both CD8+ T cells and B cells was 
significantly associated with prolonged survival in our patient cohort (Figure 5.7). The reverse 
was seen in Tregs, where higher PD-1 expression at baseline trended towards an increase in 
survival (although not statistically significant; Figure 5.7). Unfortunately, there was insufficient 
data to perform an accurate assessment of treatment effect on changing levels of PD-1 
expression (calculation of OS stratified by fold change in PD-1 expression). Without taking 
treatment effect into consideration, the prolonged survival in patients with lower PD-1 
expression on immune cells before treatment is likely a consequence of exhausted immune 
effector cells in the context of metastatic disease. Conversely, exhausted (PD-1+) Tregs 
presumably exhibit a lesser degree of immunosuppression. As such, the higher levels of PD-1 
expression that we detected at baseline, although associated with poorer survival 
independent of therapy, confer increased susceptibility to PD-1 blockade. Although in our 
data we evaluated peripheral immune cells, similar findings have been demonstrated in 
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tumour biopsies of patients receiving anti-PD-1 therapy for metastatic melanoma: patients 
who responded to therapy (CR, PR or SD) demonstrated significantly higher pre-treatment PD-
1 expression on intratumoural T cells compared to non-responders (565).  
Changes in cytokine and chemokine levels in the plasma of our pembrolizumab- and 
ipilimumab-treated patients showed some degree of concordance. Despite smaller patient 
numbers in the ipilimumab-treated group, there was a demonstrable increase in levels of IL-3, 
IL-18, MIG and SCF over the 12 week investigational period for both groups. This change was 
significant in the pembrolizumab-treated group (Figure 5.13 and Figure 5.15).  
IL-18 is a cytokine secreted by immune cells including APCs, T cells and NK cells. IL-18 works 
with IL-12 to stimulate the production of IFN-γ from T cells and NK cells and thus contributes 
to a TH1 immune response (117). It is possible, therefore, that the increase in IL-18 seen in our 
patient cohort may in some way reflect a negative feedback mechanism to the reduction 
demonstrated in plasma levels of IFN-γ. In the absence of IL-12, however, production of IFN-γ 
would have been limited. The production of IFN-γ in response to IL-12 and IL-18 is inhibited by 
IL-4 in vivo (118). The increase in IL-18 and decrease in IL-4 seen in our patient cohort 
therefore seems to contradict the fall in IFN-γ that was also evident. Indeed, treatment with 
checkpoint inhibitors is generally observed to elevate levels of IFN-γ, representing up-
regulation of anti-tumour immune responses (427,566,567). Additionally, an upregulation of 
IFN-γ production corresponds to an increase in the expression of immune checkpoint 
molecules such as PD-1/PD-L1 and CTLA-4, which should further confer greater susceptibility 
to antibody blockade (125). IL-18 also increases in response to anti-PD-L1 therapy with 
atezolizumab in patients with cancers including melanoma (427).  
As possibly anticipated with checkpoint inhibition, levels of the TH2 cytokines IL-4 and IL-5 
declined during the first 12 weeks of pembrolizumab therapy in our patient cohort. Ex vivo 
evaluation of cytokine production by WBC from melanoma patients treated with anti -PD-1 
antibody demonstrated a rise in TH1 cytokines and a reduction in TH2 cytokines (568). 
Although the changes in IFN-γ, IL-4 and IL-5 observed in our pembrolizumab patients were not 
fully replicated in the cohort of patients receiving ipilimumab, two of the three patients 
evaluated seemed to follow the same trend (Figure 5.12 and Figure 5.14). One again, due to 
the small number of patients it is difficult to draw any definite conclusions in this regard.   
As also demonstrated in patients receiving chemotherapy for CRC, levels of both MIG and SCF 
increased during both ipilimumab and pembrolizumab treatment (not significant in the 
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ipilimumab group due to small number of patients) (Figure 5.13 and Figure 5.15). In addition, 
elevated IP-10 was evident following pembrolizumab treatment. As the production of both 
MIG and IP-10 are induced by IFN-γ, it again seems contradictory that both were , in fact,  
enhanced in the context of decreasing levels of IFN-γ. The window in which we may have 
detected higher levels of IFN-γ could have been missed due to the timings of the sample 
collection. Lower IFN-γ levels, however, would fit with the finding of reduced NK cell activity 
over time as demonstrated by decreasing CD107 expression in pembrolizumab-treated 
patients (Figure 5.16).  
Treatment of melanoma cell lines with SCF induces a more immunogenic phenotype, with 
reduced production of immunosuppressive cytokines IL-10 and TGF-β alongside enhanced 
HLA-DR expression, which could potentially contribute to priming of an anti -tumour T cell 
response against melanoma-associated antigens (569). In the context of our patient cohort, 
therefore, the higher levels of SCF detected could represent an increase in immune response 
as a consequence of checkpoint inhibition.  
IP-10 and MIG are closely related and are chemokines for monocytes and T cells, attracting 
immune cell populations into sites of infection and, potentially, into the TME (460). As well as 
their chemotactic properties, both exhibit a number of pro-immune functions that would 
support an enhanced anti-tumour response in our cohort of patients treated with checkpoint 
inhibitors. Through in vivo models of NSCLC, treatment with MIG has also been shown to 
inhibit tumour growth and metastasis through the inhibition of angiogenesis and tumour 
vascularity (165). Supporting the role of MIG and IP-10 in T cell recruitment, biopsies of 
melanoma metastases confirmed higher expression of both chemokines in samples with 
enhanced T cell infiltration (461). In a variety of studies, levels of both MIG and IP-10 have 
been shown to rise in response to checkpoint inhibition: increasing levels of both MIG and IP -
10 were demonstrated in melanoma patients receiving nivolumab as part of a phase II clinical 
trial (570). Similarly, increased plasma levels of IP-10 were seen in patients receiving both 
anti-CTLA-4 and anti-PD-1 antibodies (571).  
Our data shows a rise in levels of IL-3, IL-16 and SCGF-β over the first 12 weeks of 
pembrolizumab therapy. IL-16 is another cytokine which is not only secreted by immune cells 
but acts as a chemoattractant for CD4+ cells, including T cells and APCs. As with the previously 
discussed chemokines, IL-16 also exerts a number of immune functions that would be in 
keeping with finding a greater level of this cytokine in the plasma of patients exposed to 
immune checkpoint inhibitors (Figure 5.13). Like SCF, IL-3 is a haematopoietic cytokine which, 
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in addition to GM-CSF, M-CSF and G-CSF, can differentiate stem cells into immune cells 
including lymphocytes, granulocytes and macrophages. Data about the role of IL-3 in patients 
receiving checkpoint inhibition is limited but it has been used in some clinical trials to try and 
reduce the rate of cytopenia following chemotherapy. It is currently not used in clinical 
practice due to the poorer efficacy in phase III trials compared to other treatments such as G-
CSF. In vitro, combination therapy with IL-3 and IFN-β can help to generate DCs which are able 
to effectively prime T cells against TAAs (572). These antigen-specific T cells were effective 
against target cells lines with similar efficacy to those primed by GM-CSF and IL-4 and the 
increased levels in our patient group suggests another function for IL-3 in priming immune 
responses of patients on checkpoint inhibitors (572). 
In summary, elevated levels of immune-stimulatory cytokines such as IP-10, MIG and IL-18, 
coupled with a reduction in the TH2 cytokines IL-4 and IL-5 would be in keeping with an 
augmented immune response in patients receiving checkpoint inhibitors and are indicative of 
an immune inflammatory milieu.  
NK cell function was limited against melanoma cell lines, thereby potentially masking any 
changes in response to therapy (Figure 5.17, Figure 5.18 and Figure 5.19). However, CD107 
expression against K562 cells (a natural NK cell target) was seen to diminish over time in 
patients receiving pembrolizumab (Figure 5.16). Although the ipilimumab patient group was 
too small to reach statistical significance, a similar trend was also apparent. This may have 
been due, in part, to the low expression of PD-1 on NK cells (< 5 % in patients treated with 
pembrolizumab, data not shown) (Figure 5.18). If both PD-1 and CTLA-4 were expressed on NK 
cells, checkpoint inhibition should increase their cytotoxic potential. Elevated expression of 
both CTLA-4 and PD-1 on NK cells has been shown in patients with cancer and is associated 
with functionally inhibited cells (25,26,30). It should also be noted that CTLA-4 and PD-1 are 
not the only inhibitory receptors: expression of KIRs and other checkpoint inhibitors such as 
TIM-3 can be upregulated on the surface of NK cells from patients with melanoma (25). 
Decreasing functionality in our patient cohort could be due to upregulation of these and other 
inhibitory receptors in response to therapy. Further investigations into these markers (TIM-3, 
LAG-3 and NK cell receptors) may reveal additional information about NK cell function in 
melanoma during checkpoint therapy.  
In addition to investigating the innate immune response to checkpoint inhibition, the adaptive 
T cell response was also examined using ELISpot assays. The patients included in this study 
demonstrated variable T cell responses to either CEF viral peptide pool or MART-1 peptide, 
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although other groups have shown evidence of MART+ CTLs in the peripheral blood of 
melanoma patients (575). Due to this variability, there was not enough data here to 
accurately gauge the effects of either pembrolizumab or ipilimumab on T cell response to 
antigen, as demonstrated by IFN-γ production. Outside this cohort, an increase in MART-
specific T cells has been shown to correspond to disease response in a phase I study of 
patients receiving nivolumab (with or without a peptide vaccine) following ipilimumab therapy 
in a phase I trial (556).  
As seen in the group of patients receiving chemotherapy for CRC, a number of patient T cell 
responses in ELISpot assays reflected results seen in other immune assays. In patient 12 in 
particular (pembrolizumab group), a reduced T cell response to CEF peptide was echoed in 
both decreased CD69+ activated T cells and in innate immune function of NK cells 
(Figure 5.23). As previously discussed, given the complicated but tightly interwoven nature of 
both innate and adaptive immune responses, this is perhaps unsurprising. Larger cohorts 
would be needed to evaluate whether these responses meaningfully correlated to disease 
outcome or survival.  
Although we attempted to match peripheral blood with biopsy samples in our study, this 
proved prohibitive in the recruitment of patients. Matched tumour and peripheral samples in 
other data sets have revealed that PD-1 expression on peripheral T cells can be significantly 
raised when compared to those within the TME (200,571). Moreover, treatment with 
nivolumab can successfully abrogate PD-1 expression on peripheral T cells, while a higher 
proportion of TILs will continue to express PD-1 and not be saturated by binding of 
therapeutic antibody (571). Interestingly, a similar phenomenon has been noted in regard to 
antigen-specific T cells in peripheral blood vs. tumour (200) and may explain the low levels of 
T cell responses to the MART antigen that was demonstrated in our patients. In keeping with 
the observation that TILs express higher levels of PD-1 than peripheral blood lymphocytes, 
MART antigen-specific TILs from patients with melanoma also demonstrate diminished 
effector function and lower levels of IFN-γ production in response to immune stimulation 
(200). It may be, therefore, that the small number of patients who had circulating peripheral 
MART-specific T cells in this study (Figure 5.22) had functional cells, as demonstrated by the 
production of IFN-γ in ELISpot assays. The majority, however, did not have circulating 
peripheral antigen-specific cells but may have had exhausted T cells within the tumour, or be 
primed against different melanoma-associated antigens (other than MART-1).  
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Finally, as also seen in the cohort of patients receiving chemotherapy for colon cancer, there 
was a significantly shortened OS in melanoma patients who had a high NLR prior to treatment 
(Figure 5.24). Unfortunately, once again, due to the smaller number of melanoma patients 
and the availability of PBMCs for immune assays, it was not possible to draw any meaningful 
conclusions regarding NK cell function or cytokine production at baseline stratified by NLR. 
Further assessment of other immune parameters according to baseline NLR did not show any 
appreciable difference. This remained the case if the NLR threshold was moved to NLR ≥ 4 or ≥ 
3 and no correlation was seen between baseline immune function and NLR even with the se 
parameters (data not shown). NLR has been shown in a number of other datasets to correlate 
with prognosis and survival in patients with melanoma (576,577). In cohorts of patients 
receiving ipilimumab, an NLR of less than 5 (as in our data) was associated with improved OS 
and PFS (576). As with the data from our patients with CRC, there are variations in what is 
deemed to be the cut-off value for NLR: a larger study of 720 patients receiving ipilimumab for 
metastatic melanoma deemed the optimal NLR to be less than 3 (although this was a derived 
rather than absolute NLR) (392). Once again, there was shown to be a significantly prolonged 
OS and PFS in patients with a dNLR of < 3 (392).  
In summary, overall, these data illustrate some of the changes in immune response that are 
observed in patients receiving treatment with checkpoint inhibitors. Although some of the 
findings are underpowered due to the small number of patients assessed, it can offer a unique 
insight into the parameters by which anti-tumour immune responses can be exploited and 
enhanced by treatment with either ipilimumab or pembrolizumab, as well as serving as an 
interesting comparison to patients receiving chemotherapy for CRC.  
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Chapter 6 Conclusion 
Overall, these data have demonstrated that it is possible to evaluate the peripheral blood 
immune response to anti-cancer therapy in a robust and reproducible manner. We have 
successfully developed a panel of immune assays that can be performed on the peripheral 
blood of patients, detecting differences in the responses to cytotoxic chemotherapy and 
immunotherapy. As the assays have been optimised to allow for batched analyses, following 
cryopreservation of PBMCs, they are amenable to being used in groups of patients undergoing 
a variety of systemic therapies, for a range of different cancers. Despite the recognition that 
the magnitude of some responses may be slightly diminished in cryopreserved cells, their 
reaction to immune stimuli appear to be comparable across time points and within patient 
samples. This allows the identification of trends in immune function, while being able to 
ensure the high quality, reproducibility of the results, which have been batch-analysed under 
identical conditions to maintain quality control. While other groups have shown the ability to 
analyse varying aspects of the immune system in patients, this assay panel is novel in being 
able to examine multiple aspects of the immune system and how it changes over time within 
a patient population. Although immune responses are widely variable across individual 
patients, we have shown that this assay panel could readily be incorporated into clinical trials 
in order to evaluate responses to treatment. In an era when the use of immunotherapy is 
rapidly expanding, being able to improve our understanding of immune responses to 
immunotherapy, chemotherapy, radiotherapy, targeted therapy and viral therapy, would 
allow us to exploit this when developing new anti-cancer treatment strategies.  
In patients with CRC, we have shown that NLR ≥ 5 before chemotherapy is associated with an 
attenuated immune response, when compared to patients with NLR < 5, supporting our 
original hypothesis. High peripheral blood NLR before treatment was associated with a 
cytokine profile that differed from patients with a low baseline NLR: amongst others, higher 
levels of the immunosuppressive cytokines IL-10 and TGF-β were observed. Similarly, there 
was a suggestion of differences between innate immune responses, as determined by CD107 
expression and 51Cr cytotoxicity assays, in patients with a higher pre-treatment NLR. In 
support of these data, increased OS was seen in patients with a more robust immune 
response, i.e. low baseline NLR. 
When interrogating the adaptive immune response to viral antigens and TAAs, it appeared 
that a greater proportion of patients with a high baseline NLR had responses to CEF viral 
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peptides (as a general recall response). Over the first 6 weeks of chemotherapy, peripheral 
blood immune responses were seen to activate as the NLR fell to < 5. Alongside this, a decline 
in TGF-β secretion was seen, as well as a fall in peripheral Tregs.  
There were also ongoing differences between the patients with a high and a low pre-
treatment NLR that would warrant further study and may explain the persisting difference 
between the groups even after chemotherapy. Levels of IL-10, for example, did not alter 
during treatment and remained elevated in the patients who had a high NLR at baseline, 
irrespective of a fall in NLR over the first 6 weeks of therapy. Once again, differences 
remained between the two groups, in that more patients with a low NLR over the first 6 
weeks of chemotherapy demonstrated greater T cell responses against TAAs. 
While NLR has been shown to correlate with outcome in CRC, the rationale behind this 
relationship is not understood. The current data may, therefore, go some way into 
understanding this, by demonstrating a diminished immune response. Although, to some 
extent, this appears to reverse with chemotherapy, differences between the groups remain 
(high vs. low baseline NLR) even if NLR falls. This also appears to correlate with other data 
suggesting that even normalisation of NLR does not improve OS to the same extent as 
patients with a low NLR at the outset. 
Immunotherapy has only been shown to be effective in a small proportion of CRC patients; 
that is, patients with dMMR tumours. The data presented here could therefore prompt 
further study into the potential role for immunotherapy after an initial period of 
chemotherapy. Although this would appear to be a valid area of further study in all patients, 
as those with a high baseline NLR continue to have poorer outcomes in terms of OS, 
effectiveness of sequential therapy in this sub-group of patients would be of particular 
interest. 
Our study also evaluated the immune response to checkpoint inhibitors in patients with 
melanoma. Firstly, the data confirmed that treatment with ipilimumab or pembrolizumab 
blocked the expression of CTLA-4 and PD-1, respectively. Although the melanoma patient 
group was smaller than the CRC patient group, similar trends were noted. In the 
pembrolizumab-treated patients, a fall in CD69 and CD25 expression was evident on some 
populations of circulating immune cells. These differences were enhanced when PBMCs 
where immunophenotyped before cryopreservation. More obviously, the cytokine profile in 
patient plasma revealed an apparent fall in IFN-γ, IL-4 and IL-5. While the decrease in IL-4 and 
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IL-5 might be expected in the context of immune stimulation by checkpoint inhibitors, the 
concurrent decline in levels of IFN-γ seem discordant. In contrast to IFN-γ, plasma levels of 
other pro-immune cytokines, including IL-3, IL-16, IL-18, IP-10 and MIG increased over the 
course of treatment. Once again, this supports the theory of an elevated anti -tumour immune 
response over the course of immunotherapy in patients with melanoma. Although these 
findings were significant in the patients receiving pembrolizumab, a similar trend was seen in 
the small group of patients receiving ipilimumab.  
There are comparisons to be made between the CRC group treated with chemotherapy and 
the melanoma patient cohort treated with immune checkpoint inhibitors. Due the different 
number of patients in each group, variable baseline characteristics, as well as different 
underlying pathology, these are limited to observations that could be taken forward for 
further study. In contrast to the CRC patient cohort, changes in innate immune responses, 
mediated by NK cells, were not demonstrated in the melanoma patient cohort. This may be 
explained by the finding that less than 5 % of the population of NK ce lls expressed PD-1 at 
baseline and, hence, the effect of anti-PD-1 antibodies on NK cell responses may be limited. 
Future work could therefore also include analysis of the activating and inhibitory receptors on 
NK cells which would further inform their function during anti -cancer treatment. There are 
inherent differences between the immune responses evidenced in the groups of patients with 
CRC and those with melanoma. One explanation of this may be the reason why 
immunotherapy is generally less effective in patients with CRC (except for the small cohort 
with dMMR). That is, due to differences in mutational load/neoantigens, the anti-tumour 
immune response of patients with melanoma may be already ‘primed’ to some extent. In 
contrast, our data may suggest that chemotherapy can prime an immune response in patients 
with CRC. This is supported by the finding that PD-1 increases over the course of treatment on 
some immune cell populations in patients with CRC. Changes in expression of PD-1 (or CTLA-4) 
over time in the melanoma cohort, however, was unable to be determined due to blockade of 
the receptor by pembrolizumab (or ipilimumab), respectively. Future studies would, 
therefore, include a broader spectrum of immune checkpoints, such as TIM-3, LAG-3 and 
BTLA-4 in order to be able to determine a fuller picture of immune activation in patients out-
with the effect of anti-CTLA-4 and anti-PD-1.  
In many of our immune assays, very little change was observed in response to therapy and 
this is probably due to the timing of samples taken. As these studies used a ‘window of 
opportunity’, blood samples were taken at scheduled patient visits and any extra were 
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ethically prohibited. For this reason, data may not have been captured if the window of 
response was missed. Hence, in future studies we would aim to not only expand the number 
of patients in order to get a meaningful data set but also change the timings of the samples to 
fully interrogate the response. In addition, the local ethics consent which allowed us to collect 
patient samples did not allow us to collect samples from healthy controls for comparison. For 
validation assays, a small number of HD blood was used but we were unable to increase these 
numbers to a level whereby an accurate comparison with an aged-matched patient 
population would be possible.  
While these data utilised the simplicity of peripheral blood collection to evaluate immune 
responses to anti-cancer therapy, for a more complete picture, comparison with the immune 
milieu in patient tumours could be enlightening. From this, we would be able to determine 
whether the peripheral blood immunome is truly a surrogate for that in the tumour or just 
part of the picture. Tumour tissue samples are of course harder to access, especially over the 
course of treatment, although in melanoma patients we initially investigated the practicalities 
of paired fresh tissue biopsies from skin metastases.  
Similarly, we have been unable to fully interrogate the neutrophil population in either CRC or 
melanoma patients, due to the difficulties in working reliably with these cells. Towards the 
end of this project, early work into the investigation of neutrophil ectosomes was started 
which could be continued further. The hypothesis being that, as a high neutrophil count 
contributes to a high NLR, isolation of neutrophil ectosomes in patient plasma may reveal, as 
other data has suggested, the production of immunosuppressive cytokines such as IL-10 and 
TGF-β. This may go some way to explaining our findings in patients with a high NLR and also 
the contribution of high peripheral blood neutrophils to a poorer prognosi s and OS in cancer.  
Finally, in summary, these data show that we have met our initial objective of optimising and 
validating a panel of assays to interrogate immune responses in peripheral blood for use in 
batch analysis scenarios. In patients with CRC being treated with chemotherapy, these 
preliminary data suggest a role for chemotherapy in priming an immune response, particularly 
in patients with a high baseline NLR, which could potentially be exploited with the sequential 
use of immunotherapy. This is of particular interest given that until now these patients in 
general have not been shown to benefit from immunotherapy and thus has the potential to 
be practice changing. Going forward into clinical trials, this data would support the use of 
immune checkpoint inhibitors after an initial period of chemotherapy. Patients with stable 
disease after 12 weeks of chemotherapy (again stratified by baseline NLR) could, for example, 
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go onto receive an immune checkpoint inhibitor. This would allow for further collection of 
clinical samples, potentially with the addition of tumour biopsies for paired analysis. It would 
also be used to evaluate the benefit of immunotherapy after chemotherapy. Similarly, given 
that we saw some changes in immune function at 6 weeks, we could also look for early 
markers of disease progression in a larger group of patients.  
In patients with melanoma being treated with checkpoint inhibitors, we have been able to 
reveal immune signatures, which may be used as initial data to investigate potential novel 
biomarkers in such patients. More particularly, these data may be more relevant in 
investigating biomarkers for toxicity and could have a role to play in patient selection and 
management of immune-mediated side effects in the future.  
This work has expanded on our understanding of immune responses to anti-cancer therapy. It 
has revealed new opportunities and generated hypotheses for further investigation into the 
role of the immune system in cancer and anti-cancer therapy and may ultimately lead to 
better patient treatment and improved survival outcomes.  
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Chapter 8 Appendix 
Table 8.1 p values for fresh and cryopreserved PBMCs either untreated or stimulated with 
1pfu/cell reovirus at stated effector:target ratios (Figure 3.5). 
 Fresh PBMCs Cryopreserved PBMCs 
E:T Ratio K562 SW620 Mel888 K562 SW620 Mel888 
100:1 0.0282 0.0204 0.0048 0.305 0.0146 0.0176 
50:1 0.0108 0.0063 0.0024 0.0091 0.0157 0.0047 
25:1 0.0325 0.0125 0.002 0.0234 0.0182 0.0064 
12.5:1 0.0289 0.0138 0.0009 0.0102 0.0176 0.0041 
6.25:1 0.0399 0.0129 0.0002 0.0109 0.0048 0.0041 
3.12:1 n/s 0.0043 0.0029 0.0130 0.0219 0.0051 
1.56:1 n/s 0.0377 0.0016 0.0131 0.0025 n/s 
0.78:1 n/s n/s 0.0051 n/s 0.0377 0.0377 
 
Table 8.2 p values for % CD69 expression on immune cell populations from ‘same-day’  and 
‘rested’ PBMCs following treatment ± 1pfu/cell reovirus (Figure 3.10). 
Population ‘Same-day’ PBMCs ‘Rested’ PBMCs 
CD4+ T cells 0.0019 0.0005 
CD8+ T cells 0.0018 0.0032 
NK cells 0.0001 0.0045 
NK cells (dim) <0.0001 0.0054 
NK cells (bright) 0.005 0.0081 
NKT cells 0.0028 0.0007 
γδT cells 0.0008 0.0012 
Monocytes 0.0054 n/s 
B cells 0.001 0.043 
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Table 8.3 Sample collection in patients with CRC on chemotherapy 
All patient sample sets collected were complete, with the exception of the following (patients 
from NLR-23 onwards only had baseline and 6 week samples collected): 
Patient Baseline Sample 6 week Sample 12 week Sample 
NLR-4    
NLR-6    
NLR-9    
NLR-14    
NLR-17    
NLR-29    
 
Table 8.4 Activation markers on immune cell populations of CRC patients which did not 
differ between those with a high or low NLR at baseline 
Activation 
Marker 
Cell Population 
CD69 CD4+ T cells, CD8+ T cells, NK cells, NKT cells, monocytes, B cells 
PD-1/PD-L1 CD4+ T cells, CD8+ T cells, NK cells, NKT cells, monocytes, B cells, Tregs 
HLA-DR 
 
Monocytes, B cells 
CCR7 CD4+ T cells, CD8+ T cells, NK cells, NKT cells 
 
Table 8.5 Activation markers on immune cell populations of CRC patients which did not 
change over the first 6 weeks of chemotherapy 
Activation 
Marker 
Cell Population 
CD69 CD4+ T cells, CD8+ T cells, NK cells, NKT cells, monocytes, B cells 
PD-1 CD4+ T cells, CD8+ T cells, NKT cells, Tregs 
PD-L1 CD4+ T cells, CD8+ T cells, NK cells, NKT cells, monocytes, B cells, Tregs 
HLA-DR Monocytes, B cells 
CCR7 CD4+ T cells, CD8+ T cells, NK cells, NKT cells 
CD62L Tregs 
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Table 8.6 Cytokines/chemokines not detected by Luminex in CRC patient plasma 
Cytokines/chemokines not detected/below standard curve 
IL-2 IL-1Rα IL-12p40 IL-15 MCP-1 TNF-α 
IL-1α IL-5 IL-12p70 GM-CSF M-CSF TNF-β 
IL-1β IL-6 IL-13 LIF Β-NGF VEGF 
 
Table 8.7 Sample Collection in patients treated with ipilimumab 
All patient sample sets collected were complete, with the exception of the following:  
Patient Baseline Sample 6 week Sample 12 week Sample 
MelIpi-01    
MelIpi-02    
MelIpi-05    
MelIpi-06    
 
Table 8.8 Sample Collection in patients treated with pembrolizumab 
All patient sample sets collected were complete, with the exception of the following: 
Patient Baseline Sample 6 week Sample 12 week Sample 
MelPem-02    
MelPem-05    
MelPem-06    
MelPem-07    
MelPem-08    
MelPem-10    
MelPem-17    
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Table 8.9 Activation markers on cryopreserved immune cell populations of patients treated 
with pembrolizumab which are unchanged over time 
Activation 
Marker 
Cell Population 
CD69 CD4+ T cells, CD8+ T cells, NKT cells, monocytes, B cells 
PD-1 NK cells, NKT cells, monocytes, B cells 
PD-L1 CD4+ T cells, CD8+ T cells, NK cells, NKT cells, γδT cells, monocytes, Tregs  
CD25 
CTLA-4 
CD4+ T cells, CD8+ T cells 
HLA-DR 
CD11c 
CD86 
Monocytes, B cells 
CCR7 CD4+ T cells, CD8+ T cells, NK cells, NKT cells, γδT cells 
CD16 NK cells, NKT cells, γδT cells 
 
Table 8.10 Cytokines/chemokines not detected by Luminex in patients receiving 
pembrolizumab  
Cytokines/chemokines not detected/below standard curve 
IL-1α IL-10 GM-CSF 
IL-2 IL-12p40 M-CSF 
IL-6 IL-15 TNF-β 
 
Table 8.11 Cytokines/chemokines with no change over time in patients receiving 
pembrolizumab 
Cytokines/chemokines with no significant change over treatment period 
IFN-α2 IL-9 CTACK MCP-1 RANTES 
IL-1β IL-12p70 Eotaxin MCP-3 SDF-1α 
IL-1Rα IL-13 G-CSF MIF TNF-α 
IL-2Rα IL-17α GRO-α MIP-1α TRAIL 
IL-7 β-NGF HGF MIP-1β VEGF 
IL-8 Basic FGF LIF PDGF-BB  
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Table 8.12 Cytokines/chemokines not detected by Luminex in patients receiving ipilimumab 
Cytokines/chemokines not detected/below standard curve 
IL-1α IL-10 IL-15 MCP-1 
IL-2 IL-12p40 β-NGF M-CSF 
IL-6 IL-12p70 GM-CSF TNF-β 
 
